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Abstract: 
Uveitis is a generic term for a wide variety of different types of intraocular inflammation with 
different clinical phenotypes and visual outcomes. The explanation for why some patients 
develop chronic anterior disease whereas others do not is unknown. It seems likely that host 
factors such as the cytokine milieu of the aqueous humor may be an important factor in 
determining outcome. In turn, their secretion is genetically determined and cytokine gene 
polymorphisms have been associated with high or low level production whatever the 
stimulus.  
Purpose: 
The aim of this study was to identify key cytokine and chemokine polymorphisms associated 
with disease susceptibility, clinical phenotype, and development of visually significant 
complications in patients with anterior uveitis.  
Methods:  
PCR amplification was used to genotype a number of biallelic SNPs in several cytokine 
genes. This genetic data was then compared between patients and healthy controls, and within 
the patient group itself for association with clinical disease outcomes.  
Results: 
Our results show that a significant difference in the frequency of TNF-857T allele in patients 
with idiopathic anterior uveitis. We found a significant association between TNF-308 allele G 
and patients with anterior uveitis who were HLA-B27 positive. Patients with HLA-B27 
associated anterior uveitis who developed visually threatening complications were more likely 
to carry the TNFRSF1A-201T or TNFRSF1A-1135T alleles. In addition, the frequency of IL-
1ra allele T was found to be significantly associated with chronicity of the disease. The 
frequency of MCP-1 (-2076T) allele was found to be significantly higher in healthy 
individuals when compared to patients with acute idiopathic anterior uveitis. 
Conclusions: 
These results suggest that genetic variations in proinflammatory mediators may influence the 
susceptibility and severity of the inflammatory response in eyes of patients with anterior 
uveitis. 
This knowledge may be useful in identifying prognosis and responsiveness to anti-TNF 
blockade in patients with anterior uveitis. 
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CHAPTER ONE 
1. INTRODUCTION 
1.1. GENERAL IMMUNOLOGY 
The immune system coordinates the immune response through two major arms that detect and 
defend against microbial challenges and discriminate between self and non-self antigens. The 
first is the innate or non-specific immune system, which constitutes a first line of host 
defences responsible for the immediate and rapid immune response against microbes. Its main 
components are the physical and chemical barriers, such as epithelia and antimicrobial 
substances produced at the site of epithelial surfaces, blood proteins including members of the 
complement system and a cellular milieu than includes neutrophils or polymorphonuclear 
cells (PMN), monocytes, macrophages, natural killer (NK) cells, and immature dendritic cells 
(Medzhitov et al. 2000).  
The other is the adaptive or specific immune system which is a highly evolved defence 
mechanism, is antigen-specific, is mediated by antigen receptors on B and T lymphocytes, 
requires clonal expansion and is characterized by immunologic memory (Table 1.1).  
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Table 1.1. Cardinal features of innate and adaptive immunity (Medzhitov & Janeway 2000). 
 
 Innate immune response Adaptive immune response 
Onset Immediate Delayed 
Components Neutrophils, monocytes, macrophages, 
mast cells, basophils, eosinophils, NK 
cells, APCs, complement system, acute 
phase proteins, cytokines and 
chemokines 
T lymphocytes, B 
lymphocytes, cytokine and 
chemokine system 
Immune 
recognition 
mechanism 
Germ-line encoded 
Pattern-recognition receptors 
Recognise PAMPs 
Not clonally expressed 
Somatically generated 
Antigen-specific receptors 
Recognise antigen epitopes 
Clonal expression, selection , 
and expansion 
Number of 
receptor 
specificities 
In the hundreds 
Specifically of each receptor is 
genetically predetermined 
Between 1014 to 1018 
Unique gene recombination 
and rearrangements to generate 
the enormous diversity of 
antigen receptors 
Immunologic 
memory 
Absent Present 
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1.1.1. Innate immunity 
Neutrophils or PMN are the most common immune cells in peripheral blood and represent an 
important component of the innate immune system since they are the first cells to arrive at 
sites of acute inflammation thus constituting the first line of defence against microbial 
organisms. Once at the site of inflammation they produce pro-inflammatory cytokines and 
chemokines that recruit and activate other immune cells, such as monocytes, macrophages, 
NK cells and immature dendritic cells (Joffre et al. 2009; Yamashiro et al. 2001). 
Monocytes are an incompletely differentiated cell type that circulates in the peripheral blood 
after leaving the bone marrow. They belong to the human mononuclear phagocyte system and 
play an important role in the innate immune response via their role in cytokine production, 
phagocytosis and chemotaxis. CD14 is a major cell surface receptor of monocytes and CD14+ 
monocytes in peripheral blood migrate into inflamed tissue where they undergo 
differentiation into myeloid dendritic cells or tissue macrophages dependent upon the 
cytokine environment, and thereby contributing to the development of adaptive immunity 
(Ziegler-Heitbrock 2007).  
Dendritic cells are terminally differentiated bone marrow cells whose main function consists 
of presenting antigens to naïve T cells. Following the capture of antigens at the site of 
inflammation they migrate to lymphatic tissues, such as the spleen and regional lymph nodes 
where they present the processed antigen to the resident lymphocytes via MHC class II 
molecules. In addition to this dendritic cells are potent stimulators of B and T cells 
lymphocytes and can modulate the development of T-cell mediated immune responses into 
Th1 or Th2 type. 
 
1.1.1.1. Toll-like receptors 
There has been an overwhelming increase in the total number of known receptors involved in 
innate immune recognition in recent years; moreover, pathogens can be extremely 
heterogeneous and mutate at much higher rate than any of their hosts. Therefore the innate 
immune system recognises only highly preserved structures called pathogen-associated 
molecular patterns, with bacterial lipopolysaccharide (LPS) being one of the best-known 
examples. The receptors of the innate immune system that recognize them are known as 
pattern-recognition receptors (PRRs).   
Structurally, PRRs belong to several families of proteins that are expressed in many effector 
cells of the innate immune system; however, functionally they can be divided in three classes, 
secreted, endocytic and signaling.  
Signaling PRRs, such as NOD2 recognize pathogen-associated molecular patterns and 
activate signal transduction pathways that induce the expression of a variety of immune 
18
response genes, including pro-inflammatory cytokines (Du et al. 2009; Medzhitov & Janeway 
2000) (Figure 1.1).  
Figure 1.1. Schematic representation of the PRR families within the innate system. From 
Barton GM (Barton 2008). 
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Toll-like receptors (TLRs) are a family of PRRs that recognize the above mentioned 
pathogen-associated molecular patterns. They are expressed on immune cells that are most 
likely to encounter microbes, such as neutrophils, macrophages and dendritic cells, and each 
TLR has a unique specificity for ligands (Takeda et al. 2005). The activation of TLRs by their 
ligands results in the production of pro-inflammatory cytokines, chemokines and activation of 
immune cells (Medzhitov et al. 2002) initiating a rapid response characterised by the 
recruitment of leukocytes to the site of infection in order to eliminate the pathogen (Takeda & 
Akira 2005) and activation of specific adaptive immune responses. 
Ten human TLRs have been identified to date and each one of them recognizes a pathogen-
associated molecular pattern from a single class of micro-organism (Table 1.2).  
The cytoplasmic portion of TLRs shows high similarity to the IL-1receptor family, and it is 
termed Toll/IL-1 receptor (TIR) domain, however the extracellular portions are structurally 
and functionally unrelated. Whereas TLR2 recognises peptidoglycans from gram-positive 
bacteria, TLR4 recognises LPS of gram-negative bacteria (Takeda & Akira 2005). Microbial 
recognition of TLRs facilitates dimerisation of TLRs, and TLR2 is shown to from a 
heterodimer with TLR1 or TLR6, which triggers the activation of signalling pathways and 
ultimately the activation of the transcription factor NF-κβ, which is essential for the induction 
of inflammatory cytokines such as tumour necrosis factor-α (TNF-α) and IL-12 (Takeda & 
Akira 2005) (Figure 1.2). Therefore, activation of specific TLRs on different antigen 
presenting cells (APCs) leads to different pathways of cytokine gene expression (Hirschfeld et 
al. 2001). At the same time these APCs can activate naïve CD4+T cells and induce their 
differentiation into Th1, Th2, or Th17 cells, providing a link between innate immune 
recognition and the triggering of the adaptive immune response.  
They have been implicated in the pathogenesis of a number of chronic inflammatory 
autoimmune disorders, including AS and IBD which interestingly can be associated with 
intraocular inflammation (Cario et al. 2000; Yang et al. 2007). 
TLRs, in particular TLR4 have been shown to be expressed in the human eye (Song et al. 
2001), and although the human iris endothelium does not appear to express TLR4 in vivo, 
cultured human iris endothelial cells have been found to express TLR4 mRNA and respond to 
LPS stimulation with the production of pro-inflammatory cytokines (Brito et al. 2004). 
Furthermore, Chang et al. demonstrated the TLR4 functional expression by resident APCs in 
the normal uvea (Chang et al. 2004), as well as changes in the expression and function of 
TLR4 and TLR2 in patients with active AAU (Chang et al. 2007). These findings support 
another potential pathogenic role of PRRs in the development of anterior uveitis (AU).  
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Table 1.2. Summary of human TLRs and their known ligands. Courtesy of Dr Kelly Mai, 
University of New South Wales, Sydney. 
 
TLRS Ligands Location 
TLR1* lipoproteins/lipopeptides (bacteria) Cell surface 
TLR2* lipoproteins/lipopeptides (bacteria) 
peptidoglycan and lipoteichoic acid (bacteria) 
zymosan (fungi) 
HSP70 (host cells) 
Cell surface 
TLR3 dsRNA Cell compartment 
TLR4 LPS (bacteria) 
HSPs (bacteria and host cells) 
hyaluronic acid fragments (host cells) 
viral proteins 
Cell surface 
TLR5 flagellin (bacteria) Cell surface 
TLR6* diacyl lipopeptides (bacteria) Cell surface 
TLR7 imidazolequinoline antiviral drug 
ssRNA 
Cell compartment 
TLR8 ssRNA (viral) Cell compartment 
TLR9 unmethylated CpG DNA (bacteria) Cell compartment 
TLR10 Unknown Unknown 
 
*TLR2 forms heterodimers with TLR1 and TLR6 
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Figure 1.2. TLR signaling and ligand specificities of TLRs. Courtesy of Dr Kelly Mai, 
University of New South Wales, Sydney. 
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1.1.2. Adaptive immunity 
The adaptive immune response involves the proliferation of antigen-specific B and T 
lymphocytes. B cells develop in the bone marrow and circulate in the lymphatic network. 
They secrete immunoglobulins or antigen-specific antibodies that are responsible for 
eliminating extracellular pathogens.  
T cells originate in the bone marrow and migrate to the thymus where they undergo a process 
of proliferation during their first encounter with an antigen. This primary immune response 
generates both effector T and B cells, as well as memory T and B cells. The presence of T cell 
receptors (TCR) enables the identification of the appropriate antigens. The main functions of 
T cells are to regulate the immune responses to protein antigens and to serve as effector cells 
for the elimination of intracellular pathogens. Cytokine production and cytotoxicity are 
critical effector cell functions, which can be attributed to two main separate T cell 
subpopulations CD4+ T cells or cytokine-secreting cells (Th) and cytotoxic cells (Tc) or 
CD8+T cells.  
The Th1 cell and Th2 cell paradigm proposed by Mosmann in the late 80s’ to explain 
different adaptive immune responses against different pathogens correlates well with their 
pattern of cytokine production (Mosmann et al. 1986). Whereas Th1 cells are defined by the 
production of IL-2 and IFN-gamma and are primarily responsible for cell-mediated 
inflammatory reactions (Sacks et al. 2002), Th2 cells are involved in humoral immunity 
(Anthony et al. 2007) and produce IL-4, IL-5, IL-10, and IL-13. 
Another characteristic of Th1 and Th2 cells is that T cell subsets produce cytokines that serve 
as own autocrine growth factor and promote differentiation of naïve T cells to that subset. 
Furthermore, cytokines produced by each subset cross-regulate others development and 
activity; however this simplified classification of T cell effector functions into cell-mediated 
and humoral immunity has been a source of debate and controversy, and efforts to resolve 
these issues in recent years have resulted in the discovery of a new subset of T-cells that 
exhibit different functions from Th1 and Th2 cells and are characterized as the main 
producers of IL-17A, IL-17F, IL-21, and IL-22 (Weaver et al. 2006) (Figure 1.3). 
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Figure 1.3. Th cell lineage. From Afzali et al. (Afzali et al. 2007). 
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While it is known that the Th1 cytokine IFN-gamma regulates cell-mediated immunity and 
Th2 cytokines regulate humoral responses, the function of IL-17 is still not well understood, 
although recent published data indicates that IL-17 is a pro-inflammatory mediator that acts in 
synergy with TNF to regulate inflammatory gene expression (Ruddy et al. 2004).   
Th17 cells are characterized by being preferential producers of IL-17, IL-22, and IL-21, and 
thus inducing variable tissue reaction in relation to the distribution of their receptors. As with 
Th1 or Th2 cells there is no single surface marker specific for Th17, although the absence of 
CCR5 in the presence of CCR2 seems to define the Th17 phenotype (Sato et al. 2007), These  
receptors are widely expressed in epithelial and endothelial cells and can therefore act as 
regulators of different immune responses. There is a mutual antagonism between Th17 and 
Th1 cells, which derives from the induction of reciprocal T-cell developmental pathways by 
IL-23 and IL-27 (Weaver et al. 2006).  
In chronically inflamed lesions in contrast to in vitro differentiated peripheral blood-derived 
Th17 cells, which are reported to produce both IFN-γ and IL-17, many infiltrating Th17 cells 
only produce low levels of IFN-γ, IL-4, or other Th2 associated cytokines, but high levels of 
IL-17 and IL-22 are produced at much higher levels (Pene et al. 2008). These findings 
corroborate earlier reports showing that the pro-inflammatory IL-22 is produced by activated 
Th17 cells in both  animal and human models of inflammatory disease (Annunziato et al. 
2007; Liang et al. 2006); and that Th17 clone cells isolated from psoriatic lesions induced the 
expression of psoriasin, an inflammatory protein in a IL-22 dependent manner (Pene et al. 
2008). 
Similarly, in EAU INF-γ secreting Th1 cells were thought to be the main inflammatory driver, 
given the elevated levels of INF- γ in the retina during the acute phase of uveitis; however IL-
12 downregulates EAU and antibodies to IFN- γ appear to exacerbate the disease, suggesting 
a paradoxical role of Th1 cells conferring protection against chronic uveitis (Tarrant et al. 
1999). 
 
Th17 cells have been found in peripheral blood mononuclear cells (PBMC) of patients with 
active uveitis, and their expression was upregulated following stimulation with IL-12. In 
addition, IL-17 expression was inhibited by IFN- γ (Amadi-Obi et al. 2007). In the same 
study, IL-27 was unexpectedly found to be ubiquitous in retinal cells, upregulated by IFN- γ 
and inhibited Th17 proliferation, suggesting that Th1 cells may have a protective role in 
uveitis by antagonizing Th17 cells through IFN- γ mediated induction of IL-27 (Amadi-Obi et 
al. 2007). 
 
Another subtype of T cell with immunoregulatory capacity has been identified and shown to 
play an important role in modulating T cell function. They are also defined by their cell 
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surface markers, mechanism of action and tissue of origin, and the expression profile and 
functional significance of some of these markers is summarized in figure 1.4 (Figure 1.4). The 
exact mechanism by which these regulatory T cells (Treg) exert their regulatory functions 
remains poorly understood, and although it is thought that they operate via a cell-to-cell 
contact, both IL-10 and TGF-β production have also been implicated (Shevach et al. 2008). 
Specifically, Treg have the capacity to actively block immune responses, inflammation, and 
tissue destruction by suppressing the functions of a wide array of cell types, including CD4+ 
helper T cells, CD8+ cytotoxic T cell, and APCs among others (Brusko et al. 2009). Among 
the different subtypes, the naturally occurring CD4+ CD25+ Treg cells are essential for the 
active suppression of autoimmunity and it has been shown that in the human and murine 
CD4+ CD25 knock-out models severe autoimmune disease develops (Wildin et al. 2001). 
Several studies have demonstrated alterations in the CD4+ CD25+ population in patients with 
uveitis (Chen et al. 2008; Hamzaoui et al. 2006; Nanke et al. 2008). 
One of the markers that the CD4+ CD25+ Treg population expresses is the forkhead-winged-
helix transcription factor Foxp3, responsible for their development and function (Fontenot et 
al. 2003; Sather et al. 2007). It also appears to be the most specific nuclear transcription factor 
for Treg, and differences observed between the percentage of CD4+ Fox3p+ lymphocytes in 
patients with active and inactive uveitis suggests that a deficiency of Treg populations may 
play a role in some uveitis entities (Yeh et al. 2009), which would correlate with the 
observation that often autoimmune disorders manifest with relapsing episodes of 
inflammation and periods of quiescence, supporting the hypothesis of a skewed Th cell profile 
towards pro-inflammatory lineage such as Th1 and Th17, or a loss of Treg lineage during 
these periods of acute flare-ups.  
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Figure 1.4. Important markers in the immunobiology of Tregs. From Brusko et al. (Brusko & 
Bluestone 2009). 
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1.2. OCULAR IMMUNOLOGY 
1.2.1. Ocular immune privilege 
Since the first experimental description of ocular immune privilege in the 1940s’ (Medawar 
1948) further research has called attention to the existence of two types of immune privilege: 
immune privilege sites and tissues. Immune privileged sites, such as the eye can be defined as 
places where foreign tissue can experience extended survival, whereas in other sites they are 
rejected and they differ from conventional ones in that they can survive when placed at 
conventional sites, whereas non-privileged tissues are promptly rejected (Streilein 2003). 
Hence immune privilege is an evolutionary process that allows immune effectors to provide 
local protection without disrupting the local tissue or specialized organs and is achieved by 
dynamic interactions between the immune system and specialized tissues.  
Several features unique to the eye contribute to its immune privilege. 
The first one is the integrity of the blood ocular barrier, which restricts inflow of blood borne 
pathogens into the eye. Secondly, the absence of lymphatics combined with the major outflow 
of aqueous humor (AqH) through the trabecular meshwork into the venous circulation, makes 
the spleen rather than lymph nodes its primary lymphoid organ. Thirdly, the existence of 
soluble immunomodulatory factors in the AqH, such as neuropeptides and cytokines such as 
TGF-β, that can suppress immune mediated inflammation and complement activation 
(Streilein et al. 1992). In addition to this, the expression of immunomodulatory ligands, such 
as FasL on the surface of parenchymal cells induces apoptosis of ingressing T cells, and 
elevated levels in AqH during episodes of active uveitis suggest they have a regulatory role in 
uveitis (Sugita et al. 2000). And finally, endogenous tolerance promoting APCs that are 
strategically located in the iris, ciliary body and retina. The result is that antigenic material 
placed in or arising from the anterior chamber elicits a different form of systemic immune 
response, which includes T and B cells that eliminate pathogens in the absence of 
inflammation, as well as Treg cells that suppress induction and expression of immunogenic 
inflammation secondary to Th1 and Th2 cells, and excludes effector CD4+ T cells that 
eliminate pathogens via immunogenic inflammation. This response is known as anterior 
chamber-associated immune deviation (ACAID). Now know that this process is mediated by 
F4/80+ macrophages that present the ocular inoculated antigen to a cluster of B cells, NK 
cells, CD4, and CD8 T cells in the spleen (Al-Mansour et al.).  
 
1.2.1.1. Experimental uveitis 
It is difficult to obtain sufficient human ocular tissue for research purposes. It is rarely 
possible to obtain ocular tissue for histology via biopsies, hence animal experimental models 
of uveitis have been developed to provide a better knowledge of the immunobiology of the 
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uvea and surrounding ocular structures during uveitis, and to test new therapeutic strategies 
(Table 1.3). 
 
1.2.1.1.1. Experimental autoimmune uveitis 
Experimental autoimmune uveitis (EAU) may be induced in several mammalian species by 
immunizing them with a soluble bovine retinal extract. EAU consists of an immune-mediated 
response against soluble retinal antigens. It is a CD4 + Th1 cell mediated disease, in which the 
T-cell infiltrate, triggers a cytokine cascade and a non-specific cellular infiltrate, that are 
responsible for cell damage. Histologically this cellular milieu consists mostly of 
mononuclear cells. In EAU the inflammation affects mainly the posterior segment, but often 
has an anterior segment inflammatory component with deposition of fibrin, as it is often seen 
in humans in severe acute presentations of uveitis.  
 
1.2.1.1.2. Endotoxin induced uveitis 
Endotoxin-induced uveitis (EIU) is an animal model for acute anterior uveitis (AAU) in the 
human, but unlike human disease, it does not induce long lasting tissue damage. Systemic 
LPS injection in Lewis rats induces the adherence of monocytes to retinal blood vessels, 
followed by invasion into the retina. The popularity of EIU in research is partly due to the 
recognized association between AAU and gram negative bacterial infection. Depending on 
the animal used the inflammatory response has a different anatomical predilection. In Lewis 
rats the uveitis will develop mostly in the anterior chamber, whereas in the mouse, the 
inflammatory infiltrate will accumulate in the vitreous and around retinal vessels. Histological 
findings include an early infiltrate of PMN leucocytes, followed by a mononuclear 
component. 
Interestingly, not all mouse strains injected with LPS develop EIU. In the C3H/HeJ mice a 
point mutation within the coding region of the TLR4 gene results in a functional disruption of 
TLR4 signaling rendering these mice resistant to LPS induced uveitis, yet highly susceptible 
to gram negative infection (Poltorak et al. 1998). 
 
1.2.1.1.3. Experimental melanin-induced uveitis 
Experimental melanin-induced uveitis (EMIU) is a recurrent uveitis observed when Lewis 
rats are immunized with bovine choroidal melanin. Like EAU is a T cell-mediated ocular 
inflammation. Histological inflammation appears as early as clinical signs are present. It 
consists mostly of an accumulation of macrophages and T cells in the uvea, but as in EAU 
PMN are also frequently seen. Whereas in EIU neutrophil infiltrate predominate, in EMIU 
mononuclear cells are the predominant type, especially in the ciliary body and they later 
migrate to the iris. Clinically is characterized by bilateral, recurrent subacute uveitis. 
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Although the clinical signs appear to resolve spontaneously, the time taken for resolution is 
longer than in the EIU model. EMIU appears to be the model more closely related to human 
disease.  
 
1.2.1.1.4. Experimental autoimmune encephalitis associated anterior uveitis 
Experimental autoimmune encephalitis associated AU (EAE/AU) is a model for recurrent 
AU, which is associated with inflammation of the spinal cord. Similar to the other models of 
autoimmune uveitis, CD4+ T cells of Th1 phenotype mediate the inflammatory response in 
response to peptides that posses both the encephalitogenic and uveiticogenic properties. 
Following immunization of Lewis rats with myelin basic protein (MBP) EAE and AU appear 
to manifest simultaneously, but AU has a longer clinical course and often persists after 
clinical signs of EAE have subside. Interestingly after the initial episode of EAE, rats develop 
a total resistance to further attempts to induce active EAE but are susceptible to further 
episodes of uveitis. The inflammatory cells in the proximity of nerve bundles and iris vessels 
consist mainly of monocytes. 
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Table 1.3. Comparison of animal models for autoimmune uveitis.  
Model Antigen Target Clinical relevance 
EAU S-Antigen 
IRBP 
Rhodopsin 
Recoverin 
Phosducin 
Retinal photoreceptors Posterior uveitis 
EIU LPS Anterior uveal epithelium Recurrent anterior uveitis 
Posterior uveitis 
EMIU Melanin Uveal melanocytes Anterior uveitis 
Posterior uveitis 
EAE/AU MBP Myelinated iris nerves and spinal cord Anterior uveitis 
MS  
 
IRBP: Interphotoreceptor Retinoid Binding Protein; MS: Multple Sclerosis 
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1.3. CYTOKINES 
Cytokines are regulatory, soluble proteins of a relative small size (10-45 Kd) produced by 
cells in different organs in response to a variety of inducing stimuli. They constitute a diverse 
group of molecules with a wide range of effects, including pro-inflammatory, anti-
inflammatory, and chemoattractant functions. They play an important role in controlling cell 
proliferation and cell differentiation phenotype. They are involved in regulating the immune 
response to foreign antigens and other forms of defence against infection by viruses and other 
pathogens. They are also required for cellular renewal, wound healing, development of 
cellular, humoral immunity, and inflammatory responses. Cytokines transduce signals from 
the outside of the cell by binding to specific cell-surface receptors, activating a series of 
intracellular protein kinases which control gene and protein expression via factors such as 
NFκβ.   
 
The combination of cytokines and their concentrations at a specific site may differ, and their 
action on a given tissue or cell can be influenced by the microenvironment of the target cell. 
These pleiotropic effects make cytokines able to induce many different types of responses, 
often on different cell types. 
Due to the overlap in their biological effects and mechanisms of action classifying these 
molecules has been difficult; in addition to this, cytokine effects are typically redundant as 
different cytokines may induce the same biological effect. Hence, although cytokines are 
generally classified according to the type of receptor they bind, their nomenclature attempts to 
reflect their main function and order of their discovery. 
Functionally, cytokines can be divided into pro-inflammatory e.g.: TNF-α, anti-inflammatory 
e.g.: IL-10, proliferative e.g.: CSF3 (GCSF), regulatory e.g.: TGF-β, and chemokines, and the 
balance between them has been shown to determine the degree of inflammatory response. 
Several studies have shown cytokine and chemokine release during intraocular inflammation 
(Ahn et al. 2006b; Hill et al. 2005; Takase et al. 2006).  
 
1.3.1. Molecular basis of cytokine action 
Cytokines work in a network where the response of an individual cell will depend upon the 
pattern of cytokines it is subjected to, and to the set of cytokine receptors that it expresses. 
Many cytokines work by causing aggregation of receptors at the cell surface, leading to the 
activation of second messenger systems.  These effects mostly occur in the same cell that 
produces them in an autocrine manner or in cells that are close by in a paracrine fashion.  
 
Cytokine action can be regulated at an extracellular level and is determined by the amount 
and duration of availability of the cytokine produced, as well as the strength and distance 
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between the target cell and the cytokine producing cell. The cellular milieu that may respond 
to the cytokine signal is in turn determined by the expression of the cytokine receptors on the 
cell surface (Ishihara et al. 2002b). 
Inside the cell, cytokine signalling is regulated at the cell membrane in the cytoplasma and in 
the nucleus. Following cytokine binding to its specific receptor, a specific transduction 
pathway is activated and regulated by different adaptor molecules. The set of genes 
transcribed by these transduction pathways will help to determine the final biological output 
(Ishihara & Hirano 2002b), and although these signaling pathways are well characterized 
most of the studies are limited to a single pathway, which fails to demonstrate the complexity 
of the inflammatory responses. 
Important mediators for the main cytokine signal-transduction pathway are the Janus kinases 
(JAKs) and signal transducers and activator of transcription (STATs). Cytokine receptors in 
general lack intrinsic tyrosine kinase activity and hence, need to liaise with receptor-
associated kinases in order to initiate a phosphorylation cascade. Ligand binding to a cytokine 
receptor induces the homo- or heterodimerization of the receptor subunits and activates the 
JAK family tyrosine kinases, which induce the tyrosine phosphorylation of the receptor’s 
cytoplasmic tail. Some of these phosphorylated tyrosines serve as docking site for STATs. 
Once bound to the receptor, STATs are then phosphorylated, resulting in the acquisition of 
high-affinity DNA-binding activity, which facilitates their action as nuclear transcription 
factors. Seven STATs arranged across three different chromosomes have been described to 
date in mammalian cells. They differ by a SH2 domain that contributes to their selective 
response to cytokines (Schindler et al. 2007). Among them, STAT3 is required for the 
regulation of naïve T cells towards the development of Th17 cell lineage and recent data has 
suggested that targeted deletion of STAT3 in CD4+ cells may prevent the development of 
EAU (Liu et al. 2008). Moreover, most of our knowledge of pro-inflammatory signaling 
pathways comes from members of the TNF, IL-1, IL-6 cytokine families and more recently 
TLRs, where this cooperative induction of gene expression is dependent on the presence of 
binding sites for STAT and NFκβ (Yoshida et al. 2004). NFκβ transcription factors not only 
regulate genes which are essential for both the innate and adaptive immune responses (Brown 
et al. 2008) , but also recent research has focused in the development of anti-inflammatory 
therapies targeting NFκβ (Karin et al. 2004), as well as demonstrated the role of NFκβ in the 
resolution of inflammation (Fong et al. 2008; Lawrence et al.) (Figure 1.5). 
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Figure 1.5. Factors involved in the determination of cell specificity of a cytokine. From 
Ishihara et al. (Ishihara & Hirano 2002b). 
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1.3.2. Cytokine genes polymorphisms 
Cytokines are key players in the regulatory mechanisms of the immune system, and it is clear 
that variations in their levels (quantitative) or changes in their structure (qualitative) have 
been associated with disease susceptibility and different clinical outcomes (Smith et al. 2009). 
One of the approaches to investigate their role is through the study of candidate cytokine gene 
polymorphisms using case-control association studies, and the genetic markers used in most 
of these population-based studies are single nucleotide polymorphisms (SNPs).   
A SNP is an inherited change of a single nucleotide in the DNA sequence, and is 
distinguished from rare variations in that the less frequent allele is required to have a 
frequency of 1% or more. Biallelic SNPs are highly abundant across the genome and are often 
used in association studies, and the frequencies of polymorphic alleles vary between different 
populations (Cross et al. 2010; Huang et al. 2007). 
Thus, multiple SNPs can often be found within the whole length of a gene but only those 
located in exons of cytokine genes can alter amino acid sequences that subsequently lead to a 
change in a protein function (Figure 1.6). Although cytokine expression is typically 
modulated by polymorphisms within the promoter regions of the cytokine genes (Lu et al. 
2008b), SNPs that are not in protein-coding regions have been found to influence 
transcription factor binding (Schena et al. 2006). 
 
A large number of polymorphisms within the coding and non-coding region have been 
identified and thousands of disease-association studies have been carried out using these 
variants. In this literature review I have summarized those cytokines and chemokines that 
have been the centre of the different studies of this thesis, which in turn have been reported in 
the literature to be associated directly with intraocular inflammation and related autoimmune 
inflammatory disorders. 
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 Figure 1.6. Cytokine gene SNPs and their possible consequences. From Ollier WER. (Ollier 
2004). 
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1.3.2.1. TNF-α 
The prominent role of TNF in inflammation has been convincingly demonstrated by many in 
vitro and animal studies, such as those that show that transgenic mice expressing human TNF 
coupled to the 3’ untranslated region of β globin developed severe arthritis. Furthermore, the 
evidence for TNF involvement in the pathogenesis of human autoimmune disease is 
highlighted by the efficacy of TNF-blockage in the management of a wide spectrum of 
autoimmune disorders such as Crohn’s disease and rheumatoid arthritis (RhA) (Lin et al. 
2008).  
However the biological functions of TNF are complex and on occasion contradictory. While 
during the acute phases of inflammation local production of TNF appears to be beneficial, as 
it increases the expression of adhesion molecules on the vascular endothelium allowing for 
neutrophils and macrophages to recruit locally at the site of inflammation, prolonged 
exposure to TNF has been associated with severe toxic shock induced by bacterial endotoxins.  
TNF is a pro-inflammatory cytokine with immunomodulatory activity. There are two forms of 
TNF, a 26 Kd membrane bound form and a mature secreted 17 Kd form which is released 
following enzymatic cleavage by a metalloproteinase disintegrin called TNF-α converting 
enzyme (TACE), which also controls the amount of circulating soluble form of TNFR2 
(Peschon et al. 1998).  
In humans TNF- α is produced mainly by monocytes/macrophages, although T and B 
lymphocytes, fibroblasts, and epithelial cells also produce significant amounts (Vassalli 1992; 
Wilson et al. 1997). Abnormally high levels of TNF-α are produced mainly by macrophages 
and T cells (Brinkman et al. 1997), in particular after the stimulation of macrophages by LPS 
following incubation of macrophages with IFN-γ (Wilson et al. 1997), gram-positive and 
gram-negative bacteria, mycobacterium tuberculosis, red blood cells infected with 
Plasmodium falciparum, different viruses, as well as major histocompatibility complex 
(MHC) class ligands such as bacterial superantigen toxic shock syndrome toxin 1 and 
staphylococcal enterotoxin B (Underhill et al. 1999). Other cytokines such as IL-2 or 
granulocyte-macrophage colony-stimulating factor may also induce TNF release from 
macrophages (Vassalli 1992).  
 
The TNF-α gene is located in the HLA class region of the MHC on the chromosome 6p21,3 
approximately 250 kilobases (kb) centromeric of the HLA-B locus and 850 kb telomeric of 
the HLA-DR in both humans and mice (Spies et al. 1989; Wilson et al. 1997). The 5’ flanking 
region of the TNF gene contains multiple regulatory sites structurally similar to these found in 
immunoglobulins and cytokine regulatory elements (Spriggs et al. 1992). The 3’ untranslated 
region, on the other hand also plays an important role in the transcription of the gene through 
clearance of mRNA transcripts.  
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 Most of the activities of TNF are mediated through two receptors TNFR1 and TNFR2. They 
belong to a family of receptors with repeating cystein-rich extracellular motifs. Both of them 
are present in almost all types of cells, but whereas TNFR1 has a ubiquitous distribution, 
TNFR2 is mostly confined to cells of the haematopoietic lineage (Armitage 1994; Ryffel et al. 
1993).  
The TNFR1 gene (TNFSF1A) is located on chromosome 12p13.2 and controls the induction 
of apoptosis (Bradley et al. 2001), cell activation (Vandevoorde et al. 1997), and B cell 
trafficking (Tkachuk et al. 1998). The TNFR2 gene is located on chromosome 1p36.2 and 
plays an important role in thymocyte and peripheral T cell proliferation, NK cell activation, 
apoptosis of activated T cell and neutrophil activation (Pantelidis et al. 1999). Binding of the 
trimeric ligands of TNF- α to the TNF receptor induces “molecular switching” of the receptor, 
which then induces the signals required for immune function (Bazzoni et al. 1996). 
 
The TNF cluster is located within the class III region of the MHC on chromosome 6p21, 
where genetic alterations in the TNF-α are involved in high TNF production (Tsukamoto et al. 
1998). TNF mediates its functions by binding to specific TNF receptors. Signalling through 
these receptors influences T cell proliferation and pro-inflammatory responses, and 
inappropriate signalling may trigger severe inflammatory reactions (Hajeer et al. 2000). This 
is based on in vitro observations that individual differences in cytokine levels after in vitro 
culture may be attributed to SNPs or microsatellite polymorphisms within the TNF gene.  
Eight DNA variants or SNPs have been described within the TNF promoter at positions -1031 
T/C, -863 C/A, -857 C/T, -575 G/A, -376 G/A, -308 G/A, -244 G/A, -238 G/A relative to the 
transcription start site (Bayley et al. 2004) (Figure 1.7). 
Among them, the two most commonly studies are -308 G/A polymorphism (rs1800629) and 
the -338 G/A polymorphism (rs361525). It is the presence of the less common A allele in the -
308 nucleotide position that is associated with enhanced TNF-α production (Mira et al. 1999). 
However; there still remains controversy with regards to the functional role of the TNF -308 
SNP. Whereas initial studies in the late 90s’ found the allele A to be responsible for a higher 
inducible levels of transcription than the allele G, suggesting that the -308 polymorphism in 
the context of TNF-α gene can effect transcription and induce elevated levels of TNF 
(Kroeger et al. 1997; Wilson et al. 1997), later reports have failed to demonstrate functionality 
for the -308 SNP (Kaijzel et al. 2001; Kroeger et al. 2000). Similarly, another putative 
functional promoter polymorphisms such as  -238 G/A (rs361525)  and -857 C/T (rs1799724) 
have also shown contradicting functionality (Bayley et al. 2001; Hohjoh et al. 2001; Kaluza et 
al. 2000), highlighting the complexity of the effect of SNPs on TNF in vitro. In summary, 
while the -308 G/A polymorphism appears not to affect TNF functionality, the function of 
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others remains controversial and haplotype analysis of the candidate gene may prove to be a 
more helpful approach (Bayley et al. 2004). 
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Figure 1.7. TNF complex in chromosome 6. From Elahi et al. (Elahi et al. 2009). 
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1.3.2.1.1. Influence of TNF-α gene polymorphisms on autoimmune disorders 
Despite the controversy on TNF gene polymorphisms on TNF production, it remains clear 
that TNF-α is a potent immune mediator and pro-inflammatory cytokine that is involved in 
the pathogenesis of many inflammatory disorders, and several studies have analysed the 
potential contribution of the above mentioned polymorphisms to susceptibility or severity of a 
wide range of conditions, in particular autoimmune diseases. Most autoimmune disorders are 
associated with specific HLA genotypes, and some of the associations between TNF-α 
polymorphisms could be explained by linkage disequilibrium (LD) with HLA and vice versa.  
There is a genetic contribution to RhA from several alleles of the HLA-DRB1 gene located in 
the MHC class II region (6p21) explained by the “shared epitope” theory (Michou et al. 
2006), however the important physiological role of the TNF-α gene within the MHC has lead 
to speculation about its role in RhA.  
A study where the data was stratified according to shared epitopes subtypes (HLA-DR1 and 
HLA-DR4) the TNF -308 A and TNF -857 T alleles were found to be associated with RhA in 
patients carrying the SE, furthermore the -308 A allele was significantly associated with RhA 
susceptibility in individuals heterozygous for the SE carrying HLA-DR4, while the -857  T 
allele was significant in individuals homozygous for the SE (Waldron-Lynch et al. 2001). 
Similarly, Date et al. demonstrated that the -857 T allele may increase the effect of the 
DRB1*0405/DQB1*0401 in predisposing to the development of systemic juvenile RhA (Date 
et al. 1999). In two different ethnic populations Ozen et al. did not find any associations 
between the TNF -238 G/A polymorphism and disease severity in juvenile idiopathic arthritis 
(Zheng et al.), but a worse outcome of disease in a Turkish children carrying the TNF -308 A 
allele (Ozen et al. 2002), which correlates with a more recent study showing a protective role 
of the TNF -308 G allele (Schmeling et al. 2006) 
 
TNF-α has a prominent role in the inflammatory process and bone resorption in patients with 
ankylosing spondylitis (AS). However, opinion remains divided as to whether TNF-α 
polymorphisms play a role in the pathogenesis of this disorder.  
Early studies by Fraile et al. and Verjans et al. failed to demonstrate any association between -
308 or -238 polymorphisms in a Spanish and Dutch populations (Fraile et al. 1998; Verjans et 
al. 1991). In another similar study in Dutch patients Kaijzel et al. found that although the 
frequency of the TNF -238 A allele was increased in HLA-B27 positive patients, this was not 
different from their HLA-B27 positive controls and therefore the authors concluded that the 
association between TNF -238 G allele and AS was secondary to the HLA-B27 gene (Kaijzel 
et al. 1999).  
In contrast, one study showed a significant association between the -238 A allele in HLA-B27 
negative patients and AS compared to the B27 negative control (Gonzalez et al. 2001). 
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Rudwaleit et al. found that HLA-B27 positive patients had lower numbers of TNF-α positive 
T cells in peripheral blood compared with controls, and heterozygous patients for the -308 
polymorphism were associated with a higher percentage of TNF-α positive T cells than 
homozygous patients for the allele G (Rudwaleit et al. 2001). Another two studies by 
McGarry et al. and Vargas-Alarcon in different populations demonstrated that TNF-α -308 
polymorphisms (allele G, and allele A, respectively) were involved in susceptibility to AS, 
but not with outcome (McGarry et al. 1999; Vargas-Alarcon et al. 2006). A more recent study 
in a Chinese population revealed a significant association between HLA-A333-B58-Cw10 
haplotypes and TNF-α -308 G/A polymorphisms independently, playing a possible role in the 
pathogenesis of AS (Lu et al. 2008a). 
A recent meta-analysis of the TNF-α -308 and -238 polymorphisms and AS susceptibility 
published recently showed no significant association in the overall population sample, nor did 
it reveal any significant association between the B27 positive patients and the matched B27 
positive controls (Lee et al. 2009).  
The frequencies of the TNF-α -308 GA and -238 GA genotypes were lower in patients with 
HLA-B27 positive associated AU than in patients who were HLA-B27 negative. In addition 
to this, when compared to healthy HLA-B27 positive individuals the frequency of the TNF-α 
-238GA genotype was also found to be lower among patients, suggesting that the presence of 
allele A at nucleotide -238 to be a risk factor for the development of intraocular inflammation 
among individuals who are HLA-B27 positive (El-Shabrawi et al. 2006). 
  
Several polymorphisms implicated in susceptibility to sarcoidosis as well as disease prognosis 
lie within the MHC class I and class II genes (Sharma et al. 2003), which are closely linked 
with the genes for TNF-α and LT-α. TNF-α not only regulates granuloma formation 
(Baughman et al. 2003) but its levels fluctuate with disease activity (Prasse et al. 2000). 
Similarly to AS, there is some heterogeneity in the TNF allelic association in different 
populations.  
A series of studies looking at the -308 and -238 polymorphisms in African American patients 
did not found any associations with sarcoidosis (Pandey et al. 2002; Rybicki et al. 2004). 
Although Yamaguchi et al. did not find any association with TNF-α polymorphisms in a 
Japanese cohort, the TNF-β allele 1 (LTA_Ncol_G) was found to be a marker for prolonged 
clinical course in Japanese patients with sarcoidosis (Yamaguchi et al. 2001). 
In an Indian population however, both TNF -308 G/A and TNF -238 G/A polymorphism were 
found to influence soluble levels of TNF-α and sACE. Additionally the haplotype GTCCGG 
was identified as a major risk factor for disease susceptibility, and increased levels of sACE in 
the patient population (Sharma et al. 2008). Grutters et al. found an increased of the rarer TNF 
-857 T allele in two different Caucasian populations from the UK and the Netherlands and a 
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subgroup analysis showed a significant increase in the less common TNF -308 A allele in 
patients with Löfgren’s syndrome, which correlates with Swider et al. findings in German 
patients (Grutters et al. 2002; Swider et al. 1999). 
 
TNF-α genes, in particular the -308 A/G polymorphism have been inconsistently associated 
with SLE where there is also a strong association with the HLA-DR antigen. A meta-analysis 
of 21 studies of this polymorphism concluded that the -308 G/A polymorphism may confer 
susceptibility to the disease in Europeans but not in Asian-derived population (Lee et al. 
2006). 
 
1.3.2.1.2. TNF-α therapy 
TNF-α has been detected in human eyes with a variety of inflammatory conditions (Ahn et al. 
2006b; Santos Lacomba et al. 2001b) and plays a key role in the regulation of the 
inflammatory process seen in EAU (Dick et al. 1998). Neutralising TNF in mice with EAU 
suppress the proliferative response seen to retinal antigens (Sartani et al. 1996). It is believed 
thought that activated T cells cannot cross the blood retinal barrier directly unless TNF-
mediated changes to the vessel endothelium occur (Xu et al. 2005). In the EAU model a 
constant feature is increased TNF expression and TNF modulates leukocyte migration. Its 
central role in ocular inflammation makes TNF-α an attractive target for immune therapy, 
although there remains some controversy as to whether TNF-blockage can suppress 
permanent histological damage (Robertson et al. 2003). 
Inhibition of TNF-α results in a decrease in adhesion molecules, pro-inflammatory cytokines 
as well as regulation of chemokines (Taylor et al. 2000).  
Accumulating evidence suggests that not only soluble TNF-α but also transmembrane TNF-α 
is involved in the inflammatory response (Horiuchi et al. 2010) and extensive clinical 
experience has shown a significant therapeutic effect from TNF inhibitors in both systemic 
and organ specific inflammatory diseases (Mitoma et al. 2008), in particular in those 
associated with inflammatory eye disease such as seronegative spondyloarthropathies, JIA, 
Crohn’s disease, and RhA (Theodossiadis et al. 2007). 
The use of anti-TNF-α antibodies has shown to be effective in the management of panuveitis 
in patients with Behçet’s disease (Sfikakis et al. 2001), and most recently the chimeric anti-
TNF-α monoclonal antibody infliximab has been shown to be safe and effective in the short 
and long-term treatment of refractory posterior uveitis (Benitez-del-Castillo et al. 2005; 
Joseph et al. 2003). Unfortunately, despite the clinical efficacy in treating joint disease in 
patients with coexisting arthritis and uveitis, the management of intraocular inflammation has 
not always been effective. This may be explained by the presence of unique cell adhesion 
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molecules, subsets of antigen-presenting cells, subsets of lymphocytes and cytokine profile in 
autoimmune diseases occurring in different organs (Smith et al. 2001).  
There are two monoclonal antibodies and a soluble receptor available for use clinically, which 
bind to soluble and membrane form of TNF-α and can neutralise the pathological effects of 
TNF-α. 
 
1.3.2.1.2.1. Etanercept 
Etanercept is a genetically engineered recombinant fusion protein that consists of two 
identical chains of the extra cellular human TNF-receptor p75 monomer fused to the Fc 
domain of human IgG1 (Mohler et al. 1993). This dimeric protein binds to circulating TNF 
and lymphotoxin-α preventing cell surface interaction and cytokine activation. It is normally 
given by subcutaneous injection at a dose of 25mg twice weekly, although studies have 
shown that 50mg once a week has equal effect to twice-weekly injections in patients with 
RhA. 
 
JIA is the most common systemic chronic autoimmune disease of childhood with about 30% 
of patients developing uveitis in the course of the disease, in particular those with 
oligoarticular or seronegative polyarticular disease (Schmeling et al. 2005). Given the 
significant clinical response seen with the use of etanercept in about 80% of patients with 
polyarticular JIA (Lovell et al. 2000), different groups have evaluated the efficacy and safety 
of etanercept in children with chronic uveitis associated with JIA that did not respond to other 
forms of immunosuppression. Reiff et al. observed that etanercept at a dosage of 0.4mg/kg 
was safe and effective in reducing intraocular inflammation in 63% of patients after 6 months 
(Reiff et al. 2001), and this effect was maintained for up to 2 years (Reiff 2003). A more 
marked difference between systemic and ocular outcomes were also demonstrated by 
Schmeling et al. who noted a significant or complete response of arthritis in 87% of patients 
with uveitis, whereas the frequency of uveitis flares seemed to be higher during the course of  
treatment with etanercept than during the pre-treatment period. In addition to this, two 
patients out of 229 developed uveitis for the first time while being treated with etanercept 
(Schmeling & Horneff 2005), suggesting that inhibition of TNF-α might contribute to the 
induction of exacerbating uveitis in certain circumstances. This paradoxical effect remains 
unexplained however, a “dechallenge-rechallenge” phenomena has been observed in EIU 
mice that were treated with either repeated injections of TNF-α or with a single injection of 
antibody against it. Although both treatments conferred protection against LPS, TNF-resistant 
mice and those treated with anti-TNF-α antibody demonstrated an exacerbation of EIU when 
compared with control mice, suggesting that this resistance to TNF involves an complex 
network of cytokines and unlike the systemic effect of LPS, TNF-α may not be the only 
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molecule involved in the pathogenesis of EIU and may even have a protective role in this 
disease (Kasner et al. 1993). 
 
1.3.2.1.2.2. Infliximab 
Infliximab is a chimeric IgG monoclonal antibody composed of human constant region and 
murine variable regions. It has a great affinity for TNF-α receptors and inhibits its activity 
(ten Hove et al. 2002). Differently to etanercept, it does not bind to lymphotoxin, and is 
administered by an intravenous infusion at baseline, 2 weeks, 6 weeks, and thereafter eight 
weekly. The dose varies from 3mg/kg in RhA to 5mg/kg in AS or psoriatic arthropathy, but 
higher doses of up to 20mg/kg have been used in a cohort of 17 children with chronic uveitis, 
with few side effects (Kahn et al. 2006). 
 
A great experience in the use of infliximab has been gained from its use in patients with AS, 
where uveitis is the most common extrarticular manifestation (Hamideh et al. 2001). A meta-
analysis by Braun et al. looking at the outcomes of 4 placebo controlled studies and 3 open 
labelled studies, showed a significant difference between the incidence of AU flares during 
placebo treatment and the incidence during treatment with anti-TNF-α agents. Although a 
subset analysis suggested that episodes of AU were less frequent in those on infliximab than 
on etanercept, this did not reached a statistically significant difference (Braun et al. 2005). A 
more recent retrospective study comparing the efficacies of anti-TNF-α antibody and the 
soluble TNF-α receptor treatments in reducing uveitis flares in patients with 
spondyloarthropathies showed a significant reduction in the number of uveitis flares per 
patient-years. However, subdata analysis showed that the soluble TNF-α receptor was not 
efficacious in reducing the occurrence of uveitis flares in these patients (Guignard et al. 
2006). In addition to this, there were two patients without any history of uveitis prior to anti-
TNF-α treatment that developed uveitis after being treated with etanercept.  
A single infusion of intravenous infliximab was highly effective in suppressing inflammation 
in a cohort of seven patients with HLA-B27 positive AAU, without any other adjuvant 
treatment other than topical cycloplegia (El-Shabrawi et al. 2002). Markomichelakis et al. 
demonstrated the effectiveness of a single dose of infliximab in reducing cystoid macular 
oedema (CMO) and improving vision in a small series of patients with refractory uveitis, 
including one patient with HLA-B27 positive AU (Markomichelakis et al. 2004). This data 
suggests that infliximab is an effective and relatively safe agent in the treatment of acute 
HLA-B27 uveitis, in particular in the management of very severe cases. 
Although it appears that in patients with JIA etanercept may be more efficacious and be better 
tolerated than infliximab (Lahdenne et al. 2003), their efficacy in controlling the course of 
uveitis is not clear, and a few small case series reporting the use of infliximab in the 
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management of refractory uveitis associated with JIA suggest a better efficacy in controlling 
ocular inflammation, in particular as an adjuvant agent to simultaneous immunosuppressive 
therapy (Murphy et al. 2004; Richards et al. 2005).  
 
1.3.2.1.2.3. Adalimumab 
Adalimumab is a fully humanised IgG1 monoclonal antibody that binds with high affinity and 
specificity to TNF and neutralises the biological activities of this cytokine by blocking its 
interaction with the p55 and the p75 cell surface receptors (Kempeni 1999; Kempeni 2000). 
Similarly to etanercept, it is given by subcutaneous administration at a usual dose of 40mg at 
two weekly intervals. It has shown to be efficacious in children with chronic uveitis 
associated with arthritis who did not respond to previous anti-TNF therapy, especially in 
younger patients and these with shorter duration of JIA (Tynjala et al. 2008). In a mixed 
cohort of children with JIA associated uveitis and of idiopathic origin, adalimumab showed an 
improvement or stabilization of the uveitis in 94% of eyes (Vazquez-Cobian et al. 2006). 
Furthermore, as opposed to the results seen in children with CAU associated to arthritis 
adalimumab seem to be much more effective in controlling intraocular inflammation that it is 
against the arthritis (Biester et al. 2007). 
 
Although treatment with TNF-blockers is generally safe and initial studies did not show a 
significant increase in adverse side effects, Kavanaugh et al. and Weinblatt et al. reported a 
number of infections in patients with RhA treated with etanercept (Kavanaugh et al. 2000; 
Weinblatt et al. 1999), and therefore TNF inhibition should be avoided in patients with acute, 
recurrent or chronic infections. Another side effect of anti-TNF therapy is the development of 
anti-double stranded DNA antibodies. This was only seen in the group of patients treated with 
infliximab and was not necessarily associated with the development of lupus-like disease. 
Interestingly, one of the side effects reported by Smith et al. was the development of 
intraocular inflammation for the first time in patients taking etenarcept (Smith et al. 2001). 
Special caution has to be paid when treating pregnant women, since the presence of TNF in 
mouse embryos suggests the role of TNF in embryogenesis and may have implications in 
anti-TNF therapy during pregnancy (Vassalli 1992). 
 
1.3.2.2. Interleukin-1 
The complexity of the cytokine network is epitomised by the IL-1 family. IL-1 is located in a 
430 kb region in the human chromosome 2q14 region and contains three related genes that 
encode the pro-inflammatory cytokines IL-1α, IL-1β, and IL-1RN (Nicklin et al. 2002) 
(Figure 1.8). 
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The product of IL-1RN is the endogenous receptor antagonist or IL-1ra (Eisenberg et al. 
1990; Seckinger et al. 1987). There are two known specific receptors for IL-1. The 
biologically active type I receptor (IL-1RI) and an inactive type II (IL-1RII), which binds IL-
1 preventing from interacting with the functional IL-1RI (Colotta et al. 1994). 
IL-1 has been implicated in the modulation of autoimmune disorders including uveitis 
(Dinarello et al. 1993), and it is upregulated in eyes with EAU and uveitis (El-Shabrawi et al. 
2000).  
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Figure 1.8. Map of the IL-1 gene cluster on chromosome 2. From Smith et al. (Smith & 
Humphries 2009). 
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1.3.2.2.1. Interleukin-1 receptor antagonist 
IL-1ra family includes one secreted isoform (sIL-1ra) and three intracellular isoforms (icIL-ra 
1, 2, and 3). The secreted isoform variety binds to IL-1 receptors (type I and type II) located 
on the plasma membrane of many different cells with similar avidity than IL-1α and IL-1β but 
without inducing intracellular responses (Hannum et al. 1990). The intracellular isoforms on 
the other hand bind to IL-1 receptors and inhibit the stimulatory effects of IL-1, making IL-
1ra the natural antagonist of IL-1 by competitive binding to a specific receptor (Merhi-Soussi 
et al. 2005).  
Imbalances in the IL-1 and IL-1ra system have been shown to be important in the 
development and outcome of inflammatory diseases (Arend 2002; Mikuniya et al. 2000). 
More recent research has confirmed downregulation of pro-inflammatory cytokines such as 
IFN-γ and IL-17 in the IL-1 knockout mice, while IFN-γ, IL-17, and TNF-α  were upregulated 
in the IL-1ra knockout mice, confirming that the IL-1/IL-1ra system is crucial for auto-
antigen-specific T cell induction and contributes for example to the development of EAE 
(Matsuki et al. 2006).   
 
IL-1ra is released in vivo during experimentally induced inflammation and is thought to be 
part of a naturally occurring feedback mechanism to limit the extent of IL-1 activity 
(Dinarello 1991). In experimental and animal models of arthritis neutralizing antibodies to IL-
1ra exacerbated the LPS-induced arthritis in rabbits, and the administration of IL-1ra 
suppressed inflammation and tissue damage (Zheng et al. 2006). Similar effects have been 
observed in other inflammatory disorders such as IBD (Ludwiczek et al. 2004).   
 
1.3.2.2.1.1. IL-1ra allele polymorphisms and disease 
The IL1RN gene contains an 86bp variable-number tandem repeat (VNTR) or IL1RN*2 in 
intron 2, which is in LD with other polymorphisms in IL1RN, among them one at position 
+2018 within exon 2 (Cox et al. 1998; Tarlow et al. 1993). Although the frequency of 
different alleles varies depending on the studied population, the frequency of allele 1 (IL-
1RN*1) in every population studied to date is more common than the allele 2 (IL-1RN*2) 
(Mwantembe et al. 2001). 
IL-1RN*2 has been associated with an increased production of IL-1ra in vitro upon 
monocytes stimulation with several cytokines including TNF-α (Danis et al. 1995). This 
findings have been replicated by Hurme et al. who found increased plasma levels of IL-1ra in 
healthy blood donors who carried the IL-1RN allele 2 (Hurme et al. 1998). However, IL-
1RN*2 allele has also been linked to decreased IL-1ra levels when compared to other alleles, 
most likely due to the heterogeneity of disorders and ethnic groups studied and in a recent 
study by Rafiqet al. 5 out of 7 genotyped IL-1RN SNPs were associated with plasma IL-1ra 
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with varying degree of significance (Rafiq et al. 2007). The authors found several SNPs to be 
in LD, in particular the IL1RN (rs579543) variant allele, which is known to influence 
circulating levels of IL-1ra with highest production in carriers of the homozygous TT 
genotype (Graziano et al. 2009). 
 
Several studies have shown an association between the IL-1RN*2 allele and a variety of 
different autoimmune or inflammatory diseases and the majority of these cases have been 
associated with severity rather than a predisposition to acquire the disease. Different authors 
have reported an association between IBD and IL-1RN*2. Andus et al. found that patients 
with IL-1ra genotype 2 had significantly reduced concentrations of IL-1ra in inflamed mucosa 
of patients with IBD, particularly these with Crohn’s disease (Andus et al. 1997). Patients 
who carried the IL-1RN*2 allele but not the IL-1β allele 2 were found to have an increased 
susceptibility to ulcerative colitis and Crohn’s disease. Since non-carriers of IL-1β allele 2 
were more often present in the subgroup of patients carrying the IL-1RN*2, and no 
association of these alleles was detected in the group of healthy controls, the authors 
concluded that the IL-1β/IL-1RN allelic cluster may participate in the susceptibility to chronic 
IBDs (Bioque et al. 1995). Given that both ulcerative colitis and Crohn’s disease are 
associated with SpA, polymorphisms in IL-1RN have also been investigated and two separate 
studies in two different European populations found that the allele IL-1RN*2 was 
significantly increased in AS, compared to healthy individuals, independently from other 
polymorphisms in the IL-1β gene (McGarry et al. 2001; van der Paardt et al. 2002).  Increased 
susceptibility but no disease activity or severity were reported in patients with JIA who had an 
increase carriage of IL-1RN*2 compared to a control group (Vencovsky et al. 2001).  
 
1.3.2.2.1.1.1. IL-1ra therapy 
Gene therapy with IL-1ra was tried with success in the animal model for the treatment of 
arthritis (Pan et al. 2000), and Bresnihan et al. confirmed both the efficacy and safety of the 
treatment with subcutaneous recombinant human IL-1ra in patients with severe and active 
RhA (Bresnihan et al. 1998). Similar studies have followed, and treatment with IL-1ra 
showed a retarded radiographic disease progression in patients with RhA (Jiang et al. 2000).  
Human recombinant IL-1ra has shown to inhibit the inflammatory response triggered by IL-1 
when injected into the anterior chamber or intravitreally as shown in different studies 
(Bhattacherjee et al. 1987; Rosenbaum et al. 1987). Rosenbaum et al. found that IL-1ra 
decreased the cellular infiltration and protein extravasation after the administration of 
intravitreal IL-1α.when given within two hours after the initial administration of IL-1α 
(Rosenbaum et al. 1991). Interestingly, intravitreal injection of IL-1ra inhibited IL-1 induced 
inflammation in the animal model, but failed to reduce the inflammation secondary to the 
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intravitreal administration of endotoxin possibly due to the presence of other pro-
inflammatory cytokines or that the effects of IL-1 were primarily intracellular and therefore 
resistant to the activity of exogenous IL-1ra (Rosenbaum et al. 1992).  
Conversely, the results of another experiment showed that human IL-1ra injected in the 
anterior chamber decreased the postoperative inflammation after intraocular lens implant in 
the rabbit eye (Nishi et al. 1994), and more recently Lim et al. showed a significant decrease 
in the cellular immune response and in the expression of cytokines such as IFN-gamma, TNF, 
IL-1β, IL-1α, and IL-6, supporting the role of IL-1ra in immune responses of immune-
mediated ocular inflammation (Lim et al. 2005).  
Current research has also shown an increase in corneal allograft survival rate following 
topical administration of IL-1ra eye drops through an inhibitory effect on CD1-positive cells 
in high risk corneal transplantation (Jie et al. 2004). 
 
1.3.2.2.1.1.1.1. Anakinra 
Anakinra is the commercially available antagonist to IL-1 receptor. It is a recombinant 
version of the human IL-1ra (rHuIL-1Ra) (Hannum et al. 1990). IL-1ra is released in vivo 
during experimentally induced inflammation as part of a naturally feedback mechanism 
(Dinarello 2005), and blocks IL-1 action by binding to its receptor (Hannum et al. 1990), but 
does not result in signal transduction (Dripps et al. 1991). It was initially used in patients with 
RhA showing significant improvement on clinical, laboratory, and radiological parameters 
(Bresnihan et al. 1998; Jiang et al. 2000). Similarly IL-1 has been implicated in the mediation 
of uveitis and is up-regulated in eyes with EAU (El-Shabrawi et al. 2000; Foxman et al. 
2002).  
Not all forms of chronic inflammatory arthritis depend on TNF. Pascual et al. found an 
increase in expression of IL-1b by circulating mononuclear cells, and a dysregulation of IL-1 
production in patients with systemic onset JIA (Pascual et al. 2005). They administered 
subcutaneous, recombinant IL-1ra to a small group of patients with systemic onset JIA, who 
did not respond to other forms of immunosuppression including anti-TNF agents. All patients 
had a significant improvement in their clinical symptoms and laboratory findings. With a 
similar rational Teoh et al. showed a successful outcome of the use of subcutaneous anakinra 
in a patient with CINCA syndrome and panuveitis who had showed resistance to previous 
treatment with etanercept (Teoh et al. 2007). Previous to this report, Matsubayashi et al. had 
already demonstrated the benefits of anakinra in the use of CINCA associated ocular 
complications (Matsubayashi et al. 2006). 
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1.3.2.3. Interleukin-6 
IL-6 is a multifunctional cytokine with a molecular weight (MW) ranging from 21 to 28 Kd 
produced by a wide variety of cells of the innate immune system, such as dendritic cells, 
monocytes, macrophages, lymphocytes and PMNs, but also by other type cells which include 
fibroblasts, epithelial cells, endothelial cells and smooth muscle cells, regulating the immune 
response, hematopoiesis, the acute phase response, and inflammation (Ishihara et al. 2002a). 
IL-6 signaling is regulated by negative feedback of suppressors of cytokine signaling and the 
protein inhibitors of activated STATs. IL-6/IL-6 receptor interaction leads to activation of 
STAT3, which in turn targets the suppressors of cytokine signaling (Kishimoto 2006). IL-6 
can also elicit the development of specific cellular and humoral immune responses, including 
end-stage B cell differentiation, and T cell activation, suggesting the importance of IL-6 in 
modulating the transition between acute and chronic inflammation (Kaplanski et al. 2003), 
and overproduction of IL-6 leads to inflammation and several autoimmune disorders (Ishihara 
& Hirano 2002a). 
 
1.3.2.3.1. Association studies of IL-6 with disease 
Since the first report indicating that high levels of IL-6 in synovial fluid from the joints of 
patients with RhA were responsible for the possible involvement of IL-6 in RhA (Hirano et al. 
1988) a vast number of studies have demonstrated the involvement of IL-6 in the 
pathophysiology of other arthritic diseases (Ishihara & Hirano 2002a). A more recent study 
looking at the gene expression of IL-6 in children with autoimmune arthritis confirmed the 
circulating monocytes as the main cellular type expressing IL-6 in children with active 
systemic JIA (Ogilvie et al. 2007). Concentrations of IL-6 in synovial fluids correlated 
positively with the amount of infiltrative cells in synovial tissue in patients with RhA 
(Matsumoto et al. 2006). Serum levels of IL-6 are found to be elevated in patients with 
Crohn’s disease and they correlate with disease activity, and treatment response (Reinisch et 
al. 1999). Analysis of inflamed intestinal mucosa in patients with IBD revealed higher 
amounts of IL-6 than in intestinal mucosa with inactive disease and local infiltrating T cells, 
macrophages and B cells as being the cellular source of localised IL-6 production in this 
patients (Mitsuyama et al. 1991; Stevens et al. 1992). IL-6 transcripts are elevated only in 
patients with active IBD, confirming not only the role of IL-6 in mediating inflammation in 
the intestinal mucosa but also its involvement in the pathogenesis of IBD (Matsuda et al. 
2009). 
IL-6 can induce T cell expression of IL-2 receptor, which in turn would activate the 
proliferation of T cells in the presence of IL-2 and consequently enhance a positive feedback 
caused by the spontaneous release of IL-2 from T cells in sarcoidosis (Lotz et al. 1988), where 
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augmented expression of the IL-6 gene has shown to correspond with increases in IL-6 levels 
in BAL fluid, alveolar macrophages and alveolar fibroblasts (Balamugesh et al. 2006).  
 
1.3.2.3.1.1. IL-6 and uveitis 
Studies from two different groups have demonstrated a high concentration of IL-6 among 
other pro-inflammatory cytokine and chemokines AqH of patients with idiopathic intraocular 
inflammation (Ooi et al. 2006; Takase et al. 2006) and more interestingly, the level of IL-6 
correlates with the number of neutrophils present in the cellular milieu in the AqH (Curnow et 
al. 2005).  Serial sampling of AqH of a murine model of EAU demonstrated an increased 
local production of IL-6 at the onset of the diseases followed by a decrease as the 
inflammation settled (Ohta et al. 2000). In agreement with this finding serum levels of IL-6 in 
a small group of heterogeneous types of uveitis were found to be significantly elevated durin 
ghte acute phase of the disease, and decreased during remission (Kramer et al. 2007). 
Furthermore a comparison between AqH and serum levels of IL-6 from patients with uveitis 
showed significant higher levels in AqH than in serum (Santos Lacomba et al. 2001a). These 
findings suggest the pathogenic role of this cytokine in uveitis.  
 
1.3.2.3.2. IL-6 gene and polymorphic sites 
The human IL-6 gene is located in the 7p21 chromosome; it is approximately 5 kb in length 
and consists of five exons and four introns. The human IL-6 is synthesized as a precursor 
protein of 212 amino acids. Whereas the first 28 amino acids can be removed without 
affecting significantly the biological activity of IL-6, the removal of only 4 amino acids from 
the C-terminal of the IL-6 molecule may result in a complete loss of its biological activity 
(Kruttgen et al. 1990). The IL-6 gene does not contain any common polymorphism within 
coding regions, and thus most of the research has focused on promoter polymorphism. There 
are four described genetic polymorphisms in the IL-6 promoter (-597G/A, -572G/C, -373A/T, 
and -174G/C) (Terry et al. 2000), which are naturally occurring haplotypes. The -174 G/C 
(rs1800795) polymorphism in the 5’ flanking region appears to affect IL-6 transcription 
(Figure 1.9).  
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Figure 1.9. Schematic representation of the 5’flanking region of the IL-6 gene, showing the 
four polymorphic sites, transcription factor binding sites, primer binding sites, and restriction 
enzyme cutting sites used for cloning. From Terry et al. (Terry et al. 2000). 
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Fishman et al. characterized this SNP in a Caucasian population from North London, by 
creating a luciferase reporter construct of the 5’flanking region (-550 to +61bp). After 
transfection into HeLa cells a reduction of the -174 C allele was observed, whereas after 
stimulation with LPS, expression of the -174 C allele did not change, but the construct 
containing the -174 G allele showed a significant increase (Fishman et al. 1998). Terry et al. 
designed a construct that contained the haplotypic variants of the proximal promoter (Terry et 
al. 2000); when using the smallest construct (-221 to +13bp) they demonstrated an increase in 
the construct containing the -174 C allele following IL-1β stimulation, although this was not 
statistically significant. Using the larger construct (-641 to +13bp), they found an increase in 
IL-1β-stimulated HeLa cells for all haplotypes, and following treatment with dexamethasone 
all haplotypes except AG28/12G showed a reduction in expression. The AG28/12G haplotype 
is a lower producer than the AG28/12C suggesting that the -174 C allele is involved in greater 
IL-1 stimulation. The authors concluded that IL-6 promoter polymorphisms may have an 
influence on transcription through complex interactions determined by the haplotype type, 
and that alone they are not functional.  
A meta-analysis of the -174 G/C and levels of IL-6 has been unable to show any correlation 
after looking at a total of 5659 subjects, adding further evidence to the existence of additional 
loci that may have a role in IL-6 expression (Huth et al. 2009). 
 
Nevertheless, higher levels of IL-6 have been associated with the presence of allele C and CC 
genotype in patients with chronic inflammation (Foster et al. 2000). The acute inflammatory 
response seen after coronary artery bypass surgery is also associated with the release of IL-6, 
specially in these patients who carried at least one C allele of either the -174 or -572 
polymorphisms compared to those who were homozygous for the allele G (Brull et al. 2001). 
Homozygous patients for allele G have been related to increased plasma levels in patients 
with primary Sjogren’s syndrome, although in this study the G/C base exchange 
polymorphism at position -174 did not predispose patients to developing the disease 
(Hulkkonen et al. 2001b). In type I diabetics of Caucasian origin, a significant increase in the 
frequency of the G allele compared to normal controls and a corresponding decrease of the C 
allele frequency was found. There was also a higher frequency of homozygous for the allele G 
in the diabetic groups compared with normal controls (Jahromi et al. 2000). There is evidence 
of increased production of IL-6 among other pro-inflammatory cytokines within inflammatory 
cells in Kaposi sarcoma lesions promoting the development of Kaposi sarcoma in HIV 
infected subjects. In this group of patients, those who were homozygous for allele G were 
associated with increased IL-6 production and were over represented (Brockmeyer et al. 
1999). On the other hand, two different studies concluded that the IL-6 G/C promoter 
polymorphism did not contribute to susceptibility to develop SLE in Caucasian patients 
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(Linker-Israeli et al. 1999; Schotte et al. 2001). Similarly, no significant differences were 
found in the allele, genotype, or carrier frequencies of this functional promoter polymorphism 
in patients with IBD (Klein et al. 2001). 
 
1.3.2.4. Interleukin-10 
IL-10 is a 40 Kd regulatory cytokine, whose main role is to inhibit the production of pro-
inflammatory cytokines. Constitutively produced endogenous IL-10 ameliorates the 
development of EAU by suppressing the de-novo priming of antigen-specific T cells and 
inhibiting leukocyte recruitment (Agarwal et al. 2008) as an example of the inhibitory 
functions of IL-10. NADPH oxidase 1 (Nox1) has been recently identified as multicompetent 
enzyme upregulated by TNF-α in colon epithelial cells (Kuwano et al. 2008), which in turn is 
down-regulated by IL-10 in colon epithelial cells (Kamizato et al. 2009). 
 
The gene encoding IL-10 is located in chromosome 1 at 1q31-32 and is expressed by CD4+ T 
cells, CD8+ T cells, monocytes, macrophages, keratinocytes, and activated B cells (Kim et al. 
1992; Powrie et al. 1997). Human IL-10 complementary DNA (cDNA) exhibits a high degree 
of nucleotide homology with mouse IL-10; the only difference being the insertion of a human 
Alu repetitive sequence element in the 3’ untranslated region of the human IL-10 cDNA clone 
(Moore et al. 2001).  
The 5’-flanking region of the human IL-10 gene contains two dinucleotide repeats, IL-10G 
and IL-10R located at 1.1 Kb and 4.0 kb respectively upstream of the transcription initiation 
site (Eskdale et al. 1995; Eskdale et al. 1996), indicating that innate differences in IL-10 
production are locus-dependent.  
The IL-10 proximal promoter region contains several SNPs including -1082 G/A (rs1800896), 
-819 C/T (rs1800871), and -592 C/A (rs1800872) which produce three haplotypes in 
Caucasians (GCG, ATA, ACC) (Smith & Humphries 2009). Rees et al. showed that the IL-10 
-1082 G/A polymorphism occurs within an ETS-like transcription factor binding site (Rees et 
al. 2002), and is in LD with the -819 C/T and  -592 C/A polymorphisms.  
 
1.3.2.4.1. Association studies of IL-10 polymorphisms with disease 
Crawley et al. examined the functional significance of the IL-10 gene in the -1137 to +25 
region from individuals homozygous for the IL-10 haplotypes mentioned above (Crawley et 
al. 1999). The ATA construct conferred weaker transcriptional activity than GCC, and IL-10 
levels measured from LPS-stimulated whole blood were found to be lower in those subjects 
who were homozygous for the ATA haplotype. These results have been reproduced by Suarez 
et al. in a Caucasian population from Northern Spain using RT-PCR quantified extracted 
mRNA. Levels of mRNA expression were significantly increased in individuals carrying the 
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GCC/GCC genotype, compared to those carrying the ATA/ACC genotype (Suarez et al. 
2003). When they analyzed the genotypes at -1082 separately, they found a significant 
difference between the -1082 genotypes independent of the -819/-592 genotype, suggesting 
that -1082 may be the most important functional SNP. They also conclude that although not 
significant, there was a trend for higher IL-10 levels among individuals who were 
homozygous for the -1082 G genotype. More recently, the same group of authors examined 
the influence of these polymorphisms in patients with IBD (Castro-Santos et al. 2006). 
Stratified analysis demonstrated a significant association between the -1082 AA genotype 
(low IL-10 producers) and severe disease, in agreement with previous findings from Tagore et 
al. who showed a decreased IL-10 G allele in patients with IBD (Tagore et al. 1999). 
Looking at patients with rheumatoid disease, Huizinga et al. demonstrated more severe organ 
damage in patients with RhA with the -1082 AA genotype compared to those with the -1082 
GG genotype (Huizinga et al. 2000).  
 
1.3.2.5. Th 17 cytokines 
One of the essential characteristics of the recently described Th17 lineage of CD4+T cells is 
their ability to produce IL-17A. Recent studies have shown that these cells also express IL-
17F, IL-22, and IL-21 and although their existence had already been reported, they were 
thought to originate from a different T cell type. Differentiation of these Th17 cells is partly 
driven by TGF-β, with contributions by IL-1, TNF-α, but mostly by IL-6 through a complex 
process that involves activation of different transducer and activator of transcription factors 
such as retinoid-related orphan receptor-γt and STAT3 (Kimura et al. 2007; Leppkes et al. 
2009).  
 
1.3.2.5.1. Interleukin-17 
The IL-17 family of cytokines includes IL-17A also called IL-17, IL-17B, IL-17C, IL-17D, 
and IL-17F. IL-17E (IL-25) is not produced by Th17 cells, but by Th2 cells, and might be 
involved in Th2-type allergic responses. IL-17A and IL-17F occupy the same location on 
chromosome 6p12 (Kawaguchi et al. 2004), and can form a hetrodimeric cytokine, which 
mediates biological activities, through shared receptors (Figure 1.10).  
Upregulated Th17 responses or increased IL-17 production has now been linked with chronic 
inflammation. Most cells expressing IL-17 receptors can produce pro-inflammatory factors 
such as IL-1, IL-6, TNF, or IL-18 among many others that are involved in the pathogenesis of 
chronic inflammatory conditions like RhA, psoriasis, IBD, or MS. In RhA, the production of 
TNF, IL-1, and IL-17 by synovial cells is predictive of joint damage (Kirkham et al. 2006). 
IL-17 together with IL-6 is highly expressed in brain lesions of patients with MS. 
Furthermore in these patients where the lesions are restricted to the optic nerve and spinal 
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cord, the levels of IL-17 and IL-8 in serum and CSF are found to be significantly higher when 
compared to patients with conventional MS (Ishizu et al. 2005). IL-17 expression is also 
increased in the intestinal mucosa and serum of patients with exacerbations of IBD (Fujino et 
al. 2003), and interestingly blockade of IL-23 in the IL-10 deficient mice has shown to 
ameliorate colitis through the inhibition of IL-17 and IL-6 (Yen et al. 2006). IL-17 is also 
elevated in patients with Behçet’s disease (Hamzaoui et al. 2002) and it is implicated in the 
trafficking of leukocytes in AU (Saruhan-Direskeneli et al. 2003) highlighting the importance 
of Th17 cells in inflammatory eye diseases. 
Jang et al. have recently investigated the influence of IL17 polymorphisms on disease 
susceptibility in a Korean population (Jang et al. 2008). Analysis for the IL-17 gene 
polymorphism identified three sites with gene variants of IL-17F on exon 3 (126A/G, 
155G/A, and 161A/G). Haplotype frequencies showed that the AG haplotype was more 
frequently seen in Behçet’s patients compared to their control group, suggesting that the GG 
haplotype of the IL-17 gene plays a protective role to the development of the disease, whereas 
those individuals carrying the AG haplotype would have a higher risk for developing the 
disease. 
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Figure 1.10. Overview of IL-17 family ligands and IL-17 receptor family and known 
functions. From Pappu et al. (Pappu et al. 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59
1.3.2.5.2. Interleukin-22 
IL-22 is one of the IL-10 family cytokines, and it was first identified as an IL-10-related T 
cell-derived inducible factor from a lymphoma cell line (Dumoutier et al. 2001). IL-22 is 
produced by fully differentiated Th17 cells and it appears to be produced by Th17 cells in 
response to IL-23 (McGeachy et al. 2007). The main target cells of IL-22 are cells of the skin, 
digestive tract, lung and kidney, and it has been found to be upregulated in psoriatic skin 
(Wolk et al. 2004). The preferential production of IL-22 by T cells (Th1, Th17) suggests that 
IL-22 plays a role in the pathogenesis of T cell mediated diseases.   
In vitro, high concentrations of IL-22 increased significantly the production of CCL2 and 
subsequent proliferation of synovial fibroblasts derived from patients with RhA, and in RhA 
IL-22 expression in synovial tissues was found to be increased (Ikeuchi et al. 2005). More 
interestingly there is new evidence that it can target human RPE cells and Li et al. found 
several genes which included IL-22 to be highly expressed in patients with a heterogeneous 
group of uveitis compared to a control group. In addition IL-22 had an apoptotic effect on 
RPE cells which had a detrimental effect on the blood retinal barrier integrity (Li et al. 2008). 
These results more importantly, are consistent with those found by another group 
demonstrating the presence of high levels of Th17 cells in peripheral blood mononuclear cells 
of patients with active scleritis or uveitis (Amadi-Obi et al. 2007), confirming the role of 
Th17 cells in intraocular autoimmune inflammation.  
 
1.3.2.5.3. Interleukin-21 
IL-21 is a novel pro-inflammatory cytokine involved in the immune response of the Th17 cell 
pathway (Korn et al. 2007). Its receptor shares the common γ chain and signals through the 
Jak/STAT pathway. Additionally IL-21 is produced by activated CD4+ T cells (Ozaki et al. 
2000; Parrish-Novak et al. 2000). IL-21 has been shown to induce proliferation and 
differentiation of T and B lymphoid cells as well as increase the activity of CD8+T and NK 
cells (Leonard et al. 2008). It has been implicated in the pathogenesis of EAE (Korn et al. 
2007), and experimental colitis (Fantini et al. 2007) by modulating the balance between Treg 
and Th17 cells. 
In a recent report Liu et al. (Liu et al. 2009) demonstrated a significant increase in expression 
of IL-21 mRNA and IL-21R during the acute phase of the disease of EAU in mice immunized 
with human IRBP peptide 161-180 compared to the recovery phase and normal controls, 
suggesting the involvement of IL-21 in the development of uveitis. Furthermore, following 
stimulated cell culture with recombinant IL-21 combined with TGF-β, IL-17 levels in the 
supernatant of mice with EAU were markedly increased, adding further evidence of the role 
of IL-21 in the development acquired immunity and association with the production of 
autoimmune disease.  
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1.4. CHEMOKINES 
Chemokines or chemotactic cytokines are group of small secreted proteins with a MW 
between 8- to 12Kd (Rollins 1997). The molecular hallmark of the chemokine family is the 
presence of four cysteine residues. To date 53 human chemokines and 23 receptors have been 
cloned and characterized (Colobran et al. 2007). This superfamily of chemokines is now 
subclassified into four groups according to their arrangement of their cysteine residues located 
in the N-terminal region, as designated C, CC, CXC, and, CX3C, in which C represents the 
number of cysteine residue in the N-terminal and X represents the number of intervening 
amino acids in between the two first cysteines (Murphy et al. 2000). 
Chemokines are not stored within cells, and their production is stimulated by a great range of 
stimuli. Although their cellular sources can vary, the majority of CXC and CC chemokines 
are produced by stimulated monocytes, macrophages and even by vascular endothelial cells. 
These structurally related cytokines with chemoattractive properties are responsible for the 
recruitment, adhesion, chemotaxis of leukocytes towards the site of inflammation (Eugenin et 
al. 2003). They also play an important role in immune homeostasis by driving the maturation, 
homing, and activation of leukocytes. With few exceptions, in vitro chemotaxis assays 
showed that CXC chemokines have an affinity to attract neutrophils, whereas CC chemokines 
act preferentially on monocyte/macrophages. However, the distinction between the two main 
subfamilies of chemokines is less well defined when the different subtypes of leukocytes are 
considered. See table 4 for a summary of the chemokines described in this chapter (Table 
1.4).  
Chemokines exert their biological actions by binding to G protein-coupled cell surface 
receptors (Haribabu et al. 1999; Murphy 1994). Although chemokine-receptor interactions 
exhibit a great degree of selectivity, there is a considerable amount of redundancy in these 
interactions with some chemokines binding to more than one receptor and vice versa.  
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Table 1.4. Systematic chemokine and chemokine receptor nomenclature. Modified from Le et 
al. and Murphy et al. (Le et al. 2004; Murphy et al. 2000). 
 
Chemokines ELR H/I Synonyms Major target cells  Chromosome 
CC chemokines  
CCL2 N/A I MCP-1, MCAF Monocytes, T cells, 
basophils, NK cells, 
progenitors 
17q11.2-q12 
CXC chemokines  
CXCL8 ELR+ I IL-8, NAP-1 Neutrophils, T cells, 
basophils, endothelial 
cells 
4q21 
Receptors Ligands Synonyms Receptor-expressing 
cells 
 
CC Receptors  
CCR2 CCL2, 7, 8, 
12, 13 
CKR2, CC 
CKR2, 
CMKBR2 
Monocytes, immature 
DCs, T cells, PMNs, 
eosinophils, platelets 
3p21 
CXC receptors  
CXCR1 CXCL2, 3, 5, 
6 , 7, 8 
IL-8RA, IL-8 
R-I, IL-8R 
PMNs, monocytes, 
astrocytes, endothelia, 
mast cells 
2q34-q35 
H: homeostatic chemokine; I: Inflammatory chemokine; ELR+: Presence of glutamic acid-
lecutine-arginine tripeptide motif; ELR-: Absence of glutamic acid-lecutine-arginine 
tripeptide motif.  
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1.4.1. CXC chemokines and chemokine receptors 
1.4.1.1. Interleukin-8 
IL-8 was identified by several groups as a neutrophil activating peptide produced by a variety 
of cells that include, monocytes, T lymphocytes, neutrophils, fibroblasts, endothelial, and 
epithelial cells (Conlon et al. 1995). It is also known as CXCL8, or NAP-1. Among its many 
properties, which include chemoattraction of T lymphocytes, and histamine release from 
basophils, it is best known for being one of the main chemoattractants for neutrophils 
(Thorburn et al. 2009).  
 
1.4.1.1.1. Association studies of IL-8 with disease 
Most of the evidence for the role of IL-8 in the trafficking of neutrophils comes from 
experiments that document chemokine expression at different inflammatory foci. In order to 
examine functionality, Hull et al. identified a common polymorphism in the promoter region -
251 T/A (rs4073) and examined IL-8 levels from LPS-stimulated whole blood. The IL-8 -251 
A allele tended to be associated with increased IL-8 production, although it did not reach 
statistical significance (Hull et al. 2000).  The authors in later study identified 9 SNPs in a 
7.6Kb segment spanning the IL-8 gene and its promoter region, and used six of these SNPs to 
define the haplotypic structure of the IL-8 locus, with two common occurring; haplotype 1 (-
251T/+396T/+781C/+1238insA/+1633C/+2767A), and haplotype 2 (-
2251A/+396G/+781T/+1238delA/+1633T/+2767T) (Hull et al. 2001). Using primary 
respiratory epithelial cells stimulated with TNF they found a moderate increase of haplotype 
2. After performing reporter analysis on the -251 T/A promoter SNP, they did not find a 
difference in promoter activity between the two alleles. Then they proceeded to systematically 
screen for allele-specific protein-DNA binding in the functional haplotype, which revealed 
significant differential binding with the +781 C/T allele (rs2227306), suggesting that the 
increased transcription from haplotype 2 may be mediated by interactions between a 
transcription factor binding complex and the promoter (Hacking et al. 2004).  
Elevated levels of IL-8 have been found in bronchoalveolar lavage (BAL) fluid from patients 
with interstitial lung disease (Meloni et al. 2004), and not only correlate with the respective 
BAL cellular differentiation but also with worse lung-function parameters (Schmidt et al. 
2009). 
Similarly, IL-8 is upregulated in the kidney in IgA nephropathy, SLE associated nephritis, and 
ANCA-associated vasculitis, and its levels correlate with disease activity. Neutralisation of 
IL-8 attenuates glomerular neutrophil infiltration and glomerular tissue injury (Rovin et al. 
2002). 
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Elevated levels of IL-8 in serum and CSF have been found in patients with ocular and CNS 
inflammation in the context of Behçet’s disease (Zouboulis et al. 2000), in particular during 
the active phase of the disease (Saruhan-Direskeneli et al. 2003), suggesting a role in IL-8 as a 
possible marker of activity and predictor of vascular involvement in Behçet’s disease 
(Durmazlar et al. 2009). 
More importantly there is a significant correlation between AqH levels of IL-8 in patients 
with uveitis and increased disease activity, especially in patients with Behçet’s disease, which 
may be related to other neutrophil chemoattractants that are involved in neutrophil 
recruitment in this particular condition. In a cohort of patients with different uveitis entities 
which included HLA-B27 related AU, systemic levels of IL-8 were found to be significantly 
elevated during exacerbations of the  active ocular disease and were decreased during 
remission (Kramer et al. 2007). 
 
1.4.1.1.2. Association studies of IL-8 polymorphisms with disease 
The IL-8 gene is mapped to the 4q13-q21 and contains 4 exons and 3 introns (Mukaida et al. 
1989). 
Among all IL-8 SNPs described, the presence of -251A/T in the transcription site is known to 
exert a strong influence in protein synthesis, and its presence has been associated with a wide 
spectrum of disorders, some of an autoimmune nature. There is a wide heterogeneity among 
the distribution of this SNP throughout the world (Fujihara et al. 2007). Since the existence of 
-251A/T IL-8 polymorphism was reported, there have been reports showing a higher IL-8 
production by allele A (Hull et al. 2000), while others showed the high production to be 
associated with the presence of allele T (Lee et al. 2005). More recent data revealed that the 
differences in IL-8 expression were linked to two main haplotypes which include up to six 
SNPs and constitute the so-called haplotype 2, which is significantly associated with higher 
IL-8 levels compared to its counteract haplotype 1 (Hacking et al. 2004). This would indicate 
that the presence of -251A allele in high haplotype producers of IL-8 has no effect on allele-
specific level of transcription, and that the functional allele is probably in LD with haplotype 
2 and that -251A/T is not the functional SNP. In keeping with these findings, the frequency of 
the haplotype TAT inferred from IL-8 -251A/T, -353A/T, and +678T/C is significantly higher 
in patients with Behçet’s disease compared to healthy individuals (Lee et al. 2007).  
 
Other SNPs associated with disease include the -845C/T in the IL-8 promoter region and 
severe renal injury in African-American patients with SLE nephritis (Rovin et al. 2002), or 
three other different SNPs located in intron or 2’UTR positions (+781T/C, +1633T/C, 
+2767T/A) found to be associated with asthma (Heinzmann et al. 2004). 
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1.4.1.2. CXCR1 
It belongs to the G-protein coupled receptor superfamily (Dohlman et al. 1991). Also known 
as IL-8RA, IL-8R, IL-8R-I. It is expressed mostly by neutrophils and immunofluoresence 
staining techniques and flow cytometry analysis demonstrated the 70% to 90% of neutrophils 
bear the CXCR1. It has with more limited expression in T cells, monocytes, dendritic cells, or 
synovial fibroblasts. CXCR1 binds to two different types of chemokines, CXCL8/IL-8 and 
CXCL2/GCP2, but is only CXCL8/IL-8 that has been able to neutralize neutrophil adhesion 
as well as cause neutrophil infiltration (Pignatti et al. 2005). 
It has been linked with inflammatory lung disease and Behçet’s disease since the expression 
levels of CXCR1 and CCR5 were down-regulated on CD8(bright)CD56+ T cells after 
systemic immunosuppressive treatment during active Behçet’s uveitis (Ahn et al. 2006a). 
 
1.4.2. CC chemokines and chemokine receptors 
1.4.2.1. Monocyte chemoattractant protein-1 
MCP-1 or MCAF now known as CCL2 was the first discovered human chemokine. It is a 
potent chemotactic factor for monocytes located on chromosome 17 (17q11.2-q21.1) and is 
13Kd in size. It belongs to a family of at least four members (MCP-1, -2, -3, -4). It is 
produced by a variety of cell types either constitutively or induced by other cytokines, but 
monocytes/macrophages are found to be the major source of CCL2. It regulates migration and 
infiltration of monocytes, T cells and NK cells (Deshmane et al. 2009)..  
Human CCL2 gene transcription is regulated by two distinct areas of the 5’ flanking region. 
The proximal region extends at least 150 bases upstream and contains a number of 
transcription factors binding sites that coordinate CCL2 gene response to other cytokines such 
as TNF and INF-γ. However it is the distal regulatory region that contains the -2518 A/G 
(rs1024611) polymorphism that regulates CCL2 expression (Rovin et al. 1999). 
 
1.4.2.1.1. Association studies of CCL2 with disease 
Macrophages, endothelial cells, and smooth muscle cells in inflammatory bowel disease 
(IBD) express CCL2 mRNA and protein; furthermore the use of immunosuppressive agents 
decreases MCP-1 expression and production in stimulated monocytes (Grimm et al. 1996). 
Atherosclerosis is accepted by many as an inflammatory condition where CCL2 as well as its 
receptor CCR2 has been found to play an important role in the recruitment of monocytes 
following injury to the vascular wall. There is evidence of CCL2 expression in human 
atheromatous plaques, which is essential for monocytes recruitment, angiogenesis and 
proliferation and migration of smooth muscle (Yla-Herttuala et al. 1991). In a similar fashion, 
in asthma sufferers the kinetics of production of MCP-1 correlates with the recruitment in 
their airways of specific leukocyte subsets expressing the CCL2 receptor (CCR2) 
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(D'Ambrosio et al. 2001). Patients with RhA were stratified for the presence for the presence 
of IgM rheumatoid factor and antibodies against cyclic citrullinated peptide (predictor for 
development of RhA) and CCL2 levels were found to be significantly increased (Rantapaa-
Dahlqvist et al. 2007). Synovial production of CCL2 by local macrophages has been 
suggested to play an important role in the recruitment of mononuclear phagocytes during 
inflammation associated with RhA (Szekanecz et al. 2001).  
In experimental autoimmune encephalitis (EAE), an animal model for multiple sclerosis 
(MS), the immune cells infiltrate in CNS consists of CD4, CD8 T cells, and macrophages 
which express CCL2 and have a direct correlation with disease severity (Jee et al. 2002). 
Tanuma et al. demonstrated increased immunoreactivity for CCL2 in hypertrophic astrocytes 
from demyelinating plaques in patients with MS (Tanuma et al. 2006). 
Another example implicating CCL2 in the pathogenesis of chronic inflammatory conditions 
and disease severity is the direct relationship between plasma levels of CCL2 in patients with 
SLE and severe renal involvement (Lit et al. 2006). In a similar study Brown et al. found that 
SLE patients had higher CCL2 concentrations than healthy individuals, and that patients with 
nephritis had higher concentrations than those without nephritis (Brown et al. 2007). 
 
1.4.2.1.1.1. CCL2 and uveitis 
Further evidence of the role that CCL2 plays in autoimmune inflammatory diseases has been 
shown in Lewis rats injected with myelin basic protein (MBP) that developed inflammation in 
the spinal cord and AU (Adamus et al. 1997).  Induction of the gene expression of CCL2 
appears to contribute to the recruitment of inflammatory cells in the eye and CNS and also to 
correlate with disease severity (Adamus et al. 2001). In another murine model, CCL2 
deficient mice that were injected Salmonella typhimurium LPS subcutaneously showed a 
significant reduction of intraocular inflammation when compared to the wild-type control 
mice. When CCL2 deficient mice were treated with recombinant rat MCP-1 (rRMCP-1) the 
inflammatory response was reconstituted intraocularly. Another observation from this study 
was the over expression of IFN gamma in serum, as well as IL-6, and an increased intraocular 
IFN gamma transcription in the CCL2 deficient mice (Tuaillon et al. 2002). In a similar study 
Fang et al. detected increased levels of CCL2 in AqH of Lewis rats immunized with melanin-
associated antigen prior to the clinical onset of intraocular inflammation, as well as an 
upregulation of mRNA of CCL2 during the evolution of the EAAU, suggesting the 
involvement of this chemokine in the initial recruitment of inflammatory cells (Fang et al. 
2004). 
 
1.4.2.1.2. Association studies of CCL2 polymorphisms with disease 
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A variety of diseases which include SLE, juvenile rheumatoid arthritis, and HLA-B27 
associated AU have been associated with this polymorphism. Patients of Caucasian origin 
diagnosed with SLE who carried the -2518 G allele had higher plasma concentrations of 
CCL2 than those who were homozygous for the allele A (Brown et al. 2007), and predisposed 
the development of renal involvement and the presence of cutaneous vasculitis (Aguilar et al. 
2001; Tucci et al. 2004). Despite different groups having failed to prove an association 
between this functional polymorphism and susceptibility to RhA (Gonzalez-Escribano et al. 
2003; Lee et al. 2003), when patients and controls were stratified according to HLA-DRB1, 
those patients who lacked the HLA shared epitope were  significantly more likely to be 
homozygous for the allele G (Gonzalez-Escribano et al. 2003). Contrary to these findings, 
another study postulated the role of the -2518 AG polymorphism in HLA-B27 positive 
patients with associated AU (Wegscheider et al. 2005). These results are in concordance with 
these of other groups who looked at patients with Behçet’s disease and associated uveitis 
(Chen et al. 2004; Cho et al. 2004).  
The -362G/C polymorphism has also been examined in the model of atherosclerotic disease in 
addition to the -2578A/G SNP. This polymorphism lies next to a number of transcription 
factor-binding regions that are linked with an increase in transcription of CCL2 and biological 
activity of its receptor CCR2. The result of the activity of CCL2/CCR2 system is an increase 
risk for the development of atherosclerotic plaques (Nyquist et al. 2009).   
 
1.4.2.2. CCR2 
CCR2 or CKR2, CC CKR2, CMKBR2 exists in two forms CR2A and CCR2B. These two 
forms differ only in the amin acid sequence of their intracellular C-terminus (Charo et al. 
1994). Therefore, their ligand binding specificities appear to be identical (Combadiere et al. 
1995; Franci et al. 1995). It is mainly expressed on monocytes, B cells, activated T cells, 
immnature dendritic cells (Frade et al. 1997). CCR2 is involved in macrophage migration 
(Mackay 2001), and its ligands have been implicated in the pathophysiology of a wide 
number of disorders such as RhA, MS, organ transplant rejection, atherosclerosis. However 
probably it is better known for its role in viral pathogenesis, supported by in vitro 
observations that CCR2B can act as a fusion co-factor for HIV-1 (Doranz et al. 1996). 
Jiang et al. demonstrated that induction of EAU in an acute model in the rat was accompanied 
by an increase in CCR2 levels in animals displaying clinical signs of the disease (Jiang et al. 
1998). Another group demonstrated the upregulation of gene expression of CCL2 and CCR2 
in the acute stages of EAU (Keino et al. 2003).  
 
1.5. UVEITIS 
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The uvea, the middle vascular coat of the eye (from the Latin uva or grape) is composed by 
the iris, ciliary body and choroid, with each one of these components having different 
histology and function. 
At present, the most widely accepted classification of uveitis is based on the primary 
anatomical location of the inflammation within the eye (Bloch-Michel et al. 1987; Deschenes 
et al. 2008) and not on the presence of structural complications, as suggested in the last 
International Workshop on Standardization of Uveitis Nomenclature (SUN) (Jabs et al. 2005) 
(Table 1.5). 
Inflammation has also been categorised according to its time course and duration into acute, 
recurrent, subacute and chronic. These terms have been used inconsistently and therefore their 
use is reserved to describe the onset of the uveitis and the duration of the attack. Hence, AAU 
usually lasts days to weeks and resolves completely between episodes. Chronic anterior 
uveitis (CAU) by definition lasts longer than three months. It may follow an episode of AAU 
or begin insidiously as a low grade and occasionally asymptomatic (Table 1.6). 
In order to assist in the evaluation and diagnosis of uveitis, the International Uveitis Study 
Group (IUSG) also recommended a clinical classification based on etiological criteria, as 
detailed in table 7 (Deschenes et al. 2008) (Table 1.7). 
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Table 1.5. The SUN working group anatomic classification of uveitis (Jabs et al. 2005). 
 
Type Primary site of 
inflammation 
Includes 
Anterior uveitis Anterior chamber Iritis, iridocyclitis, anterior 
cyclitic 
Intermediate uveitis Vitreous Pars planitis, posterior 
cyclitic, hyalitis 
Posterior uveitis Retina or choroid Focal, multifocal, or diffuse 
choroiditis, retinochoroiditis, 
retinitis, neuroretinitis 
Panuveitis Anterior chamber, vitreous, 
and retina or choroid 
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Table 1.6. The SUN working group descriptors of uveitis (Jabs et al. 2005). 
 
Category Descriptor Comment 
Sudden Onset 
Insidious 
 
Limited 3 months or less of duration Duration 
Persistent  More than 3 months of 
duration 
Acute Episode characterized by 
sudden onset and limited 
duration 
Recurrent Repeated episodes separated 
by periods of inactivity 
without treatment for at least 
3months in duration 
Course 
Chronic Persistent uveitis with relapse 
in less than 3 months after 
discontinuing therapy 
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Table 1.7. IUSG Clinical Classification of uveitis (Deschenes et al. 2008). 
 
Bacterial  
Viral 
Fungal 
Parasitic 
Infectious 
Others 
Known systemic associations Noninfectious 
Un-known systemic associations 
Neoplastic Masquerade 
Non-neoplastic 
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1.5.1. Anterior uveitis 
AU refers to disease limited to the anterior segment of the eye. AU is the most prevalent form 
of intraocular inflammation. The symptoms of an acute episode of AU may include pain, 
typically in the periorbital region, redness and photophobia. Occasionally there may be 
associated epiphora, especially in bright light.  
The signs of AAU include limbal conjunctival injection, also known as ciliary flush. The 
characteristic finding in the acute phase are the presence of cells and flare in the anterior 
chamber, which are the result of extravasated inflammatory cells and proteins respectively. 
Hypopyon formation occurs when the cells in the anterior chamber collect inferiorly, and it is 
a sign of severe inflammation. It is typically associated with HLA-B27 related uveitis and 
Behçet’s disease (Ramsay et al. 2001). Keratic precipitates (KPs) are clusters of inflammatory 
cells deposited on the corneal endothelium. They most frequently coalesce in the inferior third 
of the cornea as a result of the convection current of the AqH in the anterior chamber, or they 
may be widely dispersed over the entire corneal endothelium as it is seen in Fuchs’ 
Heterochromic Cyclitis (FHC). The mechanism by which these inflammatory cells attach to 
the corneal endothelial cells seems to be influenced by the effect of inflammatory cytokines 
on the expression of cell adhesion molecules. Iris nodules may appear along the pupillary 
margin (Koeppe) or in the iris stroma (Busacca). Posterior synechiae (PS) formation 
represents the adhesion of the posterior surface of the iris and the anterior surface of the lens. 
It tends to develop in untreated severe or persistent AU. When these adhesions occur along 
the entire 360˚ pupillary margin, the AqH outflow becomes compromised and the iris bows 
forward developing the so-called, iris bombé. The intraocular pressure may rise as a 
consequence of this pupillary block or as a result of the formation of peripheral anterior 
synechiae, between the peripheral iris and the angle structures. However, severe inflammation 
involving the ciliary body can affect the production of AqH lowering the intraocular pressure. 
It can also be secondary to ciliary body detachment caused by cyclitic membrane formation.  
 
1.5.1.1. Structure and function of Human Leukocyte Antigen (HLA) molecules 
The HLA system is genetically encoded in the chromosome 6 by the Major 
Histocompatibility Complex (MHC) in humans. The MHC is a system of glycoproteins 
molecules expressed on the surface membranes of most human cells.  
The HLA genes that are involved in the immune response fall into two classes, I and II, which 
are structurally and functionally different. 
The human class I region contains three main loci i.e.: HLA-A, HLA-B, and HLA-C. Each 
locus encodes the heavy chain of the MHC class I genes antigen. Other, less polymorphic 
class I genes include the HLA-E, -F, -G, and –H genes (Bjorkman et al. 1990). The class I 
HLA molecule consists of a non-covalently linked two-chain structure; a polymorphic heavy 
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chain or α chain encoded by a gene in the HLA class I region and a non-polymorphic β2-
microglobulin that is coded in the chromosome 15. The HLA molecule has a peptide-binding 
groove that acts as a binding site for short (8 to 12 amino acids) peptides. The complex of 
HLA molecule-antigen is then recognised by the T cell receptor of class I-restricted CD8+ T 
cell (Klein et al. 2000). Class I HLA molecules are expressed on most somatic cells with 
different level of expression. Normal endothelial corneal cells do not express HLA class I 
molecules as part of their mechanism for immune privilege. Human uveal cells normally 
expressed HLA antigens at very low levels in normal eyes, but expression is upregulated 
during inflammation in AU (Abi-Hanna et al. 1989). On the other hand, class II genes code 
for the α and β polypeptide chains of the HLA-D molecules including HLA-DR, -DQ, DP 
families, and are expressed in a limited number of cells, which include B cells,  monocytes, 
macrophages, and dendritic cells. They are also expressed by different pro-inflammatory 
stimuli as it has been observed in patients with uveitis on RPE cells (Chan et al. 1986; 
Liversidge et al. 1988) which then present retinal antigens to T lymphocytes via the HLA 
class II system .Finally, class III genes encode for the complement proteins, as well as TNF-α 
and –β.  
 
The association between the MHC complex, HLA-B27 and its spectrum of HLA-B27-
associated inflammatory diseases and uveitis was first reported almost forty years ago by 
Brewerton et al. (Brewerton et al. 1973) and it remains one of the strongest HLA-disease 
associations (Table 1.8). 
The HLA-B locus is the most polymorphic of the HLA class I genes containing over 500 
alleles (Robinson et al. 2006). Similarly, HLA-B27 is not a single allele but a family of at 38 
different subtypes (Reveille et al. 2009), named HLA-B*2701 to HLA-B*2728 that have a 
wide varied racial distribution worldwide, differing from each other by one or a few amino 
acids, and binding different peptides with some overlapping among them. There is evidence 
of the diversity of strength of association between HLA-B27 subtypes and different 
conditions (Khan 2000), including AAU. 
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Table 1.8. HLA-B27 SpA and their association with AAU. Courtesy of Dr Chang, University 
of new South Wales, Sydney. 
 
Disease HLA-B27 
prevalence (%) 
Proportion of 
patients with the 
systemic disease 
developing AAU 
(%) 
Proportion of 
patients with 
AAU developing 
the systemic 
disease (%) 
AS 90 20-30 15-50 
55-90 in HLA-
B27 AAU  
ReA 40-80 12-37 2-25 
8-21 in HLA-B27 
AAU 
PsA 40-50 40-50 0-2 
3-4% in HLA-
B27 AAU 
IBD 35-75 35-75 2-3 
1-7 in HLA-B27 
AAU 
Undifferentiated 
spondyloarthropathy 
70 70 4-12 
5-21 in HLA-B27 
AAU 
AS: Ankylosing spondylitis; ReA: reactive arthritis; PsA: Psoriatic arthropathy; IBD: 
Inflammatory bowel disease.  
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One of the most widespread subtypes is the HLA-B*2705, which is present in nearly 90% of 
HLA-B27 positive healthy individuals form Northern Europe (Khan 2000), it is also believed 
to be the common ancestral type from which other subtypes have evolved. 
Other subtypes present in Caucasian individuals of Northern European ancestry include the 
HLA-B*2702, which is present in 10% of HLA-B27 positive patients with AS, and AAU 
(Chang et al. 2005), and in a Dutch population the frequencies of HLA-B*2705 and HLA-
B*2702 subtypes in patients with AAU were found not to be different from these found in 
HLA-B27 normal controls (Derhaag et al. 1988). Interestingly, in Asian populations, such as 
the Japanese and Chinese, there is a predominance of the HLA-B*2704 subtype, which in 
addition to the weaker association of this subtype of HLA-B27 and AAU, may explain the 
lower prevalence of HLA-B27 related AAU in these two populations. 
However, despite an increase in the number of publications reporting the association between 
HLA-B27 related diseases and different B*27 subtypes, there remains no evidence of the 
predictive or diagnostic value of the various subtypes.  
 
1.5.1.2. HLA-B27 associated anterior uveitis 
HLA-B27 positive AAU is recognised as a distinct clinical entity with characteristic clinical 
features that makes it distinguishable from its HLA-B27 negative counterpart (Huhtinen et al. 
2000). The typical phenotype of HLA-B27 positive AAU has extensively been reviewed in 
the literature (Chang et al. 2005), and it is characterised by an acute onset of a red, painful 
eye, with significant inflammatory cellular and proteinaceous extravasation into the AqH, 
including the development of hypopyon in the anterior chamber, and a tendency for 
recurrences, which may involve the fellow eye (Table 1.9). 
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Table 1.9. Clinical features of HLA-B27 positive patients compared to HLA-B27 negative 
AU. From Chang et al. (Chang et al. 2005). 
 
Clinical features HLA-B27 positive AU HLA-B27 negative AU 
Age at onset (years) 32-35 39-48 
Gender (male 
preponderance) 
1.5-2.5:1 1:1 
Eye involvement Unilateral (48-59%) 
Unilateral alternating (29-
36%) 
Bilateral (21-64%) 
 
Pattern of uveitis Acute (80-87%) Chronic (43-61%) 
Recurrence Frequent Uncommon 
Fibrin in AC 25-56% 0-10% 
Hypopion 12-15% 0-2% 
Associated systemic disease 48-84% 1-13% 
Familial aggregation Yes No 
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1.5.1.2.1. Anterior uveitis associated with seronegative arthropathies 
The spondyloarthropathies (SpA) are group of chronic inflammatory disorders primarily 
affecting the axial skeleton and joints, and are genetically linked with the strongest known 
contributing factor being the MHC class I molecule HLA-B27. The National Arthritis Data 
Workgroup has estimated an overall prevalence of 1.3% with a worldwide distribution 
(Akkoc 2008). The SpAs include: AS, IBD-associated spondyloarthropathy, psoriatic 
arthropathy (PsA), and post-infectious or reactive arthritis. Due to the overlap of clinical 
manifestations within the group and often incomplete or atypical forms at presentation, two 
separate sets of diagnostic criteria, the European Spondyloarthropathy Study Group and the 
Amor criteria, which include both clinical and radiological features were developed in the 
early 90s’and still remain in use today (Amor et al. 1990; Dougados et al. 1991). Their 
clinical characteristics are summarised in table 1.10 (Table 1.10).  
Among the extra-articular manifestations AU is one of the most common manifestations 
(Collantes et al. 2007). Although the clinical features of AU in some of the subtypes i.e., AS 
or PsA, is highly consistent with typical symptoms of AAU, in other subtypes such as IBD or 
reactive arthritis, the clinical characteristics are more variable (Martin et al. 2002).   
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Table 1.10. Summary of Clinical Features of Spondyloarthropathies. From Kataria et al. 
(Kataria et al. 2004). 
 
Features AS Reactive 
arthritis 
PsA IBD-associated 
spondyloarthropathy 
Prevalence  0.1-0.2% 0.1% 0.2-0.4% Rare 
Age at onset Late teens to 
early 
adulthood 
Late teens to 
early adulthood 
35-45 years Any age 
Male to female 
ratio 
3:1 5:1 1:1 1:1 
HLA-B27 90-95% 80% 40% 30% 
Sacroiliitis 
Frequency 
Distribution 
 
100% 
Symmetric 
 
40-60% 
Asymmetric 
 
40% 
Asymmetric 
 
20%  
Symmetric 
Syndesmophytes Delicate, 
marginal 
Bulky, 
nonmarginal 
Bulky, 
nonmarginal 
Delicate, marginal 
Peripheral 
arthritis 
Frequency 
Distribution 
 
 
Occasional 
Asymmetric, 
lower limbs 
 
 
Common 
Asymmetric, 
lower limbs 
 
 
Common 
Asymmetric, 
any joint 
 
 
Common 
Asymmetric, lower 
limbs 
Enthesitis Common Very common Very 
common 
Occasional 
Dactylitis Uncommon Common Common Uncommon 
Skin lesions None Circinate 
balanitis, 
keratoderma 
blenorrhagicum 
Psoriasis Erythema nodosum, 
pyoderma 
gangrenosum 
Nail changes None Onycholysis Pitting, 
onycholysis 
Clubbing 
Oral  Ulcers Ulcers Ulcers Ulcers 
Cardiac  Aortic 
regurgitation, 
conduction 
defects 
Aortic 
regurgitation, 
conduction 
defects 
Aortic 
regurgitation, 
conduction 
defects 
Aortic regurgitation 
Pulmonary  Upper lobe 
fibrosis 
None  None None 
Gastrointestinal  None Diarrhoea None Crohn’s disease, 
ulcerative colitis 
Renal Amyloidosis, 
IgA 
nephropathy 
Amyloidosis Amyloidosis Nephrolithiasis 
Genitourinary Prostatitis Urethritis, 
cervicitis 
None None 
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1.5.1.2.2. Ankylosing spondylitis 
AS is a chronic systemic disease of unknown cause, characterized by the presence of sclerosis 
of the joint space of the axial skeleton. The prevalence of AS among Europeans is estimated 
to be 0.1-0.23% (Olivieri et al. 1998). There is a strong genetic link, with 90 to 95% of 
patients being HLA-B27 positive, and the risk of developing the disease of about 5% in 
healthy HLA-B27 positive individuals, and significantly higher in HLA-B27 positive relatives 
of patients (van der Linden et al. 1984). Although the importance of HLA-B27 is clear, there 
is now evidence of other genes associated with susceptibility to this disease, such as the TNF-
α gene. Genome wide studies suggest the influence of other genes distributed on a number of 
different chromosomes and for example, the IL-1 gene cluster in chromosome 2 appears to be 
involved in disease susceptibility or disease severity (Maksymowych et al. 2003). 
Furthermore, not only the HLA-B27 haplotype has a direct correlation with the presence of 
AU (Martinez-Borra et al. 2000), a different locus in chromosome 9p predisposes to the 
development of AU in patients with AS (Martin et al. 2005).  
AS in its classical presentation remains the prototype of the B27 related group of disorders, 
with an insidious onset of lower back pain that persists longer than 3 months, associated with 
morning stiffness that improves with activity. Typically the most common ocular 
manifestation of AS is a non-granulomatous acute-recurrent AU. It is usually unilateral, but 
can also be alternating or bilateral. Characteristically, the cellular response is severe and it is 
one of the few non-infectious forms of uveitis that may present with a hypopyon (Ramsay & 
Lightman 2001; Zaidi et al. 2010). Severe fibrinous response can lead to the formation of PS. 
Rarely the posterior segment can show signs of inflammation such as, vitritis, CMO, papillitis 
and retinal vasculitis (Rodriguez et al. 1994). Nonetheless the presence of AAU and its 
severity does not correlate with that of the spondylitis.  
 
1.5.1.2.3. Reactive arthropathy 
The second type of arthritis in this group of SpA is part of a clinical triad consisting of 
arthritis, non-gonococcal urethritis and conjunctivitis, known as reactive disease. HLA-B27 is 
present in approximately 75 % to 90 % of patients (Amor 1998).The complete form also 
described as Reiter’s syndrome. The diagnosis is usually clinical and it is summarised in table 
11.  
Over half of the patients with reactive disease will have ocular involvement with AU being 
the second most common form of ocular involvement after conjunctivitis. It may be seen in 
up to 12% of patients, especially in these patients who are HLA-B27 positive (Lee et al. 
1986). The initial attack is often unilateral, non-granulomatous, of insidious inset with a mild 
to moderate cellular reaction with or without PS and typically lasting less than 3 months. The 
presence of posterior segment manifestations is uncommon; however Kiss et al. reported a 
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64% of cases with evidence of posterior segment inflammation at some point during their 
follow-up (Kiss et al. 2003). 
 
1.5.1.2.4. Psoriatic arthritis 
Psoriatic arthritis (PsA) has often been defined as a unique inflammatory arthritis associated 
with psoriasis in up to 30% of patients. It is defined by the triad of psoriasis, chronic-
recurrent, erosive arthritis, and rheumatoid factor negative. The skin lesions often precede the 
onset of arthritis, but in up to 20% of cases the arthritis is the initial complaint. There are five 
types of recognised PsA: an oligoarticular (four or fewer joints involved), a polyarticular (five 
or more joints involved), a predominant distal interphalangeal joint involvement, arthritis 
mutilans, and psoriatic spondylitis. The oligoarticular pattern accounts for more than 70% of 
cases (Gladman et al. 2005). See table 1.10 for summary (Table 1.10) 
Early studies on PsA associations with MHC alleles found a link between HLA-B27 positive 
patients and spinal involvement, whereas HLA-B38 and B39 were associated with peripheral 
disease (Gladman et al. 2003). Interestingly these latter two alleles are highly correlated with 
HLA-Cw*1203. Subsequent genome wide studies have identified the association between the 
psoriasis susceptibility locus 1 (PSORS 1) located in the MHC class I region and HLA-
Cw*0602 and HLA-Cw*1203 (Veal et al. 2002). Furthermore, the presence of the shared 
epitope HLA-DRB1 from the MHC class II region is reported to be associated with 
radiological erosions in PsA (Korendowych et al. 2005). Other susceptibility genes such as 
TNF-α polymorphisms at the promoter positions -238 and -308 have been demonstrated to be 
in LD with HLA-Cw*0602, and TNF-857 allele T appears to be involved in the development 
of PsA independently of the PSORS1 allele (Reich et al. 2007). 
With the exception of the MHC, linkages and association of other susceptibility genes have 
not yet been replicated in all cohorts. However, an association with alleles of the IL-23 
receptor, which are also risk factor for other SpA have been found, suggesting a shared 
inflammatory pathway mediated by IL-23R in these group of disease (Nograles et al. 2009). 
Th17 cells are characterised by the production of IL-17 and IL-22 cytokines which have been 
found to be expressed in psoriatic skin lesions, however it is still unclear whether they play a 
role in the pathogenesis of joint disease. Nevertheless treatment with human 12/23 p40 
monoclonal antibody has shown to reduce the signs and symptoms of PsA, supporting the role 
Th17 cytokines in influencing the clinical course of PsA (Nograles et al. 2009).  
AU in the presence of PsA is more likely to have a more insidious onset, longer episodes, 
posterior segment involvement, and bilateral when compared with uveitis in patients with 
other spondyloarthropathies. It is also more likely to manifest in HLA-B27 positive patients 
with axial disease (Durrani et al. 2005; Paiva et al. 2000). 
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1.5.1.2.5. Inflammatory bowel disease 
IBD comprises two different entities, Crohn’s disease and ulcerative colitis. Arthritis 
manifests in two different ways, an axial and a peripheral. Whereas the latter has a 
predilection for the large joints of the lower extremities, and its activity parallels that of the 
intestinal symptoms often disappearing following proctocolectomy (Salvarani et al. 2001), the 
less common axial presentation mimics that seen in  AS and its clinical course is unrelated to 
the gastrointestinal involvement. 
Although the incidence of HLA-B27 and HLA-DRB1*0103 in patients with IBD is higher 
than in the normal population and is associated with the development of extra-intestinal 
disease manifestations, HLA associations in this subgroup have given inconclusive results.  
NOD 2 (nucleotide-binding oligomerisation domain protein 2)/CARD15 SNPs located in 
chromosome 16 have been associated with different clinical manifestations of Crohn’s disease 
(Economou et al. 2004). In addition, there is evidence of TLR4 being involved in the 
pathogenensis of IBD, with the 299Gly allele frequency of the TLR4 gene and the T allele 
and TT genotype frequencies of the CD14 promoter were significantly higher in CD patients 
only compared to healthy individuals (Gazouli et al. 2005) and the Asp299Gly+/NOD2- 
polymorphism being a strong predictor of the stricturing disease phenotype (Brand et al. 
2005).  
Ocular involvement occurs in less than 10 % of cases of IBD (Mintz et al. 2004). A recent 
prospective randomized study conducted to evaluate the prevalence of ocular involvement in 
Turkish patients with IBD showed a higher prevalence of ocular inflammation in patients with 
Crohn’s disease compared to these with UC, with conjunctivitis being the most common 
ocular complication seen in 9 % of patients, followed by uveitis in about 5 % of cases 
(Yilmaz et al. 2007). Compared to other HLA-B27 related spondyloarthropathies, the 
intraocular inflammation associated with IBD tends to be more insidious in onset and chronic 
in duration, and typically bilateral (Lyons et al. 1997). Nevertheless, the most common type 
of IBD-associated uveitis is a non-granulomatous, low-grade recurrent-AAU, seen in 60% of 
patients, with a third of patients manifesting with panuveitis (Salmon et al. 1991).  
 
 
1.5.2. Fuchs’ Heterochromic Cyclitis 
FHC is a form of chronic low-grade AU of unknown aetiology. The prevalence of FHC varies 
from 1 % to 5 % of all cases of AU, although the prevalence might be higher due to the fact 
that the symptoms are subtle in the majority of cases. It is characterised by the presence of 
fine, white, non-pigmented, stellate KPs spread widely over the entire corneal endothelium, 
which are virtually pathognomonic. Atrophy of the iris may eventually result in the 
appearance of heterochromia and in some cases an irregular pupil or even a dilated pupil in 
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the affected eye. Typically, heterochromia is caused by the atrophy of the anterior layer of the 
iris stroma, which although it might make a brown iris look lighter, a blue iris will appear 
darker due to the revealing underlying iris pigmented posterior epithelium, resulting in a 
paradoxical “reverse heterochromia”. PS never develop in patients with FHC, unless the eye 
has had intraocular surgery (Rothova et al. 1994). Iris and trabecular meshwork show 
abnormal vessels (Bonfioli et al. 2005) that may sometimes lead to a hyphema or spontaneous 
haemorrhage (Amsler’s sign) in the anterior chamber following paracentesis in eyes with 
FHC. Cataract formation, secondary glaucoma and vitreous cells and opacities are the most 
common complications of this disorder. The presence of cataract formation in FHC is often 
present at the time of the diagnosis and often manifests as posterior subcapsular lens opacity 
(Jones 1991a), with a variable speed in its progression. Therefore, FHC should be considered 
in any young patient with unilateral cataract with no history of trauma or use of steroid. 
Cataract surgery in eyes with FHC has evolved considerably and although the incidence of 
complications reported in the literature varies considerably (Jakeman et al. 1990; Jones 1996; 
Razzak et al. 1990; Sherwood et al. 1992; Tejwani et al. 2006), cataract extraction and 
intraocular lens implant in eyes with FHC is a safe procedure with good visual outcome. 
Glaucoma is said to be the most damaging complication of FHC and occurs in about 25 % of 
patients (Jones 1991a). Although the mechanism of raised intraocular pressure in FHC 
remains poorly understood, the glaucoma is typical of chronic open-angle, but it can also be 
secondary to the presence of peripheral anterior synechiae, rubeosis, lens-induced angle 
closure and recurrent spontaneous hyphaema (Jones 1991b). The management of glaucoma in 
these patients is one of the most difficult challenges, and although the majority of patients 
show a good response to topical medication alone, a significant proportion of eyes will 
require filtration surgery in order to control the progression of visual field loss (Al-Mansour et 
al.) 
Vitreous opacities are present in 50%of patients (Al-Mansour et al.) but in contrast to 
intermediate uveitis there is no macular oedema. Even if their presence is not found to be 
generally symptomatic, in some patients these can be quite debilitating even if their Snellen 
visual acuities appear to be relatively good. Two retrospective studies of patients with FHC 
who underwent pars plana vitrectomies for removal of vitreous floaters showed not only an 
excellent visual outcome, but also appeared to be safe with no exacerbation of any pre-
existing intraocular inflammation (Scott et al. 2001). 
 
The aetiology is unknown and many pathogenic mechanisms have been proposed. Although 
the presence of peripheral chorioretinal scars similar to the ones seen in Toxoplasma 
retinochoroiditis has raised the hypothesis of an infective cause (Toledo de Abreu et al. 1982), 
there has been no proof of such relationship after analyzing humoral and cell-mediated 
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immunity against toxoplasma gondii in blood and AqH in patients with uveitis and a control 
group (La Hey et al. 1992). Other theories include herpes simplex and rubella infection as 
possible agents in the pathogenesis of the disease, and a recent study correlating the 
percentage of new cases of idiopathic intermediate uveitis including FHC before and after the 
rubella vaccination program in the United States, showed a decrease in the number of new 
cases following the introduction of the US rubella vaccination scheme, supporting the link 
between rubella infection and FHC (Birnbaum et al. 2007). The cellular phenotype and 
cytokine profile in the AqH of patients with FHC and idiopathic AAU has been compared 
(Muhaya et al. 1998).  The higher CD8+ T cell and IL-10 levels seen in FHC compared to the 
idiopathic AAU, where there was a predominance of CD4+ T cells and IL-2 levels might 
explain the low-grade inflammation seen in eyes of patients with FHC compared to that seen 
in idiopathic AAU. 
The course of the inflammatory process is unchanged by the use of corticosteroids and the 
management of this condition should be aimed to the treatment of its complications i.e., 
cataract, glaucoma, and vitreous opacities. 
 
1.6. BEHÇET’S DISEASE 
Behçet’s disease is a chronic, relapsing multisystem, inflammatory disorder of unknown 
aetiology with systemic and ocular manifestations.  
It has a worldwide distribution but it is more frequently seen in the countries of the Eastern 
Mediterranean and Asia that correspond to the old Silk Route (Verity et al. 1999a), and 
interestingly patients who are HLA-B5 distribute among the same areas. The incidence varies 
from approximately one case per 1,000 population in Turkey which has the highest incidence, 
to one in 500,000 in the UK (Suzuki Kurokawa et al. 2004). Although many reports have 
shown a higher prevalence in young male patients, the number of cases of female patients has 
increased, reaching a male female ratio of almost one to one (Zouboulis et al. 1997). 
The disease is rather heterogeneous with variable involvement of many organ systems. The 
diagnosis is based on the presence of different clinical findings, and it is characterised by the 
triad of recurrent oral and genital aphthous ulcers, ocular inflammation, and skin lesions such 
as erythema nodosum or acneiform eruptions. The most widely used diagnostic criteria in the 
UK is the one published by the International Study Group for Behçet’s Disease (Criteria for 
diagnosis of Behcet's disease. International Study Group for Behcet's Disease 1990), 
originally developed as a tool for aid classifying patients with the disease rather than that a 
diagnostic criteria (Table 1.11). In order to improve the accuracy of the diagnosis, the 
Behçet’s Disease Research Committee of Japan has revised the criteria using clinical and 
laboratory data and includes a list of major diseases for the differential diagnosis. The main 
characteristics of these revised criteria include recurrent aphthous ulcers on the oral mucosa, 
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genital ulcers, skin lesions and ocular lesions. Additional symptoms include arthritis, 
epididymitis, gastrointestinal, vascular and central nervous system lesions. The revised 
criteria includes clinical and laboratory data such as, pathergy test and prick test for dead 
Streptococcus, HLA-B51 and pathological findings of erythema nodosum divides the disease 
into four types: complete, incomplete, suspected or special lesions (Suzuki Kurokawa & 
Suzuki 2004)  
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Table 1.11. International criteria for diagnosis of Behçet’s disease (Criteria for diagnosis of 
Behcet's disease. International Study Group for Behcet's Disease 1990). 
 
Recurrent oral ulceration Minor aphthous, major apthous, or 
herpetiform ulceration observed by physician 
or patient, which recurred at least three times 
in one 12 month period 
Plus two of: 
Recurrent genital ulceration Aphthous ulceration or scarring, observed by 
physician or patient 
Eye lesions Anterior uveitis, posterior uveitis, or cells in 
vitreous on slit lamp examination; or retinal 
vasculitis observed by ophthalmologists 
Skin lesions Erythema nodosum observed by physician or 
patien, pseudofolliculitis, or papulopustular 
lesions; or acneiform nodules observed by 
physician in postadolescent 
Positive pathergy test Read by physician at 24-48 hours (findings 
applicable only in absence of other clinical 
explanations) 
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So far, the pathogenesis of Behçet’s disease remains unclear. It has been accepted that an 
exaggerated response to a microbial, viral or auto-antigen stimuli with increased cytokines 
and chemokines production and function is responsible of the clinical manifestations of the 
disease, it is not clear what is responsible for he initial onset and persistence of the disease. 
 
Behçet’s disease has a wide spectrum of clinical manifestations, but oral ulceration remains 
the most common and defining feature being present in over 95 % of cases (Yazici et al. 
1999). Genital ulcers are less common than oral ulcers and are present in up to 80 % of cases. 
Skin lesion area present in about 80 % of patients and can be divided into erythema nodosum 
and papulo-pustular, acneiform lesions. Another form of skin lesion is the pathergy reaction, 
which represents a hyper-reactivity of the skin to minor trauma. Various other organs can be 
involved among different populations. Joint involvement is seen in about half of patients, 
typically as a non-erosive, non-deforming arthritis with an oligoarticular pattern. It has a 
transient nature involving peripheral joints, such as knees, ankles, and wrists (Kim et al. 
1997). A widespread vasculitis of vessels of all sizes, both arteries and veins may involve up 
to one quarter of patients. Neurological involvement is not uncommon, occurring in 
approximately 5 % of cases (Kontogiannis et al. 2000). It can be related to primary central 
nervous system involvement, most frequently of the brain stem but the hemispheres, 
meninges and spinal cord can be affected. It can also be secondary to the vasculitis causing 
arterial occlusions or dural sinus thrombosis. Although, cardiac involvement was thought to 
be unusual, Morelli et al. reported mitral valve prolapse and dilatation of the proximal aorta in 
50 % and 30 % of patients respectively (Morelli et al. 1997). 
Ocular involvement occurs in approximately 75% of patients with Behçet’s disease, being the 
presenting feature in up to 20% of patients (Kontogiannis & Powell 2000), and is the major 
cause of morbidity of the disease. Typically has a relapsing, remitting course and first 
manifests with an attack of severe AAU with white non-pigmented KPs’ and hypopyon 
formation. The classical finding of AAU with hypopyon formation is present in 19% to 31% 
of patients with the disease (Deuter et al. 2008). PS with or without iris bombé, iris atrophy 
and secondary glaucoma may develop as a result of repeated attacks. The natural history of 
Behçet’s disease is characterised by explosive recurrent attacks of intraocular inflammation 
that may be confined to the anterior segment or may also affect the posterior segment. The 
retinal disease is characterised by an occlusive vasculitis of arteries and veins with associated 
vitritis, retinal haemorrhages with or without neovascularisation. Macular oedema is a major 
cause of visual impairment in uveitis associated to Behçet’s disease even in these cases with 
isolated AU. The end-stage of the disease is characterised by retinal and optic nerve atrophy 
with attenuation of the retinal vessels. 
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1.7. SARCOIDOSIS 
Sarcoidosis is a multisystem granulomatous disease of unknown cause characterised 
pathobiologically by non-caseating granuloma formation in different organs. Sarcoidosis 
occurs worldwide; affecting all races but with a predilection for certain ethnic groups, such as 
African-Americans (Rybicki et al. 1997). It affects both genders but with a higher incidence 
of the disease in women and has a tendency to affect young adults under the age of 40. The 
clinical features and the natural history are variable, making the prevalence and incidence of 
the disease difficult to determine.  
 
The clinical manifestations of sarcoidosis can be widespread or may involve only one organ 
system. The majority of patients present with non-specific constitutional symptoms such as 
fever, weight loss, fatigue, and malaise. The most common involved organs are the lung, 
lymph nodes, skin and eye. Pulmonary involvement is almost universal at some point in the 
course of the disease. Most typically, sarcoidosis is an interstitial disease, bilateral involving 
alveoli, blood vessels and bronchioles leading to characteristic radiological features. Intra-
thoracic and peripheral lymphadenopathy is common, with hiliar-node enlargement seen in up 
to 90 % of patients. Frequently the disease is asymptomatic and discovered by chest 
radiography. The radiographic features are usually used to classify the different stages of 
pulmonary sarcoidosis: stage 1 represents bilateral hiliar lymphadenopathy without 
parenchymal involvement, stage 2 bilateral adenopathy with parenchymal involvement, stage 
3 is pulmonary infiltrates without associated lymphadenopathy including cystic changes 
(Miller et al. 1995). Approximately 25 % of patients will manifest skin lesions during the 
course of the disease. These range from erythema nodosum to a wide variety of macular, 
papules, or subcutaneous nodules. The clinical presentation of erythema nodosum is that of an 
erythematous, warm, raised, and tender swelling typically over the anterior aspects of the 
lower legs. Multiple lesions can be present at different stages. The most easily recognizable 
form of cutaneous sarcoidosis is lupus pernio, which consists of purple papules involving the 
nose, cheeks, lip, ears, eyelids, and sometimes the tips of fingers. It is often associated with 
the presence of lung disease in up to 74 % of patients, and has a strong association with the 
presence of ocular involvement (James 1992). Less frequently seen cutaneous manifestation 
of sarcoidosis may also include nail dystrophy, alopecia, areas of hypo or hyperpigmentation, 
and leukocytoclastic vasculitis. Non-specific arthralgia occurs in up to one quarter of patients. 
It manifests as an acute migratory polyarthropathy affecting most commonly the ankles and 
knees. It tends to resolve completely, although it may recur. Chronic arthritis has a similar 
distribution to the acute form but it may also affect the metacarpophalangeal and 
interphalangeal joints (Thelier et al. 2008).  
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Ocular disease may be the initial manifestation and may progress to severe visual impairment 
(Lobo et al. 2003). There are two peaks of incidence of ocular sarcoidosis, the first at the ages 
of 20 to 30 and the second at ages 40 to 50 years (Rothova 2000). Depending on the 
population studied the incidence of ocular involvement ranges from 25 % to 60 % (Rothova 
2000). AU is the most common ocular manifestation, affecting around two thirds of patients 
with systemic sarcoidosis (Jabs et al. 1986). It characteristically presents as a bilateral 
granulomatous uveitis, but it can also manifests as CAU together with skin lesions, such as 
erythema nodosum and bilateral hiliar lymphadenopathy.  
The 1st International Workshop on Ocular Sarcoidosis (Herbort et al. 2009) has laid down a 
diagnostic criteria based on a combination of ophthalmic signs and laboratory investigations 
(Tables 1.12-1.14). 
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Table 1.12. Diagnostic criteria for ocular sarcoidosis. 
Definite Biopsy-supported diagnosis with a compatible uveitis 
Presumed Biopsy not done; presence of BHL with compatible uveitis 
Probable Biopsy not done; BHL negative; presence of three suggested intraocular signs 
and two positive investigational tests 
Possible Biopsy negative; four suggested intraocular signs and two positive 
investigational tests 
All other possible causes of uveitis, in particular tuberculosis have to be previously excluded 
 
BHL: Bilateral Hiliar Lymphadenopathy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
89
 Table 1.13. Clinical signs suggestive of ocular sarcoidosis. 
Mutton fat KPs and/or iris nodules at pupillary margin or stroma 
Tabecular meshwork nodules and/or tent-shaped peripheral anterior synaechia 
Snowballs/string of pearls vitreous opacities 
Multifocal peripheral chorioretinal lesions (active and atrophic) 
Nodular and/or segmental periphlebitis(with or without candle-wax exudates) and/or 
macroaneurysm 
Optic disc nodules/granuloma and/or solitary choroidal nodule 
Bilateral inflammation (evident on clinical examination or on investigational imaging) 
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Table 1.14. Laboratory investigations in suspected ocular sarcoidosis. 
Negative tuberculin test in a patient who either had BCG vaccination or previously had a 
positive tuberculin test 
Elevated sACE and/or elevated serum lysozyme*  
Chest X-ray showing BHL 
Abnormal liver enzyme tests (any two of: alkaline phosphatase, aspartate transaminase, 
alanine transaminase) 
Chest CT-scan in patients with normal chest X-ray 
 
* Lysozyme required in patients taking ACE inhibitors 
BHL: Bilateral Hiliar Lymphadenopathy 
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The KPs tend to have the mutton-fat appearance, and it is characterised by the presence of iris 
nodules. A Japanese study revealed the presence of nodules or granulomas on the trabecular 
meshwork in nearly half of the patients (Mizuno et al. 1986). Patients with CAU may develop 
macular oedema more frequently than patients with acute or relapsing disease; corneal band 
keratopathy may also develop. Occasionally intermediate uveitis with vitritis with or without 
peripheral vasculitis and snowball infiltrates is seen. This type of uveitis may precede more 
severe posterior segment changes (Rothova 2000). Posterior segment involvement include the 
presence of periphlebitis with typical segmental cuffing or more extensive perivenous 
exudates, in addition to these features the presence of multiple small round chorioretinal 
lesions mostly in the peripheral retina not associated with retinal vessels are seen. Optic nerve 
leakage on fluorescein angiography might be seen and it should be differentiated from true 
optic nerve involvement, since it appears to be a higher involvement of the central nervous 
system in sarcoidosis in the presence of posterior uveitis (Menezo et al. 2009).  
 
Systemic investigations that help in the diagnosis of sarcoidosis are chest radiograph. 
Findings on chest x-ray suggestive of sarcoidosis have been classified in a staged system from 
0 to III (Miller et al. 1995). Laboratory values are affected to some extent by the 
epidemiology of uveitis of the geographical area were they are performed. Among them, 
levels of serum angiotensin-convertase enzyme (sACE) produced by local macrophages 
appears to correlate with disease activity (Weinreb et al. 1984), however the test is not useful 
in patients who are taking ACE inhibitors. In these cases determining lysozyme levels in 
serum would be recommended. In fact a Japanese study has shown lysozyme levels to have a 
better predictive value than sACE (Kawaguchi et al. 2007). 
Chest CT-scans have been shown to be helpful in those cases where chest radiography fails to 
provide diagnostic support and can assist targeting of the biopsy site (Kaiser et al. 2002). 
Newer functional imaging techniques such as PET-scan allow not only detecting localised 
foci of inflammation; assess activity and determining treatment efficacy (Shulman et al. 
2009).  
The gold standard for confirmation of the diagnosis of sarcoidosis is the histological 
demonstration of non-caseating granuloma formation in the involved tissue, together the 
presence of other clinical manifestations. The presence of non-caseating granuloma on tissue 
biopsy and clinical features compatible with sarcoidosis are considered a proof of a definite 
diagnosis. Histological confirmation can be challenging, and therefore more accessible sites 
such as skin lesions or the conjunctival mucosa have been proposed (Bastiaensen et al. 1985; 
Leavitt et al. 1998; Spaide et al. 1990). Fibreoptic bronchoscopy with transbronchial biopsy 
has reported to be positive in up to 90 % of patients with positive findings on chest x-ray 
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(Koerner et al. 1975). In these cases with negative findings in transbronchial biopsy, BALmay 
be of value (Society 1990; Vallee et al. 1990).  
 
1.8. RESEARCH HYPOTHESIS 
1.8.1. AIM OF STUDY 
The study aims to evaluate the role of specific gene polymorphisms in determining the 
outcome of patients with AU. The specific hypothesis to be tested is:  
1. Polymorphisms of certain key cytokine(s) gene(s) are associated with the development of 
complications leading to a poorer visual outcome including macular oedema, glaucoma 
and cataract in patients with AU, and  
2. That posterior synaechia formation is associated with an increased complication rate. 
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CHAPTER TWO 
2. MATERIALS AND METHODS 
2.1. PATIENT CLASSIFICATION 
Patients with uveitis presenting to Professor Lightman’s uveitis clinics at Moorfields Eye 
Hospital clinic were characterised on clinical grounds, and were divided into those with acute-
recurrent AU, CAU, and those with FHC. 
The groups of patients identified were idiopathic acute-recurrent AU (n=98), acute-recurrent 
AU associated with systemic disease (n=30), idiopathic CAU (n=21), CAU associated with 
systemic disease (n=7), FHC (n=11). AU with associated disease was defined as AU related 
to systemic conditions such as AS (n= 19), Reiter’s syndrome (n=4), reactive arthritis (n=3), 
psoriatic arthropathy (n=3), IBD (n= 1), sarcoidosis (n=4), Behçet’s disease (n=1), systemic 
vasculitis (n=1), multiple sclerosis (n=1).  
All patients had a complete ocular examination including best corrected Snellen visual acuity, 
biomicroscopy, Goldmann applanation tonometry and dilated fundus examination. 
Fluorescein angiography, visual fields and ultrasonography were performed when indicated. 
Initial laboratory investigations included full blood cell count, renal and liver function, 
treponema serology, serum angiotensin-convertase enzyme and HLA-B27 typing. Chest x-
rays were requested for these patients suspected of having associated sarcoidosis. Patients 
with clinical and laboratory evidence of associated systemic disease were referred to the 
appropriate medical team for further evaluation. 
Patients were divided further into either a uveitis-related complication group or a no 
complication group. These complications would have been detected on the day of clinical 
phenotyping or venepuncture. The ocular complications analysed were the presence of 
posterior iris synaechia, posterior subcapsular lens opacity, ocular hypertension and/or 
glaucoma, steroid response, and clinical or angiographic macular oedema. Posterior iris 
synaechia was defined as the presence of iris adhesions to the anterior lens capsule post-
dilatation. Only the presence of posterior subcapsular lens opacities was considered as 
cataract secondary to uveitis. Ocular hypertension was defined as intraocular pressure greater 
than 21mmHg without associated optic disc or visual field damage prior to treatment with 
corticosteroids. Glaucoma secondary to uveitis consisted of raised intraocular pressure over 
21 mmHg with associated optic disc damage and/or correspondent visual field defect. 
Clinically significant macular oedema was considered when thickening of the central macula 
and or loss of the normal foveal depression was present on biomicroscopy confirmed or not 
by fluorescein angiography.  Patients with uveitis of infectious aetiology (i.e., herpetic 
simplex or zoster uveitis), postoperative uveitis, or those with a previous history of glaucoma, 
macular and or other retinal disease were excluded. 
94
This study was approved by the Ethics Committee of Moorfields Eye Hospital and was 
conducted according to the Tenents of the Declaration of Helsinky. 
 
2.2. CONTROL POPULATION 
A total number of 586 subjects from an ethnically matched population were recruited. All the 
controls were of Caucasian origin from the Southeast of England to avoid any ethnic genetic 
differences (Grutters et al. 2002; Pantelidis et al. 2001). Peripheral blood was collected from 
patients undergoing routine cataract surgery for age related cataract and from blood and organ 
donors. They were screened to have no past or present ocular or medical history. 
Data from the control population described in chapter 5 was collected from 66 patients who 
underwent routine cataract surgery and who had no previous history of ocular disease or 
related systemic co-morbidity. 
Control data described in chapters 4 and 6 included the 66 patients described in chapter 5 and 
in addition to these the remaining group of control subjects came from blood and organ 
donors from South England, as well as cadaver donors from Oxford, England.  
 
2.3. PERIPHERAL BLOOD SAMPLES 
Fifteen ml of peripheral blood were obtained by venepuncture from patients undergoing 
cataract surgery who had no previous history of ocular disease or autoimmune related 
systemic disorders. Willing patients were asked to sign a control sample specific consent form 
[Appendix 1] and an ethics approved information leaflet was given to each patient [Appendix 
2]. A record of the patient’s ethnic group was kept. All blood samples were anticoagulated 
with Na3citrate or Na2EDTA in four 4.5ml BD Vacutainer TM or polypropylene tubes and 
kept on ice before being frozen and stored at minus 20°C for later manipulation. Samples 
were not stored in heparin coated tubes as an anticoagulant since it inhibits both reverse 
transcriptase and Taq polymerase reactions (Beutler et al. 1990; Wang et al. 1992; Willems et 
al. 1993). 
 
2.4. GENETIC ANALYSIS 
2.4.1. DNA extraction methods 
Genomic DNA from all frozen bloods were extracted either using a salting out DNA 
extraction method or by using the commercial DNA extraction kit, QIAamp®DNA Blood 
Maxi Kit (QIAGEN Ltd., UK). No significant difference in the quality of the DNA was seen 
between the two methods used. 
 
2.4.1.1. Salting-Out DNA Extraction Method 
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A modified salting-out method originally described by Miller et al. (Miller et al. 1988) was 
used for DNA extraction. Assuming 20 ml of blood (scaleable as required), anticoagulated 
blood was thawed in room temperature and decanted into a 50 ml centrifuge tube. The tube 
was then top up to 50 ml with fresh TE solution (5 ml 1M Tris, pH 7.35; 1 ml 0.5M EDTA, 
pH 8.0). The mixture was then centrifuged at 2500 rpm for 20 minutes at room temperature. 
Thirty ml of the supernatant was then decanted into Virkon or Hycolin and left for 2 hours 
before discarding. The residual pellet after centrifuge was resuspended to 40 ml of swelling 
buffer and left on ice for 20 minutes. The mixture was then centrifuged at 2500 rpm for 15 
min at 4 °C (step 1). The supernatant was poured off and discarded after. The residual pellet is 
re-suspended in 10 ml of red cell lysis buffer and left at room temperature for 15 minutes 
(step 2). The mixture was further centrifuged at 2500 rpm for 15 minutes at room 
temperature. After which, the supernatant was discarded. The pellet should be white with a 
pink halo. If the pellet was still dark in colour at this stage, steps 1 and 2 were repeated until it 
was. When the pellet was homogenously white, it was either stored at minus 70 °C to be 
processed another day or processed immediately. The pellet was resuspended in 3 ml nuclei 
lysis buffer, 200 c of 10% w/v sodium dodecyl sulphate (SDS) and 600 ml Proteinase K 
solution (10 mg/ml) in a sterile 15 ml tube and left overnight at 37°C. The mixture was later 
added with 1 ml of 6M NaCl and shaken vigorously for 30 seconds. It was then centrifuged at 
3000 rpm for 30 minutes. The supernatant was aspirated into a sterile 15 ml tube, added with 
10 ml cold absolute ethanol, and mixed gently until the DNA was precipitated. The 
precipitated DNA was removed and placed into a sterile tube and washed with 75% ethanol. 
The mixture was then left to dry with the lid open. Finally, the DNA was re-suspended in an 
appropriate volume of sterile water, approximately 400 µl, and stored at minus 20 °C. 
 
2.4.1.2. QIAmp®DNA Blood Maxi Kit 
Five hundred µl of QIAGEN protease were pipetted into the bottom of a 50 ml centrifuge tube 
and 8 ml of blood were added and vortexed briefly. 9.6 ml of Buffer AL were added (6ml 
Buffer when using 5 ml of peripheral blood) and mixed by vortexing three times, for at least 5 
seconds each time. This mixture was then incubated at 70 °C for 10 minutes, as DNA yield 
reaches a maximum after lysis for 10 minutes at 70 °C. Eight ml of ethanol (96-100 %) were 
added to the mixture and vortexed. When the initial sample was 5ml of peripheral blood, the 
volume of ethanol was reduced to 5 ml. One half of the solution was transferred into the 
QIAamp Maxi column placed in a 50 ml centrifuge tube and centrifuged at 3000 rpm (1850 g) 
for 3 minutes. The QIAamp Maxi column was removed, the filtrate discarded into Virkon and 
the column was placed back again in the tube. The remainder of the solution was loaded and 
centrifuged again at 3000 rpm for another 3 minutes. Five ml of Buffer AW1 were added to 
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the QIAamp Maxi column and centrifuged at 5000 rpm (4500 g) for 1 minute. Without 
discarding the flow-through from the centrifuge tube, 5 ml of Buffer AW2 were added to the 
QIAamp and centrifuged at 5000 rpm (4500 g) for 15 minutes. The QIAamp column was then 
placed in a clean 50 ml centrifuged tube. 960 µl of Buffer AE equilibrated at room 
temperature was pipetted directly onto the membrane of the QIAamp Maxi column and 
incubated at room temperature for 5 minutes and centrifuged at 5000 rpm for 5 minutes. In 
order to maximise the DNA concentration the eluate containing the DNA was reloaded onto 
the membrane of the QIAamp Maxi column, incubated at room temperature for 5 minutes and 
centrifuged at 5000 rpm for another 5 minutes. This eluate containing the DNA was then 
stored in Eppendorf tubes at minus 20 °C. 
 
2.4.2. Determination of the concentration of the DNA extracted 
The concentration of the DNA extracted was determined by means of spectrophotometry.  
For quantifying the amount of DNA readings should be taken at wavelengths of 260 nm and 
280 nm. The reading at 260 nm allows calculation of the concentration of the nucleic acid in 
the sample, and the ratio between the readings at 260 nm and 280 nm provides an estimate of 
the purity of the nucleic acid. 
It was anticipated that spectrophotometric reading of Absorbance260/280 would be in the 
range 1.7–2.0. In order to determine the Absorbance260/280 ratio, 69µl of sterile water for 
injection and 1µl of the extracted sample DNA were transferred using a Gilson pipette (P100) 
into a 0.5ml Eppendorf TM tube. The concentration of DNA was calculated multiplying the 
Absorbance260/280 ratio by 50 and by 70 as dilution factor. The concentration of DNA was 
required so that the DNA obtained could be diluted to a concentration of 50 ng/µl, as required 
by the genotyping protocol at the Division of Genomic Medicine, University of Sheffield. 
There was no need for dilution whenever a sample was found to have a concentration of less 
than 50ng/µl. 
 
2.4.3. Genotyping of single nucleotide polymorphisms. PCR analysis 
Polymerase chain reaction (PCR) is a technique designed to allow for selective amplification 
of a target DNA sequence within a heterogeneous collection of DNA sequences by in vitro 
enzymatic replication. Since its original description in 1985, PCR has evolved into a group of 
different technologies almost universally used in diagnostic or clinical research.  
PCR involves the enzymatic synthesis of millions of copies of a specific DNA segment. The 
exponential amplification of the template DNA is carried out by heat-stable DNA 
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polymerases with a 3’→5’ exonuclease activity, which will result in the synthesis of defined 
portions of the original DNA sequence. 
It is based on three steps: denaturation of the template into single strands by heating the 
template of DNA to high temperature, annealing of primers to each original strand for new 
strand synthesis, and extension of the new DNA strands from the primers.  
Double-stranded DNA containing the sequence to be copied and amplified is mixed with a 
large molar excess of two single-stranded DNA oligonucleotides or primers. The first primer 
is identical to the 5’ end of the sense strand of the DNA to be copied, and the second primer is 
identical to the anti-sense strand at the 3’ end of the sequence.  
The PCR reaction is initiated by melting the double-stranded DNA at high temperature 
(typically 90 to 95°C) and then cooling the mixture to allow DNA annealing, so the first 
primer will hybridize to the 3’ end of the anti-sense strand and the second primer will 
hybridize to the 3’ of the sense strand. This annealed mixture is then incubated with DNA 
polymerase and all four deoxynucleotide triphosphates (dATP, dTTP, dGTP, dCTP) to allow 
new DNA to be synthesized. The original sense strand is used as a template to make the new 
anti-sense strand and then allowed to re-anneal with the primers.  
A second cycle commences when the reaction mixture is re-melted and the allowed to re-
anneal with the primers. In this synthetic step of the second cycle, each strand synthesized in 
the first cycle serves as an additional template after having hybridized with the appropriate 
primers. This second cycle is completed when DNA polymerase extends the primers to 
synthesize the complement of the templates. These reactions are performed at the optimum 
temperature for the heat-stable polymerase (68 to 72°C) automated by temperature controlled 
cyclers that regulate denaturation of the template into single strands, annealing and DNA 
synthesis. The most commonly used polymerase is the enzyme isolated from Thermus 
aquaticus (Taq DNA polymerase). 
The three-stage cycle of denaturation, annealing and primer extension is repeated 25 to 40 
times in a typical PCR procedure. The product of such reaction is a large quantity of double-
stranded DNA whose length is determined by the distance between the primer sites on the 
original template molecule.  
 
2.4.3.1. Components 
2.4.3.1.1. DNA polymerase 
The most commonly used DNA polymerase for a wide range of DNA polymerases is a cloned 
heat-stable DNA polymerase from Thermus aquaticus.  
 
2.4.3.1.2. Oligonucleotide primers 
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PCR primers are normally between 18 and 30 nucleotides in length and should have a guanine 
and cytosine context of about 50%. The melting temperature at which half the oligonucleotide 
is annealed to its exact complement (Tm) should be similar for the two primers in a reaction 
and about 5°C above the annealing temperature. Despite software being currently available to 
calculate the ideal Tm, empiric testing of annealing temperatures is often necessary for a well-
optimized PCR assay.  
 
2.4.3.1.3. Thermal cycling equipment  
PCR process involves thermal cycling between the different cycles of denaturation, annealing 
and extension. During denaturation temperatures of 94°C are often required, although after 
several cycles, it can be lowered to 90 to 92°C to reduce loss of polymerase activity during 
the course of PCR. The choice of annealing temperature is in the range of 50 to 60°C, but will 
ultimately depend on primer Tm. Finally, samples will be heated at 68 to 72°C during 
extension.  
Thermal cyclers that can monitor progress of the amplification reaction while it is taking 
place are called real-time thermal cyclers. They monitor the emission of fluorescence from 
labels whose emission intensity is proportional to the amount of amplified DNA. When Taq 
DNA polymerase cleaves a probe labelled with a fluorophore it will dissociate the probe from 
the quencher, and hence amplification will be detected by the correspondent increase in 
fluorescence. 
 
2.4.3.1.4. Post-PCR analysis 
Traditionally, once PCR reaction is complete the amplified DNA fragments are analysed and 
visualised by gel electrophoresis. However, Real-Time PCR allows the analysis of the 
products while the reaction is actually in progress and facilitates the quantitation of the DNA. 
This is achieved by using various fluorescent dyes which react with the amplified product and 
can be measured simplifying the process of quantification. Identification of the amplification 
products by probe detection in real-time is highly accurate compared with size analysis on 
gels, and since it is not necessary to perform electrophoresis or other manipulations after the 
DNA amplification reaction Real-Time PCR assays can be completed very rapidly (Heid et al. 
1996). 
Another variant of PCR, allele-specific PCR is designed to amplify a DNA sequence while 
excluding the possibility of amplifying other alleles. It is based on the requirement for precise 
base matching between the 3’ end of a PCR primer and the target DNA. 
 
2.4.3.1.5. TaqMan 
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The TaqMan system is a method of following real time-PCR, used for the analysis of 
polymorphisms. We used the 5’ nuclease (TaqMan®) allelic discrimination assay for 
genotyping cytokine polymorphisms in which the Taq polymerase cleaves the so-called 
TaqMan probe during the extension phase of the PCR (Hui et al. 2008).  
With this method, the region flanking the polymorphism is amplified in the presence of two 
probes since we are dealing with a bi-allelic system. There is one specific probe to an allelic 
variant, and they were labelled with a different reporter dye, 6-carboxy-fluorescein (FAM) 
and tetrachloro-6-carboxy-fluoresecein (TET). These probes consists of an oligonucleotide 
that is complementary to the sequence of interest located over the SNP, labelled with the 
reporter dye at the 5’ end and with the quencher dye 6-carboxytetramethylrhodamine 
(TAMRA) at the 3’ end. As long as the probe is intact the proximity between the reporter and 
quencher dyes reduces the emission of fluorescence. During the degradation of the probe by 
the 5’→ 3’exonuclease activity, the reporter and quencher dyes are separated resulting in an 
increase of the reporter fluorescence emission. In this way, fluorescence is a measure of each 
probe binding to a specific allele.  
As well as the samples being analysed, a series of controls were included. No template control 
containing no DNA. Allele 1 control where a DNA sample homozygous for allele 1, and 
allele 2 control in which the DNA sample is homozygous for allele 2 are amplified. The 
fluorescence levels in the allele 1 and 2 control reflect the cleavage of the allele specific 
fluorophore.  
This process is measured by the ABI PRISM™ 7200 Sequence Detector (Applied 
Biosystems, Warrington ,UK). 
 
2.4.3.1.5.1. Primer design and optimization 
Probes and primers for detection of the SNP were designed using the Primer Express® 
software (Applied Biosystems) (Table 2.1). We followed the guidelines for oligonucleotide 
design in Primer Express® using the same principles as in the design of standard PCR 
primers. The optimal probe concentrations are determined by comparing a range of TET 
concentrations against a constant FAM concentration prior to PCR, and identifying those who 
produce approximately equal levels of fluorescence signal. 
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Table 2.1. TaqMan probes and primers sequences. 
 
 Sequence (All 5' - 3') N 
bases 
TNF-α (-308 )   
Allele 1 (TET Label) ACC  CCG  TCC  CCA  TGC  CC 17  
Allele 2 (FAM 
Label) 
AAC  CCC  GTC  CTC  ATG  CCC  C 19  
Forward Primer GGC  CAC  TGA  CTG  ATT  TGT  GTG T 22 
Reverse Primer CAA  AAG  AAA  TGG  AGG  CAA  TAG  GTT 24  
TNF-α (-238)    
Allele 1 (TET Label) CCT CCC TGC TCC GAT TCC G 19  
Allele 2 (FAM 
Label) 
TCC TCC CTG CTC TGA TTC CGA 21 
Forward Primer GCA TCA AGG ATA CCC CTC ACA 21  
Reverse Primer ATC AGT CAG TGG CCC AGA AGA  21  
IL1ra( +2018)    
Allele 1 (FAM 
Label) 
AAC  AAC  CAA  CTA  GTT  GCT  GGA  TAC  TTG  
CAA 
30  
Allele 2 (TET Label) ACA  ACC  AAC  TAG  TTG  CCG  GAT  ACT  TGC 27 
Forward Primer GGG  ATG  TTA  ACC  AGA  AGA  CCT  TCT  ATC  T 28  
Reverse Primer CAA  CCA  CTC  ACC  TTC  TAA  ATT  GAC  ATT 27 
IL-10(-1082)   
Allele 1 (FAM 
Label) 
CTA  CTT  CCC  CCT  CCC  AAA  GAA  GCC  T 25  
Allele 2 (TET Label) CCT  ACT  TCC  CCT  TCC  CAA  AGA  AGC  C 25 
Forward Primer GAT  AGG  AGG  TCC  CTT  ACT  TTC  CTC  TTA 27  
Reverse Primer CAC  ACA  CAA  ATC  CAA  GAC  AAC  ACT  AC 26  
IL-6(-174)    
Allele 1 (FAM 
Label) 
ACG  TCC  TTT  AGC  ATC  GCA  AGA  CAC  AAC 27 
Allele 2  (TET 
Label) 
ACG  TCC TTT  AGC  ATG GCA  AGA  CAC  AAC 27 
Forward Primer GCT  GAT  TGG  AAA CCT  TAT  TAA  GAT  TGT 27  
Reverse Primer AAT  GAC GAC  CTA  AGC  TGC  ACT  TT 23 
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2.4.3.1.5.2. PCR conditions 
All reactions were performed using a 96-well PCR plate. Each reaction well represented one 
of the specific allelic polymorphism for the DNA sample of each patient and a template 
control.  
Each well contained 7.5 µl of TaqMan Mastermix. The volume for each primer and probes for 
the different cytokine polymorphisms were optimized as follow: 
TaqMan 7200 Protocol for IL-1ra (+2018): 
0.375 µl of forward primer, 0.375 µl of reverse primer, 0.15 µl of FAM probe, 0.525 µl of 
TET probe and 4.875 µl of distilled H2O.  
TaqMan 7200 Protocol for IL-6 (-174): 
0.025 µl of forward primer, 0.025 µl of reverse primer, 0.09 µl of FAM probe, 0.18 µl of TET 
probe 5.88 µl of distilled H2O. 
TaqMan 700 Protocol for IL-10 (-1082): 
0.075 µl of forward primer, 0.45 µl of reverse primer, 0.15 µl of FAM probe, 0.375 µl of TET 
probe 5.25 µl of distilled H2O. 
TaqMan 7200 Protocol for TNF-α (-238): 
1.35 µl of forward primer, 1.35 µl of reverse primer, 0.15 µl of FAM probe, 0.225 µl of TET 
probe 3.225 µl of distilled H2O. 
TaqMan 7200 Protocol for TNF-α (-308): 
0.45 µl of forward primer, 0.45 µl of reverse primer, 0.15 µl of FAM probe, 0.375 µl of TET 
probe 4.875 µl of distilled H2O. 
All reactions were carried out using a DNA Engine Tetrad Machine PTC-225 Peltier Thermal 
Cycle and run according to the following protocols (Tables 2.2-2.6):  
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Table 2.2 TaqMan 7200 Protocol for IL-1ra (+2018). 
Step 1 2 minutes 50°C 
Step 2 10 minutes 95°C 
Step 3 15 seconds 95°C 
Step 4 1 minute 64°C 
Step 5 Go to step 3 and repeat 40 
times 
 
Step 6 Hold 15°C 
Step 7 End  
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 Table 2.3. TaqMan 7200 Protocol for IL-10 (-1082). 
Step 1 2 minutes 50°C 
Step 2 10 minutes 95°C 
Step 3 15 seconds 95°C 
Step 4 1 minute 62°C 
Step 5 Go to step 3 and repeat 40 
times 
 
Step 6 Hold  15°C 
Step 7 End  
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 Table 2.4. TaqMan 7200 Protocol for IL-6 (-174). 
Step 1 2 minutes 50°C 
Step 2 10 minutes 95°C 
Step 3 15 seconds 95°C 
Step 4 1 minute 62°C 
Step 5 Go to step 3 and repeat 40 
times 
 
Step 6 Hold  15°C 
Step 7 End  
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 Table 2.5. TaqMan 7200 Protocol for TNF-α (-238). 
Step 1 2 minutes 50°C 
Step 2 10 minutes 95°C 
Step 3 15 seconds 95°C 
Step 4 1 minute 58°C 
Step 5 Go to step 3 and repeat 40 
times 
 
Step 6 Hold  15°C 
Step 7 End  
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 Table 2.6. TaqMan 7200 Protocol for TNF-α (-308). 
Step 1 2 minutes 50°C 
Step 2 10 minutes 95°C 
Step 3 15 seconds 95°C 
Step 4 1 minute 58°C 
Step 5 Go to step 3 and repeat 40 
times 
 
Step 6 Hold  15°C 
Step 7 End  
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2.4.3.1.6. PCR-SSPs 
PCR with sequence-specific primers (PCR-SSP) uses sequence-specific primers with 3’ end 
mismatches and identifies the presence of specific allelic variants through PCR amplification.  
 
2.4.3.1.6.1. Primer design and optimization 
TNF, LT-α, TNFR primer design 
Seventeen SNPs were investigated in this study, including TNF -1031, -863, -857, -308, -238 
(all promoter, NCBI RefSNP: rs1799964, rs1800630, rs1799724, rs361525, and rs1800629), 
LTA +720 (exon 3, NCBI RefSNP: rs1041981), +365 (intron 1, RefSNP: rs746868), +249 
(intron 1, RefSNP: rs909253); TNFRSF1A -201, -230, -845, -839, -1135 (all promoter, 
RefSNP: rs4149570, rs4149621, rs767455, rs4149584, and rs1800692); TNFRSF1B +1663 
(exon 10, RefSNP: rs1061624), +1668 (exon 10, RefSNP: rs5030792), +1690 (exon 10, 
RefSNP: rs3397), +676 (exon 6, RefSNP: rs1061622). For the polymorphisms in the TNF-α 
and LT-α genes, we used the primer sequences and primer mixtures previously described by 
Fanning et al. and Grutters et al. (Fanning et al. 1997; Grutters et al. 2002) (Tables 2.7-2.9). 
The primer sequences used for polymorphisms of TNFR1 gene are shown in table 2.10 (Table 
2.10). For identifying the polymorphisms in the TNFR2 gene, we used the primer sequences 
and primer mixtures described by Pantelidis and colleagues (Table 2.11) (Pantelidis et al. 
1999).  
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Table 2.7. TNF-1031, -863, -857 primer sequences. From Grutters et al. (Grutters et al. 2002). 
Primer TNF-α  Sequence Conc. 
(ng/µl) 
Product size 
(bp) 
 (-1031 )    
1 T CAAAGGAGAAGCTGAGAAGAT   
2 C CAAAGGAGAAGCTGAGAAGAC   
3 Reverse 
primer 
CCGGGAATTCACAGACCCC 20 433 
 (-863)    
4 C CGAGTATGGGGACCCCCC   
5 A GAGTATGGGGACCCCCA   
6 Forward 
primer 
CCGGGAATTCACAGACCCC 20 263 
 (-857)    
7 C CTACATGGCCCTGTCTTCG   
8 T TCTACATGGCCCTGTCTTCA   
9 Forward 
primer 
AAGGATAAGGGCTCAGAGAG 10 270 
All 
5’→3’ 
    
Conc.: Concentration 
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 Table 2.8. TNF-238, -308 primer sequences. From Fanning et al. (Fanning et al. 1997). 
TNF gene 
SNPs 
Primer 
Mix No 
238 308 
Primer 
No* 
Conc(µM) Primer 
No* 
Conc(µM) Product 
Size (bp) 
1 A - 1 0.58 5 0.57 763 
2 G - 1 0.58 6 0.57 763 
3 A - 2 0.47 5 0.57 763 
4 G - 2 0.47 6 0.57 763 
5 G G 3 0.49 7 0.56 109 
6 A G 4 0.62 7 0.56 109 
7 G A 3 0.49 8 0.56 109 
8 A A 4 0.62 8 0.56 109 
9 - G 1 0.58 7 0.56 835 
10 - A 1 0.58 8 0.56 835 
11 - G 2 0.47 7 0.56 835 
12 - A 2 0.47 8 0.56 835 
Conc.: Concentration 
 
* Primer 1: 5’ GCA TCC CCG TCT TTC TTC AC 
Primer 2: 5’ GCA TCC CCG TCT TTC TCC AT 
Primer 3: 5’ CTC CCC ATC CTC CCT GCT CC 
Primer 4: 5’ CTC CCC ATC CTC CCT GCT CT 
Primer 5: 5’ GAA GCA CCC CCT CGG AAT CA 
Primer 6: 5’ GAA GCA CCC CCT CGG AAT CG 
Primer 7: 5’ ATA GGT TTT GAG GGG CAT CG 
Primer 8: 5’ ATA GGT TTT GAG GGG CAT CA 
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Table 2.9. LT-α primer sequences. From Fanning et al. (Fanning et al. 1997). 
LT-α gene 
SNPs 
Primer 
Mix No 
365 249 
Primer 
No* 
Conc(µM) Primer 
No* 
Conc(µM) Product 
Size (bp) 
1 G - 1 0.6 5 0.64 390 
2 C - 1 0.6 6 0.61 390 
3 G - 2 0.6 5 0.64 390 
4 C - 2 0.6 6 0.61 390 
5 G A 3 0.7 7 2.3 153 
6 C A 4 2.2 7 2.3 153 
7 G G 3 0.7 8 1.7 153 
8 C G 4 2.2 8 1.7 153 
9 - A 1 0.6 7 2.3 507 
10 - G 1 0.6 8 1.7 507 
11 - A 2 0.6 7 2.3 507 
12 - G 2 0.6 8 1.7 507 
Conc.: Concentration 
 
* Primer 1: 5’ GAG CAG CAG GTT TGA GGG 
Primer 2: 5’ GAG CAG CAG GTT TGA GGT 
Primer 3: 5’ GAC CTC CCG CCC TGG GAG AC 
Primer 4: 5’ GAG CTC CCG CCC TGG GAG AG 
Primer 5: 5’ GGG GTC GGG GGG TGC TG 
Primer 6: 5’ GGG GTC GGG TGC TC 
Primer 7: 5’ ATT CTC TGT TTC TGC CAT 
Primer 8: 5’ ATT CTC TGT TTC TGC CAT GG 
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Table 2.10. TNFR1 primer sequences. 
TNFR1 gene SNPs Primer 
Mix 
No 
201 230 845 839 1135 
Primer 
No* 
Conc(Mm) Primer 
No* 
Conc(mM) Product 
Size 
(bp) 
1 G - G - - 1 0.82 5 1.05 681 
2 G - A - - 1 0.82 6 0.98 681 
3 T - G - - 2 0.76 5 1.05 681 
4 T - A - - 2 0.76 6 0.98 681 
5 - G G - - 3 0.69 5 1.05 657 
6 - G A - - 3 0.69 6 0.98 657 
7 - A G - - 4 0.67 5 1.05 657 
8 - A A - - 4 0.67 6 0.98 657 
9 - - - G C 7 0.63 9 0.68 300 
10 - - - A C 8 0.50 9 0.55 300 
11 - - - G T 7 0.63 10 0.65 300 
12 - - - A T 8 0.50 10 0.52 300 
 
Conc.: Concentration 
 
* Primer 1: 5’ TGGAAAACAGATCCAGACAGG (sense) 
Primer 2: 5’ ATTGGAAAACAGATCCAGACAGT (sense) 
Primer 3: 5’ GTTATGTGTCTGAGAAGTTCATTTG (sense) 
Primer 4: 5’ AGTTATGTGTCTGAGAAGTTCATTTA (sense) 
Primer 5: 5’ TCCCTGGTCTCACCAGC (antisense) 
Primer 6: 5’ GTCCCTGGTCTCACCAGT (antisense) 
Primer 7: 5’ TCTTCTTGCACAGTGGACCG (sense) 
Primer 8: 5’ TCTTCTTGCACAGTGGACCA (sense) 
Primer 9: 5’ CGGCACAGCTAAAGGAGG (antisense) 
Primer 10: 5’ GCGGCACAGCTAAAGGAGA (antisense)   
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Table 2.11. TNFR2 primer sequences. From Pantelidis et al. (Pantelidis et al. 1999). 
Primer 
No 
TNFR2 gene SNPs Concentration  
(µM) 
Exon 
 1663 1668 1690 676  
1 G - - - 0.92 10 
2 A - - - 3.2 10 
3 - T - - 1.38 10 
4 - G - - 1.38 10 
5 - - C - 1.34 10 
6 - - T - 0.9 10 
7 - - - T 0.69 6 
8 - - - G 0.69 6 
 
Primer 1: 5’ AGAGCAGAGGCACGG (sense) 
Primer 2: 5’ AGAGCAGAGGCAGCGA (sense) 
Primer 3: 5’ AGAGGCAGCG(A/G)GTTGT (sense) 
Primer 4: 5’ AGAGGCAGCG(A/G)GTTGG (sense) 
Primer 5: 5’ GCCTCTGCTGCCATGGC (sense) 
Primer 6: 5’ GCCTCTGCTGCCATGGT (sense) 
Primer 7: 5’ GACGTGCAGACTGCATCCA (antisense) 
Primer 8: 5’ GACGTGCAGACTGCATCCC (antisense) 
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IL-8, CXCR1, MCP-1, CCR2 primer design 
To locate potential SNPs, multiple sequences for IL-8, CXCR1, MCP-1 and CCR2 deposited 
in GenBank were analysed. Chemokine polymorphisms affecting the promoter region and 
exon were preferably selected, and where it was not possible, UTR (untranslated region) and 
intron polymorphisms were selected. To verify the presence of these polymorphisms, 
sequence specific primer PCR (SSP-PCR) was used (Table 2.12).  
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Figure 11. CC and CXC chemokine and receptor primer sequences. 
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2.4.3.1.6.2. PCR conditions 
All PCR amplifications were carried in a PTC200 thermal cycler (MJ Research, GRI, UK). 
Two different cycle parameters were used. 
PCR amplifications for the TNF-α promoter polymorphisms (-1031, -863, -857, -308, and -
238), Lymphotoxin-α (+720, +365, + 249), TNFRSF1A (-201, -230, -845, -839, -1135), 
TNFRSF1B (+1663, +1668, +1690, +676) were as follow: 
The DNA mixtures were heated at 96°C for 1 min in the first round of denaturation and then 
subjected to 5 cycles of 25 sec at 96°C, 45 sec at 70°C, and 25sec at 72°C; then followed by 
21 cycles of 25 sec at 96°C, 50 sec at 65°C, 30 sec at 72°C; and 4 cycles of 30 sec at 96°C, 60 
sec at 55°C, 90 sec at 72°C. Ten µL Orange-G loading buffer (0.5mM) was added into the 
final PCR mixtures and they were loaded onto a 1% agarose-0.5× Tris-borate-
ethylenediamine tetra-acetic acid gel containing 0.14 µg/mL ethidium bromide. 
Electrophoresis was performed for about 20 minutes at 200 V/cm2 in 0.5× TBE buffer (1× 
TBE = 89 mM Tris base, 89 mM boric acid, 2 mM EDTA, pH 8.0). The gels were visualized 
over ultraviolet light (320nm) and photographed.  
 
PCR amplifications for the IL-8 polymorphisms (38366, 37511, 36849, 36831), CXCR1 
(4205, 6694, 10188), MCP-1 (62534, 63997, 63555), CCR2 (50490, 49776, 49715, 49652, 
49105, 46295, 39353) were as follow: 
The cycling parameters for 23 µl reactions consisted of a first round of denaturation at 96°C 
for 1 min, followed by 5 cycles of 25 seconds at 96°C, 45 seconds at 70°C, 45 seconds at 
72°C followed then by 21 cycles of 25 seconds at 96°C, 50 seconds at 65°C, 30 seconds at 
72°C followed by 4 cycles of 30 seconds at 96°C, 60 seconds at 55°C, and 120 seconds at 
72°C (Bunce et al. 1995). 
After PCR amplification, the sealing mat was removed and 10 µl of Orange G loading buffer 
consisting of 150 ml of glycerol, 350 ml 0.5× TBE (1L of 0.5× TBE = 54g of Tris base, 27.5g 
of orthoboric acid and 20 ml of EDTA (0.5M, pH 8.0) or 3.72g of EDTA Na-dihydrate) and 
0.125 g Orange G were added to each well to allow visualization during agarose gel 
electrophoresis.  
The 1.5% agarose gel was prepared by dissolving 7.5g agarose powder (Baxter, UK) in 500 
ml of 0.5x TBE aided by heating in a microwave. Fourteen µl of ethidium bromide were then 
added to the dissolved agarose mixture and the final mixture is then left to set and solidify at 
room temperature. The agarose gel is then loaded onto a gel tank (Flowgen model MH3025 
with 26 well combs) containing 0.5 x TBE. After which the mixture in each reaction well 
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from the PCR plate was loaded into the agarose gel and electrophoresed for 15 minutes at 
200V. The agarose gel was then photographed over ultraviolet light.  
A positive reaction was defined as the presence of an allele-specific band of the expected size, 
in conjunction with a control band. The absence of an allele-specific band in the presence of a 
control band was considered to be a negative reaction. 
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CHAPTER THREE 
3. THE DEVELOPMENT OF COMPLICATIONS IN PATIENTS WITH CHRONIC 
ANTERIOR UVEITIS 
3.1. INTRODUCTION 
AU is the most common form of intraocular inflammation seen in the clinical setting and the 
duration of the attack of inflammation defines whether the disease is acute or chronic 
(Rodriguez et al. 1996; Rothova et al. 1996). Specifically an attack that lasts longer than three 
months is termed CAU and distinguishes the disease process from those with acute 
inflammation in whom the inflammatory process resolves in less than 3 months although it 
may recur. The explanation for why some patients develop chronic anterior disease whereas 
others do not is unknown but it is not due to inadequate treatment. In some patients, it is 
associated with a systemic disease such as sarcoidosis but in many it is idiopathic with no 
detectable evidence of any systemic inflammatory process (Weiner et al. 1991). Uveitis 
patients with associated spondyloarthropathy are nearly always HLA-B27 positive and 
usually present with a sudden onset of AU, whereas patients with IBD associated uveitis are 
less frequently HLA-B27 positive and have a more insidious onset of uveitis and more 
chronic course (Feltkamp et al. 1998). Since the HLA-B27 antigen is less frequently found 
associated with other specific uveitis entities and systemic diseases such as sarcoidosis, than 
in uveitis associated with spondyloarthropathies, this suggests that the development of 
chronicity is not related to the presence of HLA-B27. 
 
The primary aim of this study was to determine the visual outcome and long-term 
complications of patients with CAU treated aggressively as described above to achieve the 
best control of the inflammation.  
 
3.2. METHODS 
The clinical records of a total of 68 patients (91 eyes) consecutive patients with CAU were 
reviewed from Professor Lightman uveitis clinics at Moorfields Eye Hospital between 
January 1999 and June 2004.  In all cases the intraocular inflammation was active for more 
than 3 months despite treatment. All patients had a complete ophthalmic examination 
including best corrected visual acuity, biomicroscopy, applanation tonometry and fundus 
examination. Fluorescein angiography, visual fields and ultrasonography were performed 
when indicated.  Laboratory investigations included full blood cell count, renal and liver 
function, treponemal serology, and serum angiotensin-convertase enzyme. Chest or sacroiliac 
spine x-rays were requested for these patients suspected of having associated sarcoidosis or 
seronegative spondyloarthropathy respectively. HLA-B27 typing was performed according to 
the clinical features and the absence of coexistent systemic disease i.e., sarcoidosis. Patients 
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with clinical and laboratory evidence of associated systemic disease were referred to the 
appropriate medical team for further evaluation. 
 
For the purpose of the study AU was defined as the presence of inflammatory cells in the 
anterior chamber and corneal endothelium (KPs) with or without flare and absence of 
posterior vitreous cells and other features of intraocular inflammation other than macular and 
optic disc edema. Other indicators such as ciliary flush, pain and photophobia, common 
features of AAU, were absent in most of the cases. When the intraocular inflammation 
persisted for more than three months it was categorized as CAU. Idiopathic uveitis was 
defined on the basis of the absence of a detectable associated systemic disease regardless of 
whether the patient was HLA-B27 positive or not. Visual acuity wit best spectacle correction 
was recorded with Snellen chart (logMAR visual acuity was calculated from the relation; 
logMAR visual acuity = Log of the reciprocal of Snellen visual acuity). Poor outcome was 
defined as visual acuity of 0.3 logMAR (6/12 Snellen equivalent) visual acuity or worse.  
 
The ocular complications analyzed were the presence of posterior iris synechiae, posterior 
subcapsular lens opacity, ocular hypertension and/or glaucoma, and clinical or angiographic 
macular edema. Posterior iris synechiae (PS) was defined as the presence of iris adhesions to 
the anterior lens capsule post-dilatation. Only the presence of posterior subcapsular lens 
opacities was considered as cataract secondary to uveitis. Ocular hypertension was defined as 
intraocular pressure greater than 21mmHg without associated optic disc or visual field 
damage prior to treatment with corticosteroids. Glaucoma secondary to uveitis consisted of 
raised intraocular pressure over 21 mmHg with associated optic disc damage and/or 
correspondent visual field defect. Clinically significant macular edema was considered when 
thickening of the central macula and or loss of the normal foveal depression was present on 
biomicroscopy confirmed or not by fluorescein angiography.  Patients with a previous history 
of glaucoma, macular and or other retinal disease were excluded from the study. 
 
The medical treatment of all patients during the acute attack consisted of intensive topical 
corticosteroids followed by a slow reduction and in addition to this all patients received 
topical mydriatics for at least one month.  When either clinical or angiographic macular 
edema was present, patients were offered periocular or systemic corticosteroids. Some 
patients also required systemic corticosteroids for their systemic disease. Patients with raised 
intraocular pressure only during the acute episodes of uveitis were treated by increasing the 
frequency of topical corticosteroids with or without anti-hypertensive drops. When specific 
anti-hypertensive therapy was required the drug of choice was a topical non-selective beta-
adrenergic antagonist e.g., levobunolol 0.5% bid. The prostaglandin analogue latanoprost or 
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the α-adrenergic agonist apraclonidine for short-term management were the preferred second 
line agents (Sacca et al. 2001). Systemic carbonic-anhydrase inhibitors were given for the 
short-term management of raised intraocular pressure over 35mmHg. 
Patients with evidence of clinical or angiographic macular edema at any time during the 
disease who were listed for cataract surgery were given systemic corticosteroids (40mg/daily) 
for two weeks before surgery followed by the reduction of 5mg per week starting at the 
beginning of the second postoperative week (Okhravi et al. 1999).  
 
3.3. STATISTICAL ANALYSIS 
For statistical purposes patients were divided into those with idiopathic CAU, those with 
associated systemic disease, and those with FHC. Statistical analysis was performed using 
Statistical Package for the Social Sciences (SPSS) software (version 9.05, SPSS Inc., 
Chicago, ILL for Windows). 
The distributions of demographic, ocular and systemic characteristics at base line were 
compared using chi-square or by Fisher’s exact test. Product-limit or Kaplan –Meier method 
was used to estimate survival rates (Mathew et al. 1999). Log-rank test was used to compare 
survival curves among the different groups. P values less than 0.05 were considered 
statistically significant. No computation was carried out for missing data.  
 
3.4. RESULTS 
A total of 91eyes of 68 patients had AU that lasted more than 3 months. Twenty four patients 
(35.3%) were male and 44 (64.7%) were female. The median duration of follow up was 7.6 
years (1.4 to 39.9 years). The median age was 55.5 years +/- 14.1 SD (range 24 to 74). The 
commonest ethnic group was Caucasian (60.3%), followed by patients from the Indian 
subcontinent (19%) and of Afro-Caribbean origin (10.3%). About one third of the patients 
(35.3%) were diagnosed with FHC. Patients with CAU (64.7%) were subdivided into those 
with idiopathic CAU (50%) and those where the intraocular inflammation was associated to a 
systemic disease (14.7%) that may account for the uveitis. Sarcoidosis associated AU and the 
seronegative spondyloarthropathy groups with 5 patients in each group (7.4%) were the 
commonest systemic disease associations identified.  
The best corrected mean (+/- SD) logMAR visual acuity at presentation was 0.27 +/- 0.45. 
Fifty six eyes (61.5%) had a logMAR visual acuity at presentation of 0.17 or better. The 
frequency of complications is shown in table 3.1 (Table 3.1). Nineteen eyes (20.9%) 
presented with posterior subcapsular lens opacities. Overall, visual acuity was significantly 
worse in these patients with had evidence of cataract formation when they first presented (p = 
0.005 OR 5.92 95% CI 1.7-20.7). There were no significant differences between patients with 
CAU and those with FHC or those with idiopathic CAU compared to those with non-
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idiopathic CAU.  Nineteen eyes (20.9%) had evidence of PS formation at presentation. As 
expected, compared to these eyes with CAU none of them had a diagnosis of FHC, however 
no significant difference was found between patients with idiopathic CAU and those with 
CAU associated to a systemic disease. Fourteen eyes (15.4%) had an intraocular pressure of 
22mmHg or higher when they first presented, but only 2 eyes (2.2%) showed glaucomatous 
disc cupping. There was only one patient who presented with raised intraocular pressure, and 
he had a diagnosis of FHC. There was only one patient who presented with cystoid macular 
edema in one eye. There were no other significant differences between patients with CAU and 
those with FHC, or between those patients with idiopathic CAU compared to those with an 
associated systemic disease.  
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Table 3.1. Complications seen at presentation in patients with CAU. 
 CAU (n=66) FHC (n=25) 
 Idiopathic CAU (n=48) Non-idiopathic CAU (n=18)  
Raised IOP 10 3 1 
PSCLO 9 3 7 
PS 15 4 0 
CMO 0 1 0 
Cupped optic disc 2 0 0 
 
IOP: Intraocular pressure; PSCLO: Posterior subcapsular lens opacification; PS: Posterior 
synechiae; CMO: Cystoid macular oedema. 
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 Although there was no difference in the presence of PS between patients with CAU and those 
with FHC, cumulative survival curve at 5 years of follow-up showed a significant risk of 
developing PS in patients with CAU (log-rank = 3.98, p = 0.045), and it was increased 3 
years after i.e., 8 years after first presentation (log-rank = 5.23, p = 0.022) (Figures 3.1 and 
3.2). Although there were no significant differences at 5 years in terms of raised intraocular 
pressure, a trend in patients with CAU to develop glaucoma was found (log-rank = 3.08, p = 
0.08). This was maintained 3 years later (log-rank = 2.69, p = 0.100). When we looked at the 
risk of developing CMO, we found there were no significant differences between patients 
with CAU and those with FHC at 5 or 8 years follow-up (log-rank = 1.96, p = 0.161 and log-
rank = 2.15, p = 0.142 respectively). We then, compared the 2 subgroups of patients with 
CAU. There was no significant difference between patients with idiopathic uveitis compared 
to those with associated systemic disease in developing PS at 5 or 8 years of follow-up (log-
rank = 0.47, p = 0.49 and log-rank = 0.4, p = 0.52 respectively). There was a trend towards 
developing CMO after 5 and 8 years in patients with non-idiopathic CAU compared to these 
patients with idiopathic disease (log-rank = 2.17, p = 0.14 and log-rank = 2.43, p = 1.12 
respectively) (Figures 3.3 and 3.4). 
 
When we looked at visual outcome at 5 and 8 years after patients first presented in our 
department, we did not find any significant differences between patients with CAU and FHC 
or between patients with idiopathic CAU and non-idiopathic CAU.  
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Figure 3.12 Kaplan-Meier curve showing cumulative survival of eyes with a potential for 
developing posterior iris synechiae in CAU (dashed line) versus FHC (solid line) after 5 years 
of follow-up. x=CAU censored. 
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Figure 3.2. Kaplan-Meier curve showing cumulative survival of eyes with a potential for 
developing PS in CAU (dashed line) versus FHC (solid line) after 8 years of follow-up. 
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Figure 3.3. Kaplan-Meier curve showing cumulative survival of eyes with a potential for 
developing CMO in idiopathic CAU (I-CAU, solid line) versus non-idiopathic CAU (NI-
CAU, dashed line) after 5 years of follow-up. 
 
 
 
 
 
 
 
 
 
 
126
Figure 3.4. Kaplan-Meier curve showing cumulative survival of eyes with a potential for 
developing CMO in idiopathic CAU (I-CAU, solid line) versus non-idiopathic CAU (NI-
CAU, dashed line) after 8 years of follow-up. 
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3.5. DISCUSSION 
It is generally perceived that although any patient with AU may develop significant visual 
sequelae, patients with CAU do less well than those with acute recurrent disease. Patients 
with CAU often have no symptoms and minimal signs of inflammation and may be first 
diagnosed at a routine eye examination or when they present with visual loss. PS formation is 
much commoner feature in patients with chronic rather than acute inflammation. In addition 
to this, patients with CAU may need long term treatment, which is aimed at minimizing 
damage from the inflammation. Long term topical corticosteroids are the mainstay of 
treatment for CAU however, periocular corticosteroids can be given for macular edema but 
are contraindicated in steroid responders (Levin et al. 2002; Riordan-Eva et al. 1994). 
Systemic corticosteroids are indicated for bilateral macular edema in patients who cannot 
tolerate or do not respond to periocular corticosteroids. They may also be needed for the 
management of any underlying systemic disorder. Patients on chronic therapy are kept on the 
minimum possible medication to control the inflammation in order to minimize the side 
effects of corticosteroids such as cataract formation, especially the posterior subcapsular type, 
and raised intraocular pressure with or without optic disc damage and secondary visual field 
loss (Carnahan et al. 2000; Stanbury et al. 1998). In contrast, patients with FHC never 
develop PS and the inflammatory component of the disease does not respond to 
immunosuppression. Complications of this disease include cataract formation, glaucoma and 
vitritis (Jones 1993). 
 
Our data shows that the overall outcome of patients with AU that persists more than 3 months 
is encouraging. Although there was a trend in patients with non-idiopathic CAU to develop 
CMO compared to these patients with idiopathic disease, no significant differences in visual 
outcome were found between any of the groups after long term follow up. As expected there 
was a significant difference in the formation of PS between patients with FHC and the overall 
group of patients with CAU, which appears to increase with time. Analysis of follow-ups 
longer than 8 years were not included, since the increased of censored observations resulted in 
a considerable reduced number of patients followed-up.  
 
Posterior segment clinical manifestations in patients with acute/recurrent AU have been 
widely reported in the literature, however no definite conclusions as to what might be the 
cause other than the possible association with the presence of the HLA-B27 haplotype have 
been made. In these series of patients with chronic uveitis the two more common associated 
diseases were the group of seronegative arthropathies and sarcoidosis, and so the increased 
risk of CMO in non-idiopathic CAU patients might be related to systemic immune alterations 
of these systemic disorders. There are likely to be other genetic influences on disease outcome 
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in CAU. Different cytokine profiles have been found to correlate with the different clinical 
phenotypes, disease chronicity and response to treatment in the different types of AU 
(Muhaya et al. 1998; Muhaya et al. 1999). In addition to this, genotypic variations in cytokine 
promoter region may account not only for inter-individual variations in cytokine production 
but also susceptibility to the disease (Seki et al. 1999; Verity et al. 1999b). The correlation of 
certain SNPs in Caucasian patients with CAU was studied by Menezo et al. (abstract ARVO 
2004). IL-1ra (+2018) T allele may predispose to the development of chronicity in patients 
with acute-recurrent AU, whereas the TNF (-238) GG genotype may contribute to the 
development of potentially sight threatening complications in British Caucasian patients with 
CAU. In theory, the identification of such variations of these SNPs could lead to more 
accurate ways of predicting outcome of disease and response to treatment in patient s with 
intraocular inflammation. 
 
Despite the limitations that a retrospective study has, our results suggest that posterior 
segment complications in patients with CAU are more likely to occur in these patients with an 
underlying systemic disorder; however this does not appear to have a negative impact in the 
visual outcome of these patients.  
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CHAPTER FOUR 
4. TNF-857T, A GENETIC RISK MARKER FOR ANTERIOR UVEITIS 
4.1. INTRODUCTION 
Uveitis, an umbrella term for intraocular inflammation, is of varying clinical phenotypes. It is 
largely T-cell mediated and many cytokines have been detected in uveitis patients (De Vos et 
al. 1992; Franks et al. 1992; Huhtinen et al. 2002; Muhaya et al. 1998; Ongkosuwito et al. 
1998; Santos Lacomba et al. 2001b). Idiopathic AAU, in which there is often a severe 
inflammatory response in the anterior chamber or front of eye is the most common type seen 
in the general population. The disease severity and course varies between individuals and 
some patients, but not all, develop ocular complications that can threaten sight. Many 
different cytokines have been identified in the inflamed eye (De Vos et al. 1992; Franks et al. 
1992; Huhtinen et al. 2002; Muhaya et al. 1998; Ongkosuwito et al. 1998; Santos Lacomba et 
al. 2001b; Verma et al. 1997), including TNF-α. High serum levels of TNF-α have been 
associated with a recurrent pattern of uveitis (Santos Lacomba et al. 2001b) and decreased 
inflammation was found in TNF receptor-deficient mice in immune complex-induced uveitis 
(Brito et al. 1999). TNF-α, produced predominantly by macrophages, plays a key role in 
many infectious and inflammatory diseases (Brennan et al. 1992; Grutters et al. 2002; Mannel 
et al. 2000; Taylor 2001). Lymphotoxin-α (LT-α; previously known as TNF-β) is produced 
mainly by lymphocytes and NK cells and displays a similar spectrum of biological activity in 
vitro, but is often less potent or displays apparent partial agonist activity (Bazzoni & Beutler 
1996). TNF-α and LT-α both activate many genes involved in inflammatory and 
immunoregulatory responses and are structurally related molecules displaying 50% amino 
acid homology (Ware et al. 1995). TNF-α and LT-α compete for binding to the same 
receptors, TNFR1 and TNFR2. TNFR1 (55Kd) and TNFR2 (75Kd) (Aggarwal 1991; Bradley 
& Pober 2001; Inoue et al. 2000) are expressed on most nucleated cell surfaces and control 
the cascades of regulated signals. Binding of the trimeric ligands of TNF-α to the TNF 
receptor induces “molecular switching” of the receptor which then induces the signals 
required for immune function (Bazzoni & Beutler 1996). Excessive or inappropriate signaling 
through these receptors may cause severe inflammatory reactions and tissue injury (Bradley & 
Pober 2001; Hajeer et al. 2001).  
Many SNPs exist in the TNF-α, LT-α, TNFR1 and TNFR2 genes (TNF, LTA, TNFRSF1A, 
and TNFRSF1B respectively) (Hajeer & Hutchinson 2001). It has been shown that 
differences in TNF-α production can be determined by genetic polymorphisms (Abraham et 
al. 1993; Grove et al. 1997; Higuchi et al. 1998; Jacob et al. 1990; Kroeger et al. 1997; 
Kroeger et al. 2000; Wilson et al. 1997). Meanwhile, a lot of evidences suggest that these 
polymorphisms may influence susceptibility and severity of inflammatory mediated disease 
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(Gonzalez et al. 2001; Grutters et al. 2002; Louis 2001; Negoro et al. 1999; Verity et al. 
1999b; Waldron-Lynch et al. 2001). The aim of this study was to determine whether 
polymorphisms in genes critical to the inflammatory process have an effect in idiopathic 
AAU. Our objective was to investigate the association between published SNPs in TNF-α, 
LT-α, TNFR1, and TNFR2 genes and idiopathic AAU. As HLA-B27 is closely linked to 
TNF, the association between these SNPs and HLA-B27 was also studied. Furthermore, the 
role of these SNPs in determining the clinical phenotypes in AAU was evaluated. 
 
4.2. MATERIALS AND METHODS 
Subjects 
Patients with idiopathic AAU, referred mainly from the southeast UK, were identified from 
the uveitis clinics (SL) of Moorfields Eye Hospital, London. AAU was defined as 
inflammation confined to the anterior chamber and/or anterior vitreous for less than 3 months. 
As uveitis is a clinically very heterogeneous disease, it would be impossible to look at these 
polymorphisms in a mixed group as the clinical outcomes would be so variable. Some AU 
may occur in patients with systemic disease and polymorphisms in the promoter region of 
TNF -1031T/C, -863C/A, and -857C/T have been reported to be associated with Crohn's 
disease and sarcoidosis (Grutters et al. 2002; Louis 2001). However the presence of systemic 
disease could generate confounding factors so we chose to limit the group studied still further 
to those with no detectable underlying disease, so a restricted clinical phenotype of idiopathic 
AU (IAU). Idiopathic disease was identified when there were no symptoms, signs or 
investigation results which suggested a relevant underlying disease process. Patients with any 
following situations were excluded from this study. 1) AU of infectious etiology (e.g. herpetic 
simplex or zoster uveitis, etc) 2) AU secondary to the inflammation from neighbouring tissues 
(e.g. scleritis, keratitis, post-operative uveitis, etc) 3) AU associated with known systemic 
diseases (e.g. AS, Reiter’s syndrome, sarcoidosis, Behcet’s disease, etc) 4) Acute uveitis 
secondary to other ocular diseases (e.g. FHC, Posner-Schlossman syndrome, etc)  
A total of 98 patients were studied, including 24 patients with single episode IAU and 74 with 
recurrent IAU. All patients received a detailed ocular examination on several occasions, 
including corrected visual acuity, applanation tonometry for intraocular pressure, slit lamp 
examination, and fundus examination with 90-D diopter lens or indirect ophthalmoscope. 
Fluorescein angiography was performed if the vision had dropped and visually significant 
macular edema was considered possible. The following clinical parameters were also 
collected: age, sex, episodes of disease recurrence, HLA-B27, the presence or absence of PS, 
lens opacity and glaucoma. All patients were divided into either a inflammation-related 
complication group or a no complication group. The complication group contained the 
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patients with any of the following complications, which had been detected by the day of 
phenotyping and blood collection and included poor treatment response to topical steroids, 
secondary glaucoma, complicated cataract, cystoid macular edema, and requirement for 
cataract, glaucoma or retinal surgery. All these complications were related to inflammatory 
process. 
 
Genetic analysis  
Ten to 15 mLs of peripheral venous blood were collected for DNA extraction in all patients. 
Genomic DNA was extracted from EDTA-chelated peripheral whole blood, either with 
commercial kits (Qiagen UK Ltd, UK) according to manufacture’s instructions or by a 
modified salting-out procedure (Bunce et al. 1995). Polymorphisms were determined using 
sequence-specific primers (SSPs). PCR-SSP utilizes SSPs with 3’-end mismatches and 
identifies the presence of specific allelic variants through PCR amplification. Seventeen SNPs 
were investigated in this study, including TNF -1031, -863, -857, -308, -238 (all promoter, 
NCBI RefSNP: rs1799964, rs1800630, rs1799724, rs361525, and rs1800629), LTA +720 
(exon 3, NCBI RefSNP: rs1041981), +365 (intron 1, RefSNP: rs746868), +249 (intron 1, 
RefSNP: rs909253); TNFRSF1A -201, -230, -845, -839, -1135 (all promoter, RefSNP: 
rs4149570, rs4149621, rs767455, rs4149584, and rs1800692); TNFRSF1B +1663 (exon 10, 
RefSNP: rs1061624), +1668 (exon 10, RefSNP: rs5030792), +1690 (exon 10, RefSNP: 
rs3397), +676 (exon 6, RefSNP: rs1061622). For the polymorphisms in the TNF-α and LT-α 
genes, we used the primer sequences and primer mixtures previously described by Fanning et 
a.l (Fanning et al. 1997) and Grutters et al (Grutters et al. 2002). The primer sequences used 
for polymorphisms of TNFR1 gene are shown in table 2.5 (Table 2.5). For identifying the 
polymorphisms in the TNFR2 gene, we used the primer sequences and primer mixtures 
described by Pantelidis and colleagues (Table 2.6) (Pantelidis et al. 1999).  
 
In all reactions, one of two different control primer pairs was used to generate a positive 
control band of 796 base pairs or 256 base pairs (Bunce et al. 1995), depending on the size of 
the target product. All PCR amplifications were carried out under identical conditions in 
PTC200 thermal cycler (MJ Research, GRI, UK) as previously described (Grutters et al. 
2002). Briefly, each reaction contained 5 µL of the appropriate primer mix (allele-specific and 
control primers) and 8 µL of PCR reaction mixture, containing 1× PCR buffer (Bioline, 
London, UK), 300 µM of each deoxynucleotide triphosphate (Bioline), 2 mM MgCl2, 0.32 U 
Taq polymerase (Bioline), and 0.01 to 0.1 µg DNA per well. The DNA mixtures were heated 
at 96°C for 1 min in the first round of denaturation and then subjected to 5 cycles of 25 sec at 
96°C, 45 sec at 70°C, and 25sec at 72°C; then followed by 21 cycles of 25 sec at 96°C, 50 sec 
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at 65°C, 30 sec at 72°C; and 4 cycles of 30 sec at 96°C, 60 sec at 55°C, 90 sec at 72°C. The 
agarose gels were visualized over ultraviolet light (320nm) and photographed. A positive 
reaction was defined as the presence of an allele-specific band of the expected size, in 
conjunction with a control band. The absence of an allele-specific band in the presence of a 
control band was considered to be a negative reaction. 
 
4.3. STATISTICAL ANALYSIS 
All genotype frequencies in each population were tested for deviation from the Hardy-
Weinberg equilibrium using the chi-square test. The genotype frequencies for each 
polymorphism were determined by direct counting and the allele and allele carriage 
frequencies calculated. Differences in genotype frequencies between patients and controls 
were analyzed with a 2x3 unisquare with 2 degrees of freedom. The allele and allele carriage 
frequency were compared using a 2x2 chi-squared test. The purpose of using three different 
comparisons in our analysis was to increase the power of our study to identify a significant 
susceptibility allele that the type 1 error was not much inflated (Ohashi et al. 2001). Statistical 
analysis was performed using chi-square contingency table analysis for all categorical data of 
clinical phenotypes and laboratory variables, depending on appropriate number of degrees of 
freedom. Fisher’s Exact test was used if any expected frequency was lower than 5. The 
Student t test was used to compare the means of the continuous variables, such as age. A 
value of p < 0.05 was considered as significant. 
 
Linkage is the association between alleles at linked loci which reflects, in part their proximity 
and the correspondingly low probability of recombination breaking the haplotype on which 
they are found (Collins A. Mol Biotechnol. 2009). 
Two alleles are in LD if their co-occurrence in the population is higher than the product of 
their allele frequencies. It denotes the non-random association of alleles at two or more loci. 
If two loci have alleles A1, A2 and B1, B2 with frequencies of pA1, pA2, pB1, and pB2 
respectively, there will be four possible haplotypes A1B1, A1B2, A2B1, A2B2 and their 
corresponding frequencies are pA1B1, pA1B2, pA2B1, pA2B2. In the event of no LD the 
frequency of the four haplotypes will be equal to the product of the frequencies of their alleles 
i.e., pA1B1 = pA1 x pB1. 
However, LD is a non-quantitative phenomenon and among the measures that have been 
proposed for a two loci haplotype data the two most important are D’ and r2.  
If the alleles at the two loci are not randomly associated, there will be a deviation (D) in the 
expected frequencies, which can be measured by: 
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D = pA1B1 x pA2B2 - pA1B2 x pA2B1, where A1B1 and A2B2 are referred as the coupling 
gametes and A1B2 and A2B1 the repulsion gametes. D is therefore the difference between 
these two gametes types.  
As a measure of LD, the value of D will depend on the allele frequencies at the two loci, and 
Lewontin (1964) thus proposed standardizing D to the maximum possible value it can take:  
D’ = D/ Dmax, where Dmax is the maximum value of D possible for the given allele frequencies. 
D’ value will varies between 0 (no LD) and +/- 1 (complete association) and allows assessing 
the extent of LD relative to the maximum possible value it can take.  
An alternative measure of LD proposed by Hill and Robertson (1964): 
r2 = D2 / pA1 x pA2 x pB1 x pB2. Where r2 will equally varies between 0 and +/- 1. 
r2 reflects statistical power to detect LD. 
nr2 is the Pearson test statistic for independence in a 2 x 2 table of haplotype counts, therefore 
a low r2 corresponds to a large sample size n that is required to detect the LD between the 
markers. 
LD measuring r2 was calculated for all pair wise combinations of SNPs within each gene. LD 
analysis was carried out in HelixTreeTM (Golden Helix Inc, Bozeman). The role of SNPs in 
TNF is still controversial; therefore the analysis of haplotype in candidate area is important 
(Bayley et al. 2004). Haplotype frequency estimations were performed using the expectation-
maximisation (EM) algorithm, which calculates maximum likelihood estimates of the 
possible haplotype frequencies, implemented in HelixTreeTM. To ensure the EM algorithm 
was producing robust estimates of haplotype frequencies, several random subsets of the data 
were selected and haplotype frequencies compared. There were no statistically significant 
differences between haplotype frequency estimations in random subsets of the data. Due to 
relatively strong LD it was possible to infer haplotypes by direct counting. Haplotype 
frequency comparisons were made by calculating the odds ratios for the frequency of each 
haplotype compared to the frequency of all other haplotypes. A correction using the 
Bonferroni method was used for multiple comparisons, using the formula of pc = p × n. (pc 
represents the corrected value, p is the uncorrected value, and n is the numbers of 
comparisons performed in individual genes.) 
The availability of high-throughput genotyping technologies and massive amounts of marker 
data for testing genetic associations is a dual-edged sword. On one side is the possibility that 
the causative gene will be found from among those tested for association, but on the other 
testing, many loci for association creates potential false positive results and the need to 
accommodate the multiple testing problem. One of the most widely used solutions involves 
correcting each test using adjustments such as a Bonferroni correction. Bonferroni 
adjustments are based on the reasoning that if a null hypothesis is true a significant difference 
(P<0.05) will be observed by chance once in 20 trials. This is the type I error, or alpha. When 
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20 independent tests are performed (for example, study groups are compared with regard to 
20 unrelated variables) and the null hypothesis holds for all 20 comparisons, the chance of at 
least one test being significant is no longer 0.05, but 0.64. The formula for the error rate across 
the study is 1-(1-alpha)n, where n is the number of tests performed. 
The Bonferroni correction for multiple comparisons used the formula pc = p × n; where pc 
represents the corrected value, p is the uncorrected value, and n is the numbers of 
comparisons performed in individual genes. We used an n value of 4 when comparing allele 
frequencies for each individual SNP, and a value of 6 when comparing genotype frequencies. 
 
4.4. RESULTS 
Forty-seven males and fifty-one females were included in this study (Mean age 46.6 years, 
SD 14.7 years). It has been demonstrated that there are ethnic variations in the frequency of 
TNF and LTα gene polymorphisms. Consequently, all the individuals (patients and controls) 
participating in this study were UK Caucasian in origin. The control population was collected 
mainly from the southeast of the UK as described before (Grutters et al. 2002; Pantelidis et al. 
2001) and included 354 individuals for TNF-α and LT-α genes polymorphism, 132 
individuals for TNFR1 gene polymorphism, and 100 individuals for TNFR2 gene 
polymorphism. The frequencies of TNF-α, LT-α and TNFR2 genes polymorphism have been 
previously reported (Grutters et al. 2002; Pantelidis et al. 2001). All genotype frequencies in 
case and control populations conformed to Hardy-Weinberg equilibrium.  
Associations between SNPs and IAU 
There was a significant increase in the allele frequency of TNF-857T in IAU patients as 
compared to controls (15.3% vs 7.3%, p = 0.0006, pc = 0.003) (Table 4.1). In the patients with 
IAU, 28.6% carried the uncommon TNF-857T allele, compared with 14.4% in the control 
subjects (p = 0.001, pc = 0.005). The pattern of LD between the 5 TNF SNPs is shown in 
figure 4.1 (Figure 4.1). The strongest evidence for LD between TNF-857 and the other SNPs 
tested was for TNF-307 (r correlation 0.19, Figure 4.1). Interestingly there was also a 
significant decrease in allele frequency of the uncommon TNFRSF1A-230G in the IAU group 
although this was not significant after correction with the Bonferroni method (1.0% vs 5.0%, 
p = 0.02, pc = 0.09) (Table 4.2). Analysis of allele carriage frequency showed similar findings. 
There was no other significant difference of SNPs in allele, allele carriage or genotype 
frequency of LT-α and TNFR2 genes between IAU and controls (Table 4.3). 
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Table 4.1. Allele, genotype, and allele carriage frequencies of TNF-857 in IAU and control. 
 
IAU (n = 98) Control (n = 354)     Polymorphism 
No.  % No.  % p value pc value 
Allele Frequency 
  C 166 (84.7)  656 (92.7)  0.0006* 0.003* TNF-857 
T 30 (15.3)  52 (7.3)     
Genotype Frequency 
  CC 70 (71.4) 303 (85.6) 0.002* 0.01*  
CT 26 (26.5)  50 (14.1)      
TNF-857 
 
  TT 2 (2.0) 1 (0.3)     
Allele Carriage Frequency 
  CC 70 (71.4)  303 (85.6)  0.001* 0.005* TNF-857 
  CT, TT 28 (28.6) 51 (14.4)     
 
IAU: idiopathic anterior uveitis 
*Statistical significance 
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Figure 4.1. Linkage disequilibrium (LD) between TNF -1031, -863, -857, -308, -238.  
 
 
LD is weak between the TNF-857 and the other SNPs in the gene. The strongest evidence for 
LD was between TNF-857 and TNF-307 (r correlation 0.19). 
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Table 4.2. Allele, genotype, and allele carriage frequencies of TNFRSF1A-230 in IAU and 
control. 
 
IAU (n = 97) Control (n = 119)     Polymorphism 
No.  % No.  % p value pc value 
Allele Frequency 
  A 192 (99.0)  226 (95.0) 0.02* 0.09 TNFRSF1A-230  
G 2 (1.0)  12 (5.0)      
Genotype Frequency           
AA 95 (98.0)  108 (90.8)  0.08 0.4 
AG 2 (2.0)  10 (8.4)      
TNFRSF1A-230 
GG 0 (0.0)  1 (0.8)      
Allele Carriage Frequency 
  AA 95 (100.0) 108 (90.8) 0.03* 0.1 TNFRSF1A-230 
  AG, GG 2 (2.0)  11 (9.2)      
 
IAU: idiopathic anterior uveitis 
* Statistical significance 
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Table 4.3. Genotype frequencies of LT-α and TNFR2 genes between IAU and controls. 
 
    IAU Control     
    (n = 98) % (n =349 ) % Chi2 p value 
LT-α+720 CC 27 28.1  133 38.1  3.53  0.17130  
 CA 51 53.1  166 47.6    
 AA 18 18.8  50 14.3    
LT-α+365 GG 36 37.5  128 36.7  0.10  0.94913  
 GC 48 50.0  173 49.6    
 CC 12 12.5  48 13.8    
LT-α+249 GG 18 18.8  50 14.3  3.53  0.17130  
 GA 51 53.1  166 47.6    
 AA 27 28.1  133 38.1    
TNFR2-663 AA 32 32.7  28 28.0  2.59  0.27327  
 AG 48 49.0  44 44.0    
 GG 18 18.4  28 28.0    
TNFR2-
1668 
TT 89 90.8  86 86.0  1.12  0.29029  
 TG 9 9.2  14 14.0    
 GG 0 0.0  0 0.0    
TNFR2-
1690 
CC 14 14.3  9 9.0  1.44  0.48670  
 CT 49 50.0  51 51.0    
 TT 35 35.7  40 40.0    
TNFR2ex6-
676 
CT 64 65.3  34 54.0  5.94  0.05121  
 TG 33 33.7  24 38.1    
 GG 1 1.0  5 7.9    
 
df = 2 
^Caculated by 2x2, df = 1 
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From the results of the SNPs in the TNF promoter, we were able to construct the TNF 
haplotypes and calculate their frequencies (Table 4.4). The frequency of haplotype 4, 
containing the T allele at nucleotide position -857, was significantly increased in IAU as 
compared to controls either by direct counting (15.4% vs 7.1%, p = 0.0003, pc = 0.002, odds 
ratio 2.4, 95% confidence interval 1.4-4.0) or by EM algorithm (15.3% vs 7.2%, p = 0.0004, 
pc = 0.002, odds ratio 2.3, 95% confidence interval 1.4-3.9). No significant association was 
found in the frequencies of the other haplotypes. 
 
Associations of SNPs and Clinical Phenotypes  
The complication group contained 9 patients (9.2%) developing at least one type of ocular 
complication related to the inflammatory process, including 4 poor responses to topical 
steroid, 4 requiring surgery (cataract or glaucoma or retina surgery), and 1 cystoid macular 
edema. There was no association between the complication group and any of these SNPs. 
However, of the sixty-one HLA-B27 positive patients in the subgroup analysis, there were 
significant differences in the frequencies of the uncommon TNFRSF1A-201T and 
TNFRSF1A-1135T alleles between HLA-B27 positive patients with complications (n=5) and 
those without complications (80.0% vs 33.6%, p = 0.006, pc = 0.03; 80.0% vs 36.6%, p = 
0.01, pc = 0.07, respectively). Analysis of the genotype and allele carriage frequencies showed 
similar significant findings in HLA-B27 positive patients (Table 4.5). 
 
Higher allele carriage frequencies in TNFRSF1A-201T, TNFRSF1A-845A, and TNFRSF1A-
1135T were found in recurrent IAU as compared to single episode IAU (71.2% vs 45.8%, p = 
0.02, pc = 0.1; 89.0%, 66.7%, p = 0.02, pc = 0.1; and 75.7%, 45.8%, p = 0.006; pc = 0.03 
respectively) (Table 4.6). Differences in the genotype frequencies of TNFRSF1A-201, -845, -
1135 were also found between recurrent and single episode IAU (p = 0.02, 0.004, and 0.008; 
pc = 0.09, 0.02, and 0.04; respectively) (Table 4.7). 
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Table 4.4. Haplotype frequencies in IAU and control. 
TNF Polymorphism DC frequency EM frequency Haplotype 
-1031 -863 -857 -308 -238 IAU Control IAU Control 
1 T C C G G 53.3% 54.4% 53.1% 54.0% 
2 T C C A G 15.4% 18.3% 15.3% 18.2% 
3 C A C G G 11.8% 14.7% 11.7% 14.0% 
4 T C T G G * 15.4% 7.1% † 15.3% 7.2% 
5 C C C G A 3.1% 4.9% 3.1% 4.8% 
6 C C C G G 1.0% 0.7% 1.0% 0.7% 
 
DC: direct counting; EM: expectation maximisation algorithm 
IAU: idiopathic anterior uveitis, n=98; Control: n=354 
* Odds ratio: 2.4, 95% confidence interval: 1.4-4.0; P = 0.0003, Pc = 0.002 
†
 Odds ratio: 2.3, 95% confidence interval: 1.4-3.9; P = 0.0004, Pc = 0.002 
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 Table 4.5. Allele, genotype, and allele carriage frequencies of TNFSF1A-201 & TNFSF1A-
1135 in HLA-B27 positive patients with complication and without complication. 
Comp (n = 5) No Comp (n = 57)   Polymorphism 
No. % No. % p value pc value 
Allele Frequency 
  G 2 (20.0)  73 (66.4) 0.006* 0.03* TNFSF1A-201 
T 8 (80.0)  37 (33.6)   
C 2 (20.0)  71 (63.4)  0.01* 0.07 TNFSF1A-1135 
T 8 (80.0)  41 (36.6)    
Genotype Frequency 
  GG 0 (0.0)  23 (41.8) 0.003*  0.02* 
GT 2 (40.0)  27 (49.1)   
TNFSF1A-201 
TT 3 (60.0)  5 (9.1)   
CC 0 (0.0)  20 (35.7) 0.003* 0.02* 
CT 2 (40.0) 31 (55.4)   
TNFSF1A-1135 
TT 3 (60.0) 5 (8.9)   
Allele Carriage Frequency 
  CC, CT 2 (40.0) 50 (91.4) 0.01* 0.07 TNFSF1A-1135 
TT 3 (60.0)  5 (8.6)    
GG, GT 2 (40.0) 51 (91.2) 0.01* 0.07 TNFSF1A-201 
  
 
TT 3 (60.0)  5 (8.8)    
 
Comp: complication group; No Comp: no complication group; IAU: idiopathic anterior 
uveitis 
* Statistical significance 
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Table 4.6. Allele carriage frequencies of TNFSF1A-201T, TNFSF1A-845A, and TNFSF1A-
1135T were found in recurrent IAU as compared to single episode IAU. 
    Recurrence (n = 74) Single episode (n = 24)         
Polymorphism Postive Negative Positive Negative Chi 2 p value   
TNFR1-201 T 52 71.2  21 28.8  11 45.8  13 54.2  5.12 0.02000 *   
TNFR1-230 A 73 100.0  0 0.0  24 100.0  0 0.0  0 1.00000    
TNFR1-845 A 65 89.0  8 11.0  16 66.7  8 33.3  Fisher 0.02000 * *** 
TNFR1-839 A 4 5.4  70 94.6  1 4.2  23 95.8  0 1.00000    
TNFR1-1135 T 56 75.7  18 24.3  11 45.8  13 54.2  7.46 0.00600 *   
 
df=1 
*Statistic significant 
*** Expected cell frequency <5, suggest correction with Fisher's exact test 
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Table 15 Genotype frequencies of TNFR1polymorphisms between recurrent and single 
episode IAU. 
 
          
    
Recurrence 
(n = 74) 
Single episode 
(n = 24) Chi2 p value 
TNFRI-201 GG 21 28.8  13 54.2  8.03  0.02  * 
 GT 39 53.4  5 20.8     
 TT 13 17.8  6 25.0     
TNFRI-230 AA 73 100.0  22 91.7  6.21  0.010  * 
 AG 0 0.0  2 8.3     
 GG 0 0.0  0 0.0     
TNFRI-845 AA 21 28.8  10 41.7  10.78  0.004  * 
 AG 44 60.3  6 25.0     
 GG 8 11.0  8 33.3     
TNFRI-839 GG 70 94.6  23 95.8  0.06  0.800   
 GA 4 5.4  1 4.2     
 AA 0 0.0  0 0.0     
TNFRI-1135 TT 12 16.2  5 20.8  9.54  0.008  * 
 TC 44 59.5  6 25.0     
 CC 18 24.3  13 54.2     
 
df = 2 
*Statistic significant 
^Caculated by 2x2, df = 1 
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HLA-B27 and SNPs 
Sixty-one of the 98 IAU patients (62.2%) were HLA-B27 positive. As expected, HLA-B27 
was significantly associated with the recurrent form of IAU (χ2 = 8.3, p = 0.004). The mean 
age of IAU patients with B27 positive was not significantly different from those with B27 
negative (44.9 ± 13.0 yrs vs 49.3± 17.0 yrs, p = 0.16). Significant differences in the 
frequencies of the uncommon TNF-1031C and TNF-308A alleles between patients with B27 
positive and B27 negative were found (11.5% vs 24.3%, p = 0.02, pc = 0.09; 6.6% vs 31.1%, 
p = 0.000005, pc = 0.00003, respectively) (Table 4.8). No significant difference in the allele 
and genotype frequency of TNF-857 was found between HLA-B27 positive patients and 
HLA-B27 negative patients. Of the haplotype analysis, the frequency of haplotype 1 of the 
TNF promoter, containing –1031T and –308G, was also significantly increased in IAU with 
B27 positive as compared to B27 negative either by direct counting (63.1% vs 37.0%, p = 
0.0003, pc = 0.002, odds ratio 3.0, 95% confidence interval 1.6-5.7) (Table 4.9) or EM 
algorithm (63.6% vs 36.5%, p = 0.0002, pc = 0.001, odds ratio 2.8, 95% confidence interval 
1.5-5.5). The frequency of haplotype 2, containing –1031T and –308A, was significantly 
decreased in IAU patients with B27 positive as compared to B27 negative by direct counting 
(6.6% vs 30.1%, p = 0.00001, pc = 0.00006, odds ratio 0.17, 95% confidence interval 0.06-
0.4) or by EM algorithm (6.6% vs 29.7%, p = 0.00001, pc = 0.00006, odds ratio 0.17, 95% 
confidence interval 0.06-0.4). 
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Table 4.8. Allele frequencies of TNF promoter SNPs in HLA-B27 positive IAU and HLA-
B27 negative IAU. 
 
B27(+) (n = 61)  B27(-) (n = 37) Polymorphism 
No.  %  No.  % 
TNF-1031 * T 108 (88.5)  56 (75.7) 
 C 14 (11.5)  18 (24.3) 
TNF-863 C 111 (91.0)   62 (83.8) 
 A 11 (9.0)  12 (16.2) 
TNF-857 C 99 (81.1)  67 (90.5) 
 T 23 (18.9)  7 (9.5) 
TNF-307 † G 114 (93.4)   51 (68.9)  
 A 8 (6.6)  23 (31.1) 
TNF-237 G 120 (98.4)   70 (94.6)  
 A 2 (1.6)   4 (5.4) 
 
* Statistical significance, p = 0.02, pc = 0.09 
†
 Statistical significance, p = 0.000005, pc = 0.00003 
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Table 4.9.16 Haplotype frequencies of TNF promoter SNPs in HLA-B27 positive and HLA-
B27negative IAU patients. 
 
TNF Polymorphism  DC frequency  EM frequency Haplotype 
-1031 -863 -857 -307 -237  B27(+) B27(-)  B27(+) B27(-) 
1 T C C G G  * 63.1% 37.0%  63.6% 36.5% 
2 T C C A G  6.6% ** 30.1%  6.6% †† 29.7% 
3 C A C G G  9.0% 16.4%  9.0% 16.2% 
4 T C T G G  18.9% 9.6%  18.4% 9.4% 
5 C C C G A  1.6% 5.5%  1.2% 5.4% 
6 C C C G G  0.8% 1.4%  0.8% 1.4% 
 
DC: direct counting; EM: expectation maximisation algorithm 
HLA-B27(+): n=61; B27(-): n=37 
* Odds ratio: 3.0, 95% confidence interval: 1.6-5.7; P = 0.0003, Pc = 0.002 
†
 Odds ratio: 0.17, 95% confidence interval: 0.06-0.4; P = 0.00001, Pc = 0.0006 
** Odds ratio: 2.8, 95% confidence interval: 1.5-5.5; P = 0.0002, Pc = 0.001 
††
 Odds ratio: 0.17, 95% confidence interval: 0.06-0.4; P = 0.0001, Pc = 0.0006 
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4.5. DISCUSSION 
The association of SNPs of TNF-α, LT-α, TNF-R1 and TNF-R2 genes in patients with IAU 
has been investigated in this study. We have demonstrated that the frequency of the 
uncommon TNF-857T allele is significantly associated with IAU even after correction for 
multiple testing. Although a haplotype effect could also be demonstrated, haplotype 4 of TNF, 
containing the T allele at nucleotide position -857, was the only haplotype significantly 
associated with IAU. In addition, there was very little LD between TNF-857 and the other 
TNF SNPs, suggesting that the effect is largely attributable to TNF-857. Our results suggest 
that the uncommon TNF-857T allele is a susceptibility marker for IAU. 
 
SNPs in the TNF promoter region are potentially functional sites influencing the expression 
of TNF-α, except TNF-α. -308G/A polymorphism (Bayley et al. 2004). The relationship 
between TNF-α expression and SNPs may be explained by the polymorphism TNF-863 
(C/A). TNF-863 (C/A) polymorphism has been proposed to alter the binding affinity of the 
p50-p50 form of NFκ-B. The p50 subunit contains a DNA binding domain but no activation 
domain and the p50-p50 homodimer plays a role as a transcriptional repressor in the promoter 
region of the TNF gene. The affinity of the p50-p50 form NF-κB to its DNA binding site is 
significantly decreased in the TNF gene containing the uncommon -863A allele. Thus, the 
change from G to T at nucleotide position -863 results in increased TNF-α production 
(Udalova et al. 2000). The uncommon TNF-857T allele could have a similar function to –
863A. Another hypothesis is that TNF-α is controlled through allele-specific binding of the 
transcription factor OCT-1. OCT-1 has been suggested to modulate TNF-α expression 
(Knight et al. 1999), and OCT-1 has been found to be associated with –857T in the promoter 
area, but not with –857G (Hohjoh & Tokunaga 2001).  
 
Our results do not suggest that TNF-857T is the causal allele for IAU, but that it can be used 
as a marker for IAU. The same allele has been found to be associated with many other 
inflammatory diseases, such as Crohn's disease, sarcoidosis, and in RhA patients carrying the 
HLA-DR 'shared epitope' (Grutters et al. 2002; Negoro et al. 1999; Waldron-Lynch et al. 
2001). The combination of the TNF -857T allele and DRB1*0405 yielded a significantly 
increased risk for developing systemic juvenile rheumatoid arthritis (Date et al. 1999). There 
may be other genes that affect susceptibility in linkage with TNF gene, such as the other HLA 
genes. TNF and HLA genes are located within the class III region of the highly polymorphic 
major histocompatibility complex (MHC) and have tight LD each other and so. It is therefore 
difficult to clarify the primary candidate marker for IAU and further study of the LD data for 
the haplotype containing TNF-857T is necessary for that. Herrmann et al reported the allele 
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frequency of TNF-857T were 13.7% and 17.8% from normal controls of Northern Ireland and 
France respectively (Herrmann et al. 1998). It is likely that these differences were due to 
differences in ethnicity since the TNF genes are situated within the MHC region, which is 
known to be both highly polymorphic and subject to ethnic variation. Ethnicity has been 
reported to be strongly associated with cytokine gene polymorphisms (Hoffmann et al. 2002). 
We suggest that differences between our control population and those reported by others are 
likely due to differences in ethnic origin. Repeating our study in other populations of different 
ethnicities is necessary to confirm the significance of our findings.  
 
Fifty to 67% of patients with AAU are HLA-B27 positive (Derhaag et al. 1989; Mooller et al. 
1980; Trevisani et al. 2001). Recurrent episodes are frequent in HLA-B27-associated AU 
(Mapstone et al. 1975; Power et al. 1998) and HLA-B27-associated AU tends to develop 
uveitis at a younger age (Rothova et al. 1987). Our results were similar. Some reports mention 
that the prognosis of the patients with HLA-B27-associated AU is similar to HLA-B27 
negative ones (Linssen et al. 1995), but others have reported that patients who are HLA-B27 
positive developed a more severe clinical course and a higher rate of ocular complication 
(Rothova et al. 1987), with a more severe outcome (Power et al. 1998). The classic role of 
MHC class I molecules is antigen presentation (Pamer et al. 1998) and recently, one study 
reported that HLA-B27 modulates NF-κβ activity in response to LPS in monocytic cells 
(Penttinen et al. 2002). NF-κβ is an important nuclear transcriptional factor in the expression 
of many genes which proteins are involved in the control of apoptosis and in the 
inflammatory processes, and NF-κβ can be activated by a variety of stimuli, including TNF-α 
(Pamer & Cresswell 1998; Penttinen et al. 2002). In this study, patients with inflammation-
related complications (poor response to topical steroids, complicated cataract, cystoid macular 
edema, surgery) showed a trend of association with TNFRSF1A-201T and TNFRSF1A-
1135T alleles in HLA-B27 positive patients. TNFR1, which is responsible for mediating most 
of the known TNF-α effects, contains two functional domains: a COOH-terminal region 
(death domain) and an NH2-terminal region. TNFR1 initiates the pathway of NF-κβ activation 
through the death domain (Bradley & Pober 2001; Tkachuk et al. 1998; Vandevoorde et al. 
1997). Binding of trimeric ligands of TNF-α to the TNFR1 induces signals required for the 
subsequent pathway activation (Bazzoni & Beutler 1996). The effect on gene expression of 
SNP in the promoter region of TNFR1 gene is still not clear. This might be associated with 
the reported increase in severity and complications in the HLA B27 positive group. But this 
association in this study should be treated as preliminary since the numbers of the patients 
with complications are small. 
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The uncommon TNF-238A allele has been reported to influence disease susceptibility in 
HLA-B27 negative primary AS but had no effect in B27 positive patients (Gonzalez et al. 
2001). From the haplotype analysis of the TNF promoter in all IAU patients, haplotype 1, 
containing the common TNF-308G, is significantly associated with HLA B27 positive 
patients; and haplotype 2, containing the uncommon TNF-308A, is associated with HLA-B27 
negative patients. The uncommon TNF-308A seems to be associated with HLA-B27 negative 
IAU patients. Both TNF-308A and TNF-238A alleles have been reported to be associated 
with a higher level of TNF-α production (Abraham et al. 1993; Grove et al. 1997; Higuchi et 
al. 1998; Jacob et al. 1990; Kroeger et al. 2000). We also found that HLA-B27 was associated 
with TNF-1031 and –308 in this study. These results strongly suggest there is LD between 
HLA-B27 and TNF-308. Therefore TNF-308A is unlikely to be an independent risk marker 
for HLA-B27 negative patients. Further work will be needed to clarify the role of the 
uncommon TNF-308A allele in the HLA-B27 negative patients. 
 
In conclusion, this is the first study linking idiopathic AAU and its clinical manifestations to 
polymorphisms in TNF-α, LT-α, TNFR1 and TNFR2 genes. A significant difference in the 
frequency of TNF-857T allele was found in patients with IAU. There is a trend toward 
developing inflammation-related complications in IAU patients carrying TNFRSF1A-201 T 
and TNFRSF1A-1135 T allele. Genetic variations of these proinflammatory mediators and 
their receptors may influence the susceptibility and severity of the inflammatory response 
within the eye of idiopathic AAU and may provide useful prognostic information. 
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CHAPTER FIVE 
5. CYTOKINE GENE POLYMORPHISMS INVOLVED IN CHRONICITY AND 
COMPLICATIONS OF ANTERIOR UVEITIS 
5.1. INTRODUCTION 
Uveitis is a generic term to describe intraocular inflammation, which has a variety of different 
clinical phenotypes and visual outcomes. AU, where there is no evidence of inflammation in 
the posterior segment, is considerably more common than posterior uveitis in which the 
inflammatory process occurs mainly in the posterior segment (McCannel et al. 1996). The 
explanation for why some patients develop chronic uveitis whereas others have a recurrent 
self-limiting type of uveitis is unknown. The development of chronicity is not due to 
inadequate treatment, is unrelated to HLA-B27 and it is likely that host factors are important 
determinants. Patients with CAU vary in their clinical phenotype. Some develop 
complications such as cataract, glaucoma and CMO, but others do not.  
 
Cytokines are regulatory proteins produced by cells in different organs in response to a 
variety of inducing stimuli. They play an important role in controlling cell proliferation and 
cell differentiation phenotype. Th1-type cytokines such as interferon-γ mediate cellular 
immune responses and have an inflammatory action. Th2-type cytokines include interleukin-6 
(IL-6) and interleukin-10 (IL-10) among others and inhibit Th1 cells suppressing 
inflammation as well as enhancing the humoral pathway of the immune response. The pro-
inflammatory cytokines IL-1 and TNF are known to act as mediators of inflammation and 
even cause tissue damage in chronic inflammatory disease and they have been associated, 
together with other cytokines produced by T cells in the pathogenesis of uveitis (Sakaguchi et 
al. 1998). The clinical outcome of many autoimmune diseases including different forms of 
intraocular inflammation appears to be influenced by the balance between inflammatory and 
down-regulatory cytokines (Foxman et al. 2002; Muhaya et al. 1999; Ongkosuwito et al. 
1998; Santos Lacomba et al. 2001a).  
 
The level of cytokine production by cells in any individual has been associated with 
polymorphisms in cytokine gene promoters (Lazarus et al. 1997; Wilson et al. 1997). Since 
the levels of cytokine gene expression are partially genetically determined through common 
polymorphisms, these may influence the susceptibility to inflammatory disease or the severity 
of the disease (Lazarus et al. 1997). In addition to this, the cytokine and chemokine milieu of 
the aqueous has been shown to be associated with the outcome of uveitis (el-Shabrawi et al. 
1998; Muhaya et al. 1998; Verma et al. 1997).  
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IL-1 is located on the long arm of chromosome 2 and contains three related genes that encode 
the pro-inflammatory cytokines IL-1α, IL-1β and their endogenous receptor antagonist IL-1ra. 
The ratio between IL1 and IL-1ra appears to be crucial in the outcome of inflammatory 
disease (Arend 2002). It has been shown in several animal models that intraocular injection of 
IL-1ra decreases the inflammatory response in AU caused by intravitreal injection of IL-1 and 
that seen after intraocular lens implantation (Nishi et al. 1994; Rosenbaum & Boney 1991). 
Some studies have linked IL-1ra gene polymorphisms with susceptibility or outcome of 
autoimmune disorders (Tountas et al. 1999; Vijgen et al. 2002; Watanabe et al. 2002).  
 
IL-6 is a multifunctional cytokine that regulates the immune phase response, acute phase 
response and inflammation (Castell et al. 1989). Human IL-6 is synthesized as a precursor 
protein of 212 amino acids. Whereas the first 28 amino acids can be removed without 
affecting significantly the biological activity of IL-6, the removal of only 4 amino acids from 
the C-terminal of the IL-6 molecule may result in a complete loss of its biological activity 
(Kruttgen et al. 1990). It is associated with systemic-onset juvenile chronic arthritis (Fishman 
et al. 1998) and it also seems to contribute to the pathogenesis of RhA by influencing the age 
at disease onset (Pascual et al. 2000). This polymorphism was associated with different 
clinical and immunological features in Caucasian German patients with systemic lupus 
erythematosus, but it did not appear to affect disease susceptibility (Schotte et al. 2001). 
There is still some controversy between the IL-6 genotype and IL-6 levels. The -174 (G/C) 
polymorphism appears to affect IL-6 transcription and IL-6 levels and whereas some authors 
have found that the presence of allele C and CC genotype in patients with chronic 
inflammation is associated with higher levels of IL-6 (Jones et al. 2001), others found that in 
patients with primary Sjögren’s syndrome those who were homozygous for allele G had 
increased plasma levels (Hulkkonen et al. 2001b). The same was true for HIV-infected male 
patients with Kaposi sarcoma (Foster et al. 2000) whereas other studies have not shown such 
association (Kilpinen et al. 2001; Rauramaa et al. 2000). 
 
IL-10 is a regulatory cytokine with predominantly anti-inflammatory actions mediated 
inhibiting the production of pro-inflammatory cytokines. It also up-regulates TNFR1 and 
TNFR2, which in turns inhibits TNF-α response (Moore et al. 2001). Chronic enterocolitis 
that mimics IBD in humans has been induced in the IL-10 knock-out mice (Kuhn et al. 1993). 
Furthermore, intravenous injection of IL-10 in the animal model has shown reduction of the 
cellular infiltration in endotoxin-induced anterior uveitis (Hayashi et al. 1996; Rizzo et al. 
1998; Rosenbaum et al. 1995).  
The G/A polymorphism at position -1082 has been linked to high/low IL-10 producer status 
respectively (Lazarus et al. 1997; Tagore et al. 1999), and although the-1082 G/A 
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polymorphism appears to be in LD with other polymorphisms at -819, -592, it seems that the 
relationship between the IL-10 A allele and increased IL-10 gene transcription in B-cells is 
independent of these other polymorphisms (Rees et al. 2002). Tagore et al. reported a higher 
frequency of allele 1 in normal controls compared to patients with IBD (Tagore et al. 1999). 
IL-10 promoter polymorphisms have been found to be associated to different inflammatory 
diseases, such as RhA, primary Sjögren’s syndrome, and SLE (Huizinga et al. 2000; 
Hulkkonen et al. 2001a; Lazarus et al. 1997).  
 
The TNF cluster is located within the class III region of the MHC on chromosome 6p21 
(Hajeer & Hutchinson 2000). TNF mediates its functions by binding to specific TNF 
receptors (Bazzoni & Beutler 1996). Signalling through these receptors influences T cell 
proliferation and proinflammatory responses (Hajeer & Hutchinson 2001). It has been shown 
that differences in TNF production can be determined by genetic polymorphisms (Higuchi et 
al. 1998; Kroeger et al. 1997; Kroeger et al. 2000; Wilson et al. 1997). As levels of cytokine 
gene expression are at least partially genetically determined through common polymorphisms, 
it is thought that these polymorphisms may influence susceptibility and severity of 
inflammatory disease. There are several SNPs within the promoter region of the TNF gene; 
among those the two most studied are the -308 G/A and the -238 G/A polymorphisms. In 
vitro stimulation of TNF-α production by cells and gene reporter assays have been used to 
investigate the relationship between circulating levels of TNF-α and their -308 and -238 
polymorphisms with inconclusive results (Huizinga et al. 1997; Louis et al. 1996; Pociot et al. 
1995). 
The TNF–238 A allele has been associated with less severity in patients with multiple 
sclerosis (Huizinga et al. 1997). In a similar study, in patients with RhA the TNF-238 GA 
genotype was associated with decreased radiologically detectable progression of the disease 
(Brinkman et al. 1997). The TNF-α promoter-238 A polymorphism has been shown to 
influence disease susceptibility in patients with HLA-B27 negative AS (Gonzalez et al. 2001). 
McGarry et al. found a significant increase in the frequency of the common allele TNF-308 A 
in HLA-B27 positive patients with AS compared to HLA-B27 positive controls (McGarry et 
al. 1999). However other studies have shown no difference in the TNF-α allele frequency 
between patients with AS and controls (Huizinga et al. 1997; Kaijzel et al. 1999).  
 
The aim of the study is to evaluate the role of specific SNPs of TNF, IL-1ra, IL-6 and IL-10 
in influencing the development of chronicity and sight threatening complications in patients 
with AU.  
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5.2. MATERIALS AND METHODS 
A total of 157 British Caucasian patients with AU were recruited from the uveitis clinics (SL) 
at Moorfields Eye Hospital between January 1999 and August 2003. Patients were divided 
into those with recurrent self-limiting AU (n = 118), those with CAU (n = 39). All patients 
had a complete ophthalmic examination including best Snellen visual acuity, biomicroscopy, 
aplanation tonometry and fundus examination. Fluorescein angiography, visual fields and 
ultrasonography were performed when indicated.  Initial laboratory investigations included 
full blood cell count, renal and liver function, Treponema Pallidum serology, serum 
angiotensin-converting enzyme. HLA-B27 typing was not requested in all patients i.e., 
patients who already had a diagnosis other than the seronegative arthropathy or those with no 
complaints of seronegative related arthropathies. Chest or sacroiliac joint x-rays were 
requested for these patients suspected of having associated sarcoidosis or seronegative 
spondyloarthropathy respectively. Patients with clinical and laboratory evidence of associated 
systemic disease were referred to the appropriate medical team for further evaluation. 
 
Controls 
Peripheral blood was collected from 66 patients undergoing routine cataract surgery for age-
related cataract and who had no previous ocular disease. 
Ethical approval was obtained and informed consent given by all the patients and controls for 
venesection, and genetic analysis.   
As many cytokine polymorphisms have different frequencies in different ethnic groups, all 
the individuals (patients and controls) in this study were British Caucasians. 
 
DNA extraction 
Between 10 and 20 ml of peripheral blood was obtained for DNA extraction in all patients 
and controls. Genomic DNA from all frozen bloods was extracted either using a salting out 
DNA extraction method or by using the commercial DNA extraction kit, QIAamp®DNA 
Blood Maxi Kit (QIAGEN Ltd., UK).  
 
PCR analysis 
Gene sequences from all individuals in this study were amplified by the TaqMan PCR 
(McGuigan et al. 2002).  
The sequences of the probes and primers used as well as the PCR conditions have been 
previously described in the literature (Table 2.1) (Clay et al. 1996; D'Alfonso et al. 1994; 
Wilson et al. 1992). 
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5.3. STATISTICAL ANALYSIS 
All genotype frequencies were tested for deviation from Hardy-Weinberg equilibrium.  
Chi square contingency table analysis was used for all categorical data. Fisher’s Exact test for 
2 X 2 tables was used if any expected frequency was lower than 5. The Kruskal-Wallis test 
for independent samples was used to compare non-parametric data. Odds ratios (OR) were 
calculated for disease susceptibility or severity in patients carrying specific alleles. The 95% 
confidence intervals (95% CI) for the OR were also determined. Multiple significance tests 
i.e.; Bonferroni adjustment were applied to all results (Bland et al. 1995). All statistical 
calculations were performed using Statistical Package for the Social Sciences (SPSS) 
software (version 9.05 for Windows).  
A sample size calculation was performed to calculate the power in order to detect two of the 
observed differences. Assuming a significant level of 5% we have 81% power to detect the 
difference in proportion of IL-1ra allele T in Caucasian patients with CAU compared to those 
with RAU and 69% power to detect the difference in proportion with TNF-α -308 allele G 
between patients with HLA-B27 negative versus HLA-B27 uveitis. 
 
5.4. RESULTS 
The different clinical entities and demographics of patients with AU in this study are 
summarised in table 5.1 (Table 5.1). 
All genotype frequencies in both the case and control populations conformed to Hardy-
Weinberg equilibrium (Salanti et al. 2005). 
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Table 5.1. Demographics and clinical characteristics of patients with anterior uveitis. 
 
RAU N % 
Male 63 53.4 
Female 55 46.6 
Mean age (+/-SD) 46.97 +/- 13.88 
Systemic Manifestation 
Idiopathic 88 74.6 
Ankylosing Spondylitis 18 15.3 
Reiter’s Syndrome 3 2.5 
Reactive Arthritis 2 1.7 
Sarcoidosis 2 1.7 
Psoriatic Arthropathy 1 0.8 
Inflammatory bowel disease 1 0.8 
Behçet’s Syndrome 1 0.8 
Other vasculitis 1 0.8 
Multiple Sclerosis 1 0.8 
CAU N % 
Male 16 41 
Female 23 59 
Mean age (+/-SD) 53.97 +/- 16.16 
Systemic Manifestation 
Idiopathic 32 82.1 
Sarcoidosis 2 5.1 
Psoriatic Arthropathy 2 5.1 
Ankylosing Spondylitis 1 2.6 
Reiter’s Syndrome 1 2.6 
Reactive Arthritis 1 2.6 
 
* All patients were of British Caucasian origin 
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Associations between SNPs and AU 
No significant differences were found in either allele or genotype frequency in any of the 
SNPs when the total of patients with intraocular inflammation were compared to the normal 
controls (Tables 5.2 to 5.5) 
Intra-group analysis showed a significant increase in the frequency of IL-1ra allele T (83.3% 
vs 66.1% pc = 0.004 OR 2.6 95% CI 1.3 – 4.9) in Caucasian patients with CAU compared to 
those with recurrent disease (Table 5.6).  
We also found a significant increase in the frequency of TNF-α 308 allele G (91.8% vs 76.7% 
pc = 0.02 OR 3.4 95% CI 1.4 – 8.5) in Caucasian patients with HLA-B27 positive AU 
compared to those who tested negative for the HLA-B27 haplotype (Table 5.7). 
 
Associations between SNPs and clinical phenotypes  
To assess the severity of CAU, we analyzed data for patients who developed at least one of 
the complications described in the methods chapter, and not individually due to the relative 
small sample size. We did not find any significant associations between any of the SNPs and 
severity of the disease. 
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Table 5.2. Total uveitis vs Controls allele and genotype frequencies 
 
IL1ra Total uveitis  Controls  % % 
Homozygote A/A 79 36  50.32  54.55  
Heterozygote A/a 63 27  40.13  40.91  
Homozygote a/a   15 3  9.55  4.55  
P Value = 0.4466   (df=2) 
Allele 1 221 99  70.38  75.00  
Allele 2 93 33  29.62  25.00  
P Value = 0.3228   (df=1) 
IL6 Total uveitis Control  % % 
Homozygote A/A 58 27  37.91  40.91  
Heterozygote A/a 65 30  42.48  45.45  
Homozygote a/a   30 9  19.61  13.64  
P Value = 0.5701   (df=2) 
Allele 1 181 84  59.15  63.64  
Allele 2 125 48  40.85  36.36  
P Value = 0.3782   (df=1) 
IL10 Total uveitis Control  % % 
Homozygote A/A 41 22  26.11  33.33  
Heterozygote A/a 75 27  47.77  40.91  
Homozygote a/a   41 17  26.11  25.76  
P Value = 0.5123   (df=2) 
Allele 1 157 71  50.00  53.79  
Allele 2 157 61  50.00  46.21  
P Value = 0.4651   (df=1) 
TNF-α (-238) Total uveitis Control  % % 
Homozygote A/A 147 59  93.63  89.39  
Heterozygote A/a 10 7  6.37  10.61  
Homozygote a/a   0 0  0.00  0.00  
P Value = 0.5531   (df=2) 
Allele 1 304 125  96.82  94.70  
Allele 2 10 7  3.18  5.30  
P Value = 0.2862   (df=1) 
TNF-α (-308) Total uveitis Control  % % 
Homozygote A/A 115 45  73.25  68.18  
Heterozygote A/a 37 19  23.57  28.79  
Homozygote a/a   5 2  3.18  3.03  
P Value = 0.7139   (df=2) 
Allele 1 267 109  85.03  82.58  
Allele 2 47 23  14.97  17.42  
P Value = 0.5151   (df=1) 
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Table 5.3. RAU vs Controls allele and genotype frequencies 
 
IL1ra  RAU Control  % % 
Homozygote A/A  53 36  44.92  54.55  
Heterozygote A/a 50 27  42.37  40.91  
Homozygote a/a   15 3  12.71  4.55  
P Value = 0.1558   (df=2) 
Allele 1  156 99  66.10  75.00  
Allele 2  80 33  33.90  25.00  
P Value =  0.0759   (df=1) 
IL6  RAU Control  % % 
Homozygote A/A  48 27  42.11  40.91  
Heterozygote A/a 45 30  39.47  45.45  
Homozygote a/a   21 9  18.42  13.64  
P Value = 0.6227   (df=2) 
Allele 1  141 84  61.84  63.64  
Allele 2  87 48  38.16  36.36  
P Value =  0.7347   (df=1) 
IL10  RAU Control  % % 
Homozygote A/A  31 22  26.27  33.33  
Heterozygote A/a 61 27  51.69  40.91  
Homozygote a/a   26 17  22.03  25.76  
P Value = 0.3654   (df=2) 
Allele 1  123 71  52.12  53.79  
Allele 2  113 61  47.88  46.21  
P Value =  0.7584   (df=1) 
TNF-α (-238)  RAU Control  % % 
Homozygote A/A  110 59  93.22  89.39  
Heterozygote A/a 8 7  6.78  10.61  
Homozygote a/a   0 0  0.00  0.00  
P Value = 0.6611   (df=2) 
Allele 1  228 125  96.61  94.70  
Allele 2  8 7  3.39  5.30  
P Value =  0.3734   (df=1) 
TNF-α (-308)  RAU Control  % % 
Homozygote A/A  86 45  72.88  68.18  
Heterozygote A/a 28 19  23.73  28.79  
Homozygote a/a   4 2  3.39  3.03  
P Value = 0.7512   (df=2) 
Allele 1  200 109  84.75  82.58  
Allele 2  36 23  15.25  17.42  
P Value =  0.5863   (df=1) 
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Table 5.4. CAU vs Normal controls allele and genotype frequencies 
 
IL1ra  CAU Control  % % 
Homozygote A/A  26 36  66.67  54.55  
Heterozygote A/a  13 27  33.33  40.91  
Homozygote a/a    0 3  0.00  4.55  
P Value = 0.252   (df=2) 
Allele 1  65 99  80.33  75.00  
Allele 2  13 33  19.67  25.00  
P Value =  
 0.158  (df=1) 
IL6  CAU Control  % % 
Homozygote A/A  10 27  25.64 40.91  
Heterozygote A/a  20 30  51.28 45.45  
Homozygote a/a    9 9  23.08 13.64  
P Value = 0.215  (df=2) 
Allele 1  40 84  51.28  63.64  
Allele 2  38 48  48.72  36.36  
P Value =  0.078  (df=1) 
IL10  CAU Control  % % 
Homozygote A/A  10 22  25.64  33.33  
Heterozygote A/a  14 27  35.90  40.91  
Homozygote a/a    15 17  38.46  25.76  
P Value = 0.38   (df=2) 
Allele 1  34 71  43.59  53.79  
Allele 2  44 61  56.41  46.21  
P Value =  0.153  (df=1) 
TNF-α (-238)  CAU Control  % % 
Homozygote A/A  37 59  94.87 89.39  
Heterozygote A/a  2 7  5.13 10.61  
Homozygote a/a    0 0  0.00  0.00  
P Value = 0.625  (df=2) 
Allele 1  76 125  97.44 94.70  
Allele 2  2 7  2.56 5.30  
P Value =  0.343  (df=1) 
TNF-α (-308)  CAU Control  % % 
Homozygote A/A  29 45  74.36 68.18  
Heterozygote A/a  9 19  23.08 28.79  
Homozygote a/a    1 2  2.56 3.03  
P Value = 0.798  (df=2) 
Allele 1  67 109  85.90  82.58  
Allele 2  11 23  14.10  17.42  
P Value =  0.527  (df=1) 
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Table 5.5. CAU vs RAU allele and genotype frequencies  
 
IL1ra CAU RAU  % % 
Homozygote A/A 26 53  66.67 44.92  
Heterozygote A/a 13 50  33.33 42.37  
Homozygote a/a   0 15  0 12.71  
P Value = 0.016  (df=2) 
Allele 1  65 156  83.33 66.10  
Allele 2  13 80  16.67 33.90  
P Value =  
 0.004  (df=1) 
IL6 CAU RAU  % % 
Homozygote A/A 10 48  25.64 42.11  
Heterozygote A/a 20 21  51.28 18.42  
Homozygote a/a   9 45  23.08 39.47  
P Value = 0.0003  (df=2) 
Allele 1  40 117  51.28 51.32  
Allele 2  38 111  48.72 48.68  
P Value =  
 
 (df=1) 
IL10 CAU RAU  % % 
Homozygote A/A 10 31  25.64 26.27  
Heterozygote A/a 14 61  35.9 51.69  
Homozygote a/a   15 26  38.46 22.03  
P Value = 0.102  (df=2) 
Allele 1  34 123  43.59 52.12  
Allele 2  44 113  56.41 47.88  
P Value =  0.191  (df=1) 
TNF-α (-238) CAU RAU  % % 
Homozygote A/A 37 110  94.87 93.22  
Heterozygote A/a 2 8  5.13 6.78  
Homozygote a/a   0 0  0.00  0.00  
P Value = 0.935  (df=2) 
Allele 1  76 228  97.44 96.61  
Allele 2  2 8  2.56 3.39  
P Value =  0.718  (df=1) 
TNF-α (-308) CAU RAU  % % 
Homozygote A/A 29 86  74.36 72.88  
Heterozygote A/a 9 28  23.08 23.73  
Homozygote a/a   1 4  2.56 3.39  
P Value = 0.962  (df=2) 
Allele 1  67 200  85.9 84.75  
Allele 2  11 36  14.1 15.25  
P Value =  0.804  (df=1) 
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Table 5.6. Frequency of IL-1ra allele T in Caucasian patients with chronic anterior uveitis 
compared to those with recurrent disease. 
 CAU RAU  Observed frequencies 
IL1ra    %  % 
Homozygote TT 26 53  66.67   44.92  
Heterozygote T/C 13 50  33.33  42.37  
Homozygote C/C  0 15  0.00   12.71  
 Pc  value =0.09   
Allele T 65 156  83.33  66.10 
Allele C 13 80  16.67  33.90 
 Pc value=0.004 OR 2.6 95% CI 1.3 – 4.9  
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 Table 5.7.  Frequency of TNF-α 308 allele G in patients with HLA-B27 positive anterior 
uveitis versus HLA-B27 negative anterior uveitis. 
 HLA-B27 
negative 
HLA-B27 
positive 
 Observed frequencies 
TNF-α -308    % % 
Allele G 46 101  76.7 91.8 
Allele A 14 9  23.3 8.2 
 Pc value=0.02 OR 3.4 95% CI 1.4 – 8.5 
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 5.5. DISCUSSION 
We have investigated the association of different SNPs of IL-1ra, IL-6, IL-10 and, TNF genes 
in patients with CAU. The data of this study shows that the frequency of IL-1ra allele T is 
significantly associated with chronic disease in Caucasian patients with AU, even after 
correction for multiple testing. Although there was an association between homozygous 
patients for the IL-1ra (+2018) allele C and patients with recurrent inflammation, this was not 
significant after Bonferroni correction. HLA-B27 is known to be a risk factor for AU, and is 
closely linked to TNF. We found a significant association between TNF (-308) allele G and 
patients with AU who were HLA-B27 positive. However we did not find any associations 
between the TNF (-238)G/A in patients with CAU, suggesting that these polymorphisms are 
unlikely to be a major cause of disease susceptibility or development of chronicity in patients 
with AU. It is known that the TNF (-238) allele G is in LD with the HLA-B27 allele and that 
increased frequencies of the TNF (-308) allele A have been found in some infectious diseases 
(Cabrera et al. 1995; McGuire et al. 1994). But it will be of interest to know whether 
increased expression of TNF (-308) allele G is also found in the normal population. Although 
this might introduce a bias on the data, as some “normal” controls may go on to develop AU. 
McGarry et al. found an increased frequency of the TNF (-308) allele G in HLA-B27 positive 
patients with AS compared to HLA-B27 positive controls, suggesting that the -308 allele G 
may contribute to disease susceptibility independently of the HLA-B27(McGarry et al. 1999). 
Kaijzel et al. could not demonstrate whether TNF polymorphisms were associated with the 
presence of AU in a cohort of patients with AS, due to reduced sample size (Kaijzel et al. 
1999). Our findings may correlate with those reported by Segundo-Gonzalez et al. where in a 
subgroup of HLA-B27 positive patients with AS the TNF (-308) allele G was found to be 
increased due to B27 LD. Therefore it still remains uncertain whether the low production of 
TNF-α associated with the -308 allele G could contribute to the clinical phenotype in patients 
with AU. 
  
IL-1ra gene may have an important genetic contribution to AU. There are several reports on 
polymorphisms occurring within cytokine genes, some of which are related to disease 
(Bidwell et al. 2001). IL-1ra, the natural endogenous IL-1 antagonist binds to the receptor but 
does not initiate intracellular signalling. It acts as a competitive inhibitor and shows an anti-
inflammatory effect in both in vivo and in vitro (Carter et al. 2001; Wilkinson et al. 1999). In 
the second intron of the IL-1ra gene there is a tandem repeat sequence 86-bp in length 
(Tarlow et al. 1993). Allele 1 is more common than allele 2 in most of the studied 
populations. Several studies have not been able to show a definite relationship between levels 
of IL-1ra and allele frequency (Mwantembe et al. 2001; Santtila et al. 1998; Tountas et al. 
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1999). Danis et al. observed that in healthy individuals allele 2 of IL-1ra was associated with 
an increased IL-1ra/IL-1α ratio (Danis et al. 1995). In addition to this, carriers of the rare IL-
1ra allele 2 also show an increase in IL-1 beta circulating levels, which results in a lower IL-
1ra/IL-1 beta ration and therefore increased inflammatory response (Hurme & Santtila 1998; 
Santtila et al. 1998). From these studies we can assume the pro-inflammatory effect of the 
rare IL-1ra allele 2. Also increased severity rather than predisposition to some inflammatory 
diseases has been associated with a higher frequency of the rare allele 2 of the IL-1ra (Arend 
2002). We have analyzed the +2081 variation described by Clay et al. which is 100% in LD 
with the two most frequent alleles of IL-1ra (VNTR) (Clay et al. 1996). From our findings, 
patients with intraocular inflammation which persisted longer than 3 months had an increased 
frequency of the common IL-1ra (+2018) allele 1 (pc = 0.004) compared to those with RAU. 
This was a surprising observation, and may look like conflicting evidence.  
The exact functional consequences of these polymorphisms remain still unknown. One of the 
reasons being, that the VNTR in IL-1ra is in LD with several polymorphisms including this 
one at position +2018. It is also known the influence of IL-1β gene to regulate the production 
of IL-1ra (Hurme & Santtila 1998). Therefore, our findings may be explained by the influence 
of the decreased frequency of allele 2 on the IL-1ra /IL-1β ratio shifting the ration towards a 
more prolonged but milder inflammation in patients with uveitis.  
We did not find any associations between the IL-6(-174)C/G, IL-10(-1082)G/A, or the TNF (-
238)G/A in patients with AU, suggesting that these polymorphisms are unlikely to be a major 
cause of disease susceptibility or development of chronicity in patients with AU. 
Not all our patients were genotyped for HLA-B27, especially these who had already been 
diagnosed with an associated systemic disease i.e., sarcoidosis, Behçet’s syndrome. In our 
study we did not measure systemic or aqueous concentrations of any of these cytokines since 
it would be difficult to correlate their levels at any single time point of the disease due to the 
different disease duration, age, duration of the current episode, and interfering factors, such as 
the natural history of the disease and therapeutic interventions, and the heterogeneous 
associated group of diseases. One of possible reasons for the differences in these results may 
also be the relatively small sample size and therefore the lack of statistical power.  
 
In conclusion, this study shows an interesting association between AU and IL-1ra gene 
polymorphism.  There is however a need for larger groups, as well as measurement of 
cytokine levels in both peripheral and organ-specific levels. 
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CHAPTER SIX 
6. CHEMOKINE GENE POLYMORPHISMS IN IDIOPATHIC ANTERIOR UVEITIS 
6.1. INTRODUCTION 
The pathogenesis of AAU is characterised by breakdown of the blood-aqueous barrier and 
acute inflammation of the ciliary body and iris and consequent leukocyte recruitment, a 
process that involves several proteins, including adhesion molecules, matrix metalloproteases, 
and chemotactic factors, which include the chemokine family. The successful trafficking of 
leukocytes to restricted places depends partly on the local secretion of chemokines and on the 
programmed expression of their chemokine receptors on cell surfaces.  
The chemokine IL-8 is a pro-inflammatory chemokine that primarily mediates the activation 
and migration of neutrophils into tissue from peripheral blood. There is support in both 
animal and human model for the role of IL-8 in ocular inflammation (de Boer et al. 1993; 
Ferrick et al. 1991). Similarly, MCP-1 expression in the iris and ciliary body upregulates local 
T cell clones and monocytes during acute episodes of AU (Adamus et al. 2001). 
There is evidence of certain polymorphisms of the human IL-8 gene have functional 
importance, and individuals homozygous for the -355A allele secrete more IL-8 than those 
homozygous for the T allele (Hull et al. 2000). Two SNPs affecting the distal regulatory 
region of the MCP-1 promoter; -2518A/G and -2076T/A transition have been reported (Rovin 
et al. 1999), and -2518A/G appears to influence transcriptional activity (Letendre et al. 2004; 
Rovin et al. 1999), and to determine the severity of organ inflammation in diseases where 
tissue leukocyte infiltration is MCP-1 dependent. 
In the two previous chapters the association between different SNPs with susceptibility to 
develop AU, chronicity of the disease or worse outcome have been evaluated. In this study 
the role of polymorphisms in chemokines and their receptors as potential pathogenic or 
protective factors in the disease, as well as, their possible role in disease phenotype prediction 
are evaluated. 
 
6.2. MATERIALS AND METHODS 
This study was approved by the Ethics Committee of Moorfields Eye Hospital and was 
conducted according to the Tenents of the Declaration of Helsinky. Sixty Caucasian patients 
with idiopathic AAU were recruited from the Uveitis Clinic at Moorfields Eye Hospital, 
London for this study. The clinical phenotype of the patients was recorded at the time of 
blood donation. After verbal and written informed consent was obtained, demographic details, 
detailed medical and ocular history were recorded for each of the patients. All patients had 
detailed ocular examination including best corrected visual acuity, slit lamp examination, 
applanation tonometry, and dilated fundus examination with 90-D diopter lens or indirect 
ophthalmoscope. Fluorescein angiography or Optical Coherent tomography (OCT) was 
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performed if macular edema was considered likely on clinical examination. The following 
clinical parameters were particularly noted; pattern of the AU (single episode versus 
recurrent), laterality, response to topical steroids, complications (high IOP, permanent PS, 
cataract and macular edema) need for systemic/periocular steroids and other 
immunosuppressants. One hundred and twenty healthy Caucasian control subjects were 
recruited from blood and organ donors from Southern England. DNA was extracted either 
using a modified salting out DNA extraction method or with a commercial DNA extraction 
kit, QIAamp® DNA Blood Midi Kit (QIAGEN Ltd., UK). 
To locate potential SNPs, multiple sequences for IL-8, CXCR1, MCP-1 and CCR2 deposited 
in GenBank were compared. Where differences between sequences were identified, SNPs 
located in promoter regions and exon were preferentially selected for analysis. To confirm the 
presence of each putative polymorphism, the SNPs were determined on a series of pooled 
Caucasian DNA samples using sequence-specific primers and PCR. This technique identifies 
the presence of specific allelic variants through PCR amplification, using sequence-specific 
primers with 3’end mismatches. All PCRs were run under identical conditions as previously 
described (Hizawa et al. 1999). The presence of an allele-specific band of the expected size, in 
conjunction with a control band, was considered positive evidence for each particular allele. 
The absence of an allele-specific band and the presence of a control band were considered 
evidence for the absence of an allele. 
 This resulted in the identification of 15 SNPs of the 2 chemokine genes and 2 chemokine 
receptor genes as shown in table 6.1, which were then determined in our IAU group and 
controls (Table 6.1).  
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Table 6.1. List of single nucleotide polymorphisms investigated. 
Gene Polymorphism site Locus NCBI dbSNP 
ID 
Gene Bank 
Accession No. 
IL-8 37511 C/T Intron rs2227306 AC112519 IL-8 
IL-8 36849 C/T 
 
Exon rs1803205 AC112520 
IL-8RA 4205 G/A 3’ UTR rs1567868 AC097483 
IL-8RA 6694 C/G 
 
Exon rs2234671 AC097484 
IL-8RA 
 IL-8RA 10188 T/C Promoter rs2671222 AC097485 
MCP-1 62534 A/T Promoter rs2867655 AC005549 
MCP-1 63997 T/C *  Promoter rs1024611 AC005550 
MCP-1 
MCP-1 63555 A/T † Promoter rs1024610 AC005551 
CCR2 50490 T/A 
 
3’ UTR rs1034382 U95626 
CCR2 49776 C/G 
 
3’ UTR rs762790 U95627 
 CCR2 49715 A/G 3’ UTR rs762789 U95628 
CCR2 49652 T/C 3’ UTR rs762788 U95629 
CCR2 49105 A/G 
 
Exon rs743660 U95630 
CCR2 46295 G/A ‡ Exon rs1799864 U95631 
CCR2 
CCR2 39353 A/G Promoter rs768539 U95632 
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6.3. STATISTICAL ANALYSIS 
The genotypes were determined by direct counting and the allele and allele carriage 
frequencies calculated. Conformation of the Hardy-Weinberg equilibrium was tested by using 
a Chi-square goodness-of fit test. Haplotypes and LD (D’= LD value) were identified using 
the estimate haplotype frequencies program ARLEQUIN (http://lgb.unige.ch/arlequin/). Data 
mining for significant associations was performed using Knowledge Seeker® (Angoss 
Software, UK), and Chi-square or Fisher’s exact test was used to test for differences in allele 
distribution between the patient and control groups, as well as within the patient group itself. 
Confidence intervals were calculated at the 95% level. A two-tailed P-value of <0.05 was 
considered significant. A correction using the Bonferroni method was used for multiple 
comparison, using the formula of pc=P x n. (pc represents the corrected value, P is the 
uncorrected value, and n is the numbers of comparisons performed in individual genes). 
QUANTO© software (http://hydra.usc.edu/gxe) was used to compute the power of study using 
the sample of 60 subjects and the power to detect the allelic frequency difference was more 
than 80% for this sample size. 
 
6.4. RESULTS 
The allele frequencies of the investigated MCP-1, CCR2, IL-8 and IL-8RA polymorphisms 
for patients and control subjects were found to fit with Hardy-Weinberg equilibrium. The 
allelic frequencies of all SNPs analysed are shown in table 6.1 (Table 6.2). 
IL-8 38366 C/T and IL-8 37511 C/T were found to be in strong LD with a D’ value of 0.99. 
All the subjects homozygous for IL-8 38366 C were also homozygous for IL-8 37511 C and 
subjects with IL-8 38366 TT genotype were never homozygous for IL-8 37511 C. Similarly, 
T allele of CR2 50490 T/A and T allele of CCR2 49652 T/C were in complete LD, as were A 
allele of 49105 A/G and A allele of 39352 A/G with a D’ value of 1.00. 
As shown in table 6.1 there was a significant difference in the genotype frequencies of MCP-1 
63555 A/T between IAU patients and controls. The frequency of the T allele of MCP-1 63555 
polymorphism was significantly higher in the control group (26.25%) compared to the patient 
group (15%) (P=0.0160, pc=0.032, OR 0.49, 95% CI: 0.27-0.88). The allelic frequencies and 
the allele carriage frequencies are shown in detail in table 6.2 (Table 6.3). 
 
As expected the frequency of HLA-B27 positive subjects was significantly higher in the 
patient group than the control group (63.3% versus 15.8%; P<0.0001, OR: 9.18, 95% CI: 
4.47-18.8). Thirty-eight out of 60 patients and 19 out of 120 controls were HLA-B27 positive 
(Figure 6.1). 
The association of the MCP-1 63555 polymorphism with IAU was independent of the HLA-
B27 gene and similarly no linkage was noted between HLA-B27 and other polymorphisms. 
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With the three SNPs of the MCP-1 promoter region, we were able to construct three common 
haplotypes. As shown in table 6.3, haplotype ATT, having the mutation T at 63555 and 
ancestral allele T at position 63997 was significantly higher in the control group (P=0.01, 
pc=0.03, OR: 0.47, 95% CI: 0.25-0.88). Also the ancestral haplotype AAT was more common 
in the IAU group (57.7% versus 47.05 in controls) although it was not statistically significant 
(Table 6.3). 
As shown in table 6.2, no other polymorphism showed any association with IAU including 
MCP-1 63997 T/C (published as MCP-1 -2518A/G) and CCR2 46295 (published as CCR2 
V64I). Also no effect of any of the SNPs was noted on the risk of developing complication 
and visual outcome in IAU.  
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Table 6.2. Genotype frequencies of chemokine SNPs in AU. 
 
* Published as MCP-1 -2518A/G polymorphism by Rovin et al. (Rovin et al. 1999). 
† Published as MCP-1 -2076A/T polymorphism by Rovin et al. (Rovin et al. 1999). 
‡ Published as CCR2 V64I by Keino et al. (Keino et al. 2003). 
  
 
 
   AU Control   
   (n = 60) % (n = 120) % p value 
CC 19 31.7  45 37.5  
CT 30 50.0  49 40.8  
IL-8 37511 C/T 
  
  TT 11 18.3  26 21.7  
0.50539  
  
  
CC 59 98.3  119 99.2  
CT 1 1.7  1 0.8  
IL-8 36849 C/T 
  
  TT 0 0.0  0 0.0  
0.61510  
  
  
GG 0 0.0  1 0.8  
GA 5 8.3  14 11.7  
IL-8RA 4205 G/A 
  
  AA 55 91.7  105 87.5  
0.60678  
  
  
CC 55 91.7  107 89.2  
CG 5 8.3  13 10.8  
IL-8RA 6694 C/G 
  
  GG 0 0.0  0 0.0  
0.59816  
  
  
TT 0 0.0  0 0.0  
TC 3 5.0  12 10.0  
IL-8RA 10188 T/C 
  
  CC 57 95.0  108 90.0  
0.25256  
  
  
AA 55 91.7  114 95.0  
AT 5 8.3  6 5.0  
MCP-1 62534 A/T 
  
  TT 0 0.0  0 0.0  
0.37879  
  
  
TT 31 51.7  63 52.5  
TC 25 41.7  48 40.0  
MCP-1 63997 T/C * 
  
  CC 4 6.7  9 7.5  
0.96504  
  
  
AA 44 73.3  65 54.2  
AT 14 23.3  47 39.2  
MCP-1 63555 A/T † 
  
  TT 2 3.3  8 6.7  
0.04537  
  
  
TT 3 5.0  6 5.0  
TA 20 33.3  43 35.8  
CCR2 50490 T/A 
  
  AA 37 61.7  71 59.2  
0.94502  
  
  
CC 43 71.7  87 72.5  
CG 17 28.3  32 26.7  
CCR2 49776 C/G 
  
  GG 0 0.0  1 0.8  
0.76160  
  
  
CA 8 13.3  11 9.2  
AG 19 31.7  42 35.0  
CCR2 49715 A/G 
  
  GG 33 55.0  67 55.8  
0.67232  
  
  
TT 3 5.0  6 5.0  
TC 20 33.3  43 35.8  
CCR2 49652 T/C 
  
  CC 37 61.7  71 59.2  
0.94502  
  
  
AA 3 5.0  6 5.0  
AG 20 33.3  43 35.8  
CCR2 49105 A/G 
  
  GG 37 61.7  71 59.2  
0.94502  
  
  
GG 52 86.7  107 89.2  
GA 7 11.7  12 10.0  
CCR2 46295 G/A ‡ 
  
  AA 1 1.7  1 0.8  
0.82549  
  
  
AA 3 5.0  6 5.0  
AG 20 33.3  42 35.0  
CCR2 39353 A/G 
  
  GG 37 61.7  72 60.0  
0.97501  
  
  
HLA B-27  positive 38 63.3  19 15.8  <0.0001 
HLA B-27  negative 22 36.7  101 84.2    
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Table 6.3. Allele, genotype, and allele carriage frequencies of MCP-1 63555 in IAU and 
control. 
IAU (n = 60) Control (n = 120)   Polymorphism 
No.  % No.  % p value pc value 
Allele Frequency  
T 18 15.0)  63 (26.3)  0.016* 0.048* MCP-1 63555 
A 102 (85.0)  177 (73.8)   
Genotype Frequency  
TT 2 (3.3) 8 (6.7) 0.045* 0.14  
AT 14 (23.3)  47 (39.2)    
MCP-1 63555 
 
  AA 44 (73.3) 65 (54.2)   
Allele Carriage Frequency  
TT,AT 16 (26.7) 56 (45.8) 0.013* 0.039* MCP-1 63555 
  AA 44 (73.3)  65 (54.2)    
 
IAU: idiopathic anterior uveitis 
* Statistical significance 
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Figure 6.13 Relationship between HLA-B27 and IAU (p<0.0001). 
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Table 6.4. Haplotype frequencies in IAU and control. 
MCP-1 Polymorphism  IAU Control     Haplotype 
62534 63997 63555  (n = 60) (n = 120) Odds Ratio† p value pc value 
1 A T A  57.7% 47.0% -  0.055 ns 
2 A T T  13.8% 25.5% 0.47 (0.25-0.88) 0.011 0.033 
3 A C A  24.3% 24.3% -  ns ns 
Others     4.2% 3.2% -  ns ns 
IAU: idiopathic anterior uveitis; ns: not significant 
† 95% confidence interval 
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6.5. DISCUSSION 
The association of chemokine gene polymorphisms in patients with AAU of who 63% of 
them were HLA-B27 positive, has been investigated in this study.  Except for MCP-1 63555 
A/T polymorphism there was no correlation noted between IAU and SNPs in IL-8, CCR2 and 
CXCR1 genes. MCP-1 is now thought to play an important role in AU (Mo et al. 1999; 
Tuaillon et al. 2002), and animal studies have demonstrated that MCP-1 is involved in 
induction of AU (Adamus et al. 1997).  
However, like other studies on immune mediated diseases (Gonzalez-Escribano et al. 2003; 
Hwang et al. 2002; Kroner et al. 2004; Liao et al. 2004; Steinmetz et al. 2004) we did not 
observe any difference in allelic frequencies of MCP-1 63997 T/C alleles (-2518 A/G) 
between patients and controls.  
Although the C allele is known to increase the expression of MCP-1 (Hizawa et al. 1999; 
Rovin et al. 1999), and many studies have shown relation between this C allele (alternatively 
designated as G allele at -2518) and MCP-1 level (Letendre et al. 2004; Tabara et al. 2003), 
other studies however failed to show any significant increase in the frequency of C allele in 
their experimental samples. In our study, the frequency of the T allele of MCP-1 63555 was 
found to be significantly higher in the control group compared to the patient group (Pearson’s 
P=0.0160, pc=0.048). The allelic frequencies in our control population were similar to those 
of Rovin et al. (Rovin et al. 1999) denoting that this allele plays some sort of protective role 
against AU. However most autoimmune mediated diseases are complex multigenetic 
disorders and it is hard to point at a single gene as causative factor. Most of the time more 
than one gene polymorphism has been implicated and haplotypes rather than single SNPs 
determine the nature and course of these complex diseases. In our study haplotype ATT was 
more prevalent in controls as compared to IAU (P=0.011, pc=0.033). This haplotype contains 
T allele at 63555 (noted to be protective in our study) and a T allele at 63977 (known to be 
associated with decreased MCP-1 production). It appears that the presence of these two alleles 
together on the same gene exert a combined protective effect against IAU. How this mutation 
confers this protection is not known. Although Rovin et al. (Rovin et al. 1999) showed that 
polymorphism at site 63555 did not effect MCP-1 expression; it is worth mentioning that in 
their study the maximum transcriptional activity of MCP-1  promoter region was noted in 
subjects with the AC haplotype (A at -2076 and G at -2518 in their study). In another study, 
the same AC haplotype was associated with accelerated progress to AIDS and death and a 
high risk of HIV associated dementia in HIV positive Caucasian Americans (Gonzalez et al. 
2002). In our study instead of the AC haplotype being associated with the disease it was the 
TA haplotype with both protective alleles, which was more common in the control group.  
Alternatively, it is quite possible that the protective effective of t allele at 63555 is 
independent of the 63977 polymorphism, as also noted by Modi et al. in AIDS patients (Modi 
175
et al. 2003), were the T allele frequency was significantly higher in high risk exposes 
uninfected subjects as compared to sero-converters. 
Although the association between IAU and MCP-1 63555 is established, whether this SNP is 
functional or not in not known. In the medical literature as mentioned above there is only one 
study that has studied functional effects of this polymorphism. Rovin et al. showed with 
electro mobility shift assay technique that there was significant difference in amount of 
nuclear protein complexes formed between the two alleles, and at last with the T allele 
sequence nuclear protein complex contains GATA (Rovin et al. 1999). By using online 
bioinformatics tool TRANFEC to study putative bindings sites for transcription factors 
(Schug 2008), not only confirms that the more GATA sites become available in the presence 
of T allele; but it also shows that the presence of the presence of A allele enables the c-MYB 
transcription factor to bind with MCP-1 promoter site. This transcription factor is believed to 
be involved in increasing the expression of its receptor gene (MCP-1 in this case) through 
DNA α polymerase activation (Venturelli et al. 1990). 
Given the lack of in vivo or in vitro functional associations thee more plausible theory of the 
role of this SNP is through linkage with other SNPs in the same gene. To the best of our 
knowledge only another study on MCP-1 63555 polymorphism (CCL2 -2076A/T) and 
outcome to autoimmune disorder has been published to date (Ambruzova et al. 2009). 
Interestingly the authors concluded that the presence of the CCL2 -2076TT genotype was 
associated with decreased organ survival following hallogenic stem cell transplantation, 
although they considered these results to be preliminary due to the wide heterogeneity of their 
clinical data and lack of correction for multiple comparisons. . 
In a similar study to ours, Wegscheider et al. showed that MCP-1 -2518G allele was 
associated with HLA-B27 associated AU (Wegscheider et al. 2005). Although we did not 
notice this association these studies together point towards the presence of genetic 
susceptibility locus for IAU in MCP-1 gene. 
In conclusion, our study has demonstrated the association of MCP-1 promoter haplotypes 
with IAU. This is most likely due to the presence of the T allele of MCP-1 63555 which 
seems to be protective against the development of IAU. While MCP-1 63555 is not the only 
pathogenic factor it may still be a crucial key in deciphering the pathogenesis of AU. This in 
future could be a useful tool for clinicians in determining the possibility of disease 
development and prognosis in AAU. 
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CHAPTER SEVEN 
7. DISCUSSION 
The research carried out in this thesis has shown the following major findings. (1) The 
presence of PS in patients with CAU is not associated with worse clinical outcome; (2) 
patients with CAU associated with a systemic autoimmune disorder were more likely to suffer 
CMO; (3) however the overall long-term visual prognosis in patients with CAU was good. 
This research also identified (4) TNF-α -857T as a marker of susceptibility in Caucasian 
patients to develop AAU; (5) TNFRSF1A -201G/T and TNFRSF1A -1135C/T as potential 
contributors to the development of complications in patients with HLA-B27 associated AU. 
Furthermore, (6) IL-1ra +2081T was identified as a predictor of chronicity in Caucasian 
patients with AU. In addition (7) the presence of the allele T of the chemokine MCP-1 -2076 
has a protective role against the development of idiopathic AAU. 
 
The work in this thesis showed that the presence of PS was not significantly associated with 
an increased rate of complications leading to poorer visual outcomes. The same outcome was 
observed for the remaining complications, which included, cataract formation, CMO, or 
raised intraocular pressure. Interestingly this was true not only when the total group of 
patients with CAU was compared to those with FHC, but also after intra-group analysis of 
patients with idiopathic and non-idiopathic CAU, since it would be expected that patients with 
FHC do not develop PS, at least pre-operatively and therefore they would be more likely to 
have an overall better visual outcome.  
Nevertheless, I showed a trend in patients with CAU associated to an inflammatory systemic 
disorder to develop CMO, however there was no difference in the long-term visual outcome 
compared to patients with idiopathic disease.  
Similarly, although FHC is typically associated with raised IOP in 15 to 59% of patients, I 
found a trend in terms of increased IOP in the overall group of patients with CAU compared 
to those with FHC; however this may only reflect a bias from the number of patients with 
sarcoidosis-associated uveitis in whom the presence of glaucoma is not uncommon or from 
the population studied from a tertiary referral centre.  
In the same way that posterior segment complications in patients with AAU have been widely 
reported in the literature, no definite conclusions as to what might be the cause can be 
extrapolated from this study. A possible explanation for the increased risk of CMO in the sub-
group of patients with non-idiopathic CAU could be related to systemic immune alterations 
associated with sarcoidosis or SpA, or other genetic factors related to variations in the 
promoter region of cytokine genes affecting cytokine production or disease susceptibility. 
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I then investigated the association of different SNPs of IL-1ra, IL-6, IL-10 and, TNF-α genes 
in patients with CAU. 
I analyzed the IL-1ra +2081 variation described by Clay et al. (Clay et al. 1996). The findings 
revealed an increased frequency of the more common IL-1ra +2018T allele in patients with 
CAU compared to those with recurrent AU. This is an interesting observation since the less 
common IL-1ra +2018C allele is linked with increased IL-1ra production in healthy 
individuals, and because IL-1ra prevents IL-1 signalling through its receptor, the presence of 
this allele would limit IL-1 mediated signals. However, the presence of the rare C allele has 
also been linked with increased levels of IL-1β and assuming its pro-inflammatory effect. 
These findings would be supported by the association between increased severity rather than 
predisposition to some inflammatory diseases and higher frequency of the rare allele C 
(Arend 2002), and would correlate with our results where the influence of the decreased 
frequency of allele C on the IL-1ra /IL-1β ratio shifts towards a more prolonged but milder 
inflammation.  
 
A second association in this group of patients was observed between TNF-α -308G allele in 
HLA-B27 positive patients with AU. However, not all our patients in this study were 
genotyped for HLA-B27, in particular these who had already been diagnosed with non-related 
HLA-B27 diseases, such as sarcoidosis or Behçet’s disease. Nevertheless this finding could 
explained by LD, given the short distance between the TNF-α gene and HLA-B locus in 
chromosome 6. For this reason a group of healthy HLA-B27 individuals could be introduced, 
although this could have introduced a bias on the results, since 1% of HLA-B27 positive 
normal controls may go on to develop AU at some stage in their lifetime.  
 
Consequently, we looked at the associations of different SNPs of the TNF-α gene, including -
308 in patients with idiopathic AAU. Interestingly we found from haplotype analysis of the 
TNF promoter in patients with IAU, that haplotype 1 containing the common TNF-α -308G 
allele is significantly associated with HLA-B27 positivity and haplotype 2 containing TNF-α -
308A is associated with HLA-B27 negativity. However we also found that TNF-α -1031T 
allele was also associated with HLA-B27 positivity, suggesting that there is LD between 
HLA-B27 and TNF-α. More importantly these results have been replicated in a separate 
population by different authors, where they found lower A allele frequencies at position -308 
of the TNF-α gene in patients with HLA-B27 positive associated AAU than those in HLA-
B27 negative control subjects (El-Shabrawi et al. 2006). However, They also included a 
second control group of HLA-B27 positive individuals in order to assess LD and similar to 
the findings in the HLA-B27 negative control group, a lower frequency of the A allele was 
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observed among patients, suggesting that the protective role of the TNF-α -308A allele is due 
to LD to HLA-B27 is unlikely.    
Another association seen in this cohort of patients was the increased frequency of TNF-α -
857T allele in patients with IAU compared to control subjects. This allele has been linked 
with other autoimmune disorders associated with HLA-DR, conferring an increased risk of 
developing juvenile rheumatoid arthritis (Date et al. 1999), and hence, there might be other 
genes in the highly polymorphic MHC in LD. Therefore these results suggest that the 
uncommon TNF-α -857T allele may not be the causal allele for IAU, but is an independent 
susceptibility marker for IAU, and TNF-α -308A is unlikely to be an independent risk marker 
for HLA-B27 negative patients. 
 
A further interesting finding from this study is the association between the uncommon 
TNFSF1A-1135T allele and the presence of recurrences of AU. Although many of these 
patients with a single episode of inflammation will develop at least one more if followed for a 
longer period of time (Levinson et al. 2002).  
 
Finally we investigated the associations of chemokine polymorphisms in patients with AAU. 
We found the frequency of MCP-1 -2076T allele was found to be significantly higher in the 
control group compared to the patient group. As expected the frequency of HLA-B27 positive 
individuals was higher in the uveitis group, however the association between the MCP-1 -
2076 polymorphism with IAU was independent of HLA-B27 gene and there was no evidence 
of LD. In addition to this, the allelic frequencies in our control population were similar to 
those of Rovin et al. (Rovin et al. 1999) suggesting that this allele may have a protective role 
against AU. 
 
These findings support the principal hypothesis of this thesis that proposes the association of 
disease susceptibility and certain cytokine polymorphisms, as well as the role of certain SNPs 
in the development of chronicity in patients with AAU. 
 
Advances in immunology continue to provide new insights about the ocular immunological 
response. Despite these insights, the clinical outcome of the different uveitis entities and the 
reasons for the diverse responses to treatment remains unclear. 
AU is a term that encompasses several clinical entities. It may occur in isolation, or be 
associated with systemic disease. It can present suddenly or have an insidious onset, with 
patients being asymptomatic until the onset of complications such as cataract or macular 
oedema. In addition, in some cases the inflammatory process is self-limited lasting a few 
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weeks and in other cases it persists, either in a relapsing fashion with long periods of 
inactivity in between attacks or it may persist, relapsing soon after discontinuing therapy.  
Often there are no differentiating clinical features that can help in predicting the clinical 
pattern of uveitis and ultimately the course and prognosis. This is typified by the clinical 
entities HLA-B27-associated AAU and Behçet’s disease-associated AU, which frequently 
share a similar form of presentation with sudden onset of symptoms, severe anterior segment 
inflammation and characteristic presence of hypopyon, yet have different outcomes. On the 
other hand, sarcoidosis-associated uveitis typically manifests with “mutton-fat” KPs, severe 
inflammatory cellular response in the anterior chamber with PS, and involvement of the 
posterior segment, but it can also present as a mild localised AU with a chronic course. 
Additionally there are entities, such as FHC where the inflammation is typically associated 
with specific complications such as cataract formation or raised intraocular pressure, but it is 
not associated with the presence of PS or CMO, and typically exhibits a lack of response to 
steroid therapy. 
 
Thought the precise pathogenesis of AU remains largely unknown, in this thesis I have 
described the current evidence showing that both innate and adaptive immune responses 
regulate different mechanisms involved in the development of uveitis and how different 
genetic markers can influence the development of AU and ultimately determine the course of 
the inflammatory process and different phenotypic manifestations of this disease.  
One of the critical links between the two arms of the immune response is a group of pattern 
recognition receptors located on the cell membrane called TLRs. They are expressed in a 
variety of cells, mostly macrophages and dendritic cells, and are known to be expressed in the 
human uveal tissue. In addition, it is known that they have a unique specificity for highly 
conserved ligands, and for instance TLR4 recognizes LPS of gram negative bacteria which is 
implicated in the pathogenesis of uveitis. 
LPS activates monocytes, macrophages, epithelial and endothelial cells to produce several 
pro-inflammatory cytokines such as TNF-α, IL-1, or IL-6, which are commonly found in the 
AqH in patients with AAU, as well as in experimental animals with EIU. In healthy 
individuals a single exposure to LPS induces a status of functional endotoxin tolerance, with 
significant reduction of TNF-α and IL-6 production following a second LPS stimulation 
results. Interestingly in patients with AAU TLR4 activation is followed by a significant 
reduction of IL-6 and IFN-γ production, whereas TLR2 stimulation results in a significant 
increase of IL-1β and TNF-α. 
Genotype analysis of TLR2 and TLR4 gene polymorphisms have been found to be associated 
with other autoimmune disorders such as RhA; however, to date no associations have been 
detected in patients with AAU, suggesting that mutations in the TLRs genes might not have a 
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role in the pathogenesis of AU, but they provide strong evidence of the role of microbial 
organisms in the pathogenesis of AAU through TLRs.  
  
Genes involved in the adaptive immune response include HLA class I molecules. They play 
an important role in the pathogenesis of immune-mediated disorders. The expression of HLA 
antigens is upregulated in uveal tissue in patients with uveitis and correlates with levels of 
IFN-γ in AqH. The strong association between the HLA-B27 antigen and inflammatory 
conditions such as AS, and AAU is well known; additionally the discovery of different HLA-
B27 subtypes determined by alterations in the antigen-binding region supports the hypothesis 
that AU may be a consequence of self-reactive cytotoxic T lymphocytes activated via 
molecular mimicry against local peptides. However despite 45 to 70% of patients with AAU 
being HLA-B27 positive compared to approximately 5% of the general Caucasian population, 
the lifetime cumulative incidence in healthy individuals to develop HLA-B27 associated 
AAU is only of 1% (Chang et al. 2005), implying that other genetic or environmental factors 
are involved in the development of AAU. 
 
Furthermore, there is also evidence from family studies and genome wide screening that other 
genes besides the HLA-B27 within and outside the MHC that play a role in disease 
susceptibility. One of them is the MHC class I chain-related gene A (MICA). Despite MICA 
allele 4 being in LD with HLA-B27, its frequency is significantly higher in HLAB27 negative 
patients with AAU suggesting that the MICA itself or another nearby gene to be involved in 
the development of AAU.  
 
Cytokines are known to regulate cell proliferation and cell differentiation phenotype. They are 
both pleiotropic and redundant, working in a network that initiates gene activation and 
suppression. They have also shown to be highly polymorphic, and these polymorphisms can 
be represented by SNPs, VNTRs, and microsatellites. The majority of them are found in the 
promoter, intronic or 3’ untranslated regions, and although the role of polymorphisms may 
vary, it is through functional SNPs in the promoter regions that ultimately transcription 
regulatory molecules such as NFκβ and other genes involved in signal transduction pathways 
may be disrupted leading to disease associations or disease outcomes.  
 
The cytokine and chemokine genes chosen in this thesis have been implicated in the 
development of uveitis, or have been used as marker of intraocular inflammation. They also 
have been shown to influence disease susceptibility or play a role in the development of the 
various clinical outcomes in different autoimmune disorders, some of them closely related to 
uveitis.  
181
In order to determine whether specific cytokine gene polymorphisms were associated 
with the development of uveitis and different clinical phenotypes we investigated 
SNPs in the promoter region since they are potentially functional sites influencing 
gene expression. 
 
7.1. LIMITATIONS 
Even when genetic analysis reveals a possible association between a cytokine gene 
polymorphism and a disease, it may still be difficult to fully establish its relationship with the 
pathogenesis of such condition. Establishing the relationship between the disease associated 
genotype and cytokine gene expression both at the mRNA using quantitative PCR technology 
or protein levels might be useful, although these methods are limited by small sample size, 
especially for rare cytokine genotypes. Furthermore the genotype might not correlate with 
cytokine levels due to other confounding factors. 
In our studies we did not measure systemic or aqueous concentrations of any of these 
cytokines since it would be difficult to correlate their levels at any single time point of the 
disease due to the different disease duration, age, duration of the current episode, and 
interfering factors, such as the natural history of the disease and therapeutic interventions, and 
the heterogeneous associated group of diseases.  
It might be too simplistic to try to consider the level of expression of a cytokine in isolation 
and they should be analysed in the context of their network and activation pathway. Similarly 
cytokine genes are up and down-regulated by their interaction with transcription factors and 
other regulatory molecules, many of which can be altered by other environmental interactions, 
such as infection.  
The findings presented here demonstrate that cytokine gene polymorphisms have an 
unquestionable role in the orchestration of the immune response, which ultimately influence 
individual disease susceptibility and outcome.  
Even though associations between cytokine and chemokine polymorphisms and different 
subtypes of AU in a Caucasian cohort of patients have been performed, it is clear that in order 
to obtain a better understanding of the genetic mechanisms involved in the pathogenesis it is 
necessary to consider that heterogeneity of this group of disorders, the occurrence of specific 
combinations of functional polymorphisms, the presence of LD with other biologically 
significant polymorphisms and considering the complex nature of the pathogenesis of uveitis, 
it is unlikely that only genetic aspects will influence the establishment or progression of 
intraocular inflammation.  
However the identification of a clear genetic susceptibility profile is a powerful tool for 
diagnostic and therapeutic intervention.   
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 7.2. FUTURE DIRECTIONS 
It appears clear from the literature presented above that although there is a great variability in 
the efficacy of TNF-α blockage in the treatment of inflammatory disease, anti-TNF drugs 
have a role in controlling intraocular inflammation. This may be in acute disease such as the 
severe relapsing episodes in Behçet’s eye disease, in chronic disease in which macular 
oedema may improve even after several months, or as a steroid sparer. However, patients 
show a great variability in their response to TNF-α blockage. Infliximab appears to be the 
more effective than etanercept, although most series are small and the dose regimen that is 
best for uveitis may be different from the very regular infusions required for the management 
of other systemic chronic diseases such as RhA. This is likely to be related to different 
pathogenic mechanisms involved in intraocular inflammation compared with inflammation 
elsewhere. 
In addition to this, and although serious side effects of these drugs such as reactivation of 
latent mycobacterium tuberculosis are reported to be infrequent,  other major side effects like 
exacerbation of demyelinating disorders or induction of neutropenia and thrombocytopenia 
have been described. The development of autoantibodies that are associated with SLE have 
been observed at different rates depending on the underlying disease (Charles et al. 2000; 
Ferraro-Peyret et al. 2004; Vermeire et al. 2003), but only in a few cases SLE-like syndrome 
have been described (Antoni et al. 2002; De Bandt et al. 2005).  
 
Since up to 40% of patients with RhA treated with anti-TNF-α agents are labelled as non-
responders (Lipsky et al. 2000), and given the marked difference in efficacy in controlling 
intraocular inflammation compared to systemic inflammation in patients with JIA (Schmeling 
& Horneff 2005), it would be useful to identify responders and non-responders to TNF-α 
inhibitor agents.  
Several SNP have been identified in the promoter region of the TNF-α gene (Allen 1999), and 
these polymorphisms may have a functional significance in modulating the magnitude of the 
secretory response of this cytokine (Bouma et al. 1996). The effect of TNF-α promoter -308 
A/G polymorphism on TNF-α production, disease susceptibility severity in patients with RhA 
has been extensively studied. Although still controversial, most studies have found that the 
less common allele A is associated with greater levels of TNF transcription (Bouma et al. 
1996; Braun et al. 1996; de Jong et al. 2002; Louis et al. 1998; Rudwaleit et al. 2001) 
Several groups have therefore, investigated the relationship between TNF-α -308 genotype 
and therapeutic response to TNF-α blockers. The first report to test this hypothesis was in 
patients with RhA and their response to infliximab (Mugnier et al. 2003). They found that 
patients with the -308 G/G genotype were more likely to respond to infliximab therapy that 
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these patients with the -308 A/G or A/A genotypes. This could be due to the higher 
production of TNF-α or increased severity in RhA patients associated with the presence of the 
-308 A/G or A/A genotypes. However, in their study they could not confirm any of these 
possibilities.  
These results were supported by another study looking at the therapeutic response of 
etanercept, infliximab and adalimumab in patients with RhA, psoriatic arthropathy and AS. A 
positive clinical outcome of anti-TNF-α treatment was significantly associated with the -
308G/G diplotype irrespective of their disease; whereas patients with RhA carrying the -308 
A/A diplotype did not respond to anti-TNF-α treatment, those carrying the G allele showed a 
moderate or good response. Similarly, patients with psoriatic arthropathy and AS with the -
308 G/G genotype were more likely to respond to anti-TNF-α treatment (Seitz et al. 2007).  
Louis et al. analysed the value of CRP and TNF-α serum levels before treatment with 
infliximab, as well as the TNF -308 gene polymorphism in the prediction of response to 
infliximab treatment in Crohn’s disease (Louis et al. 2002). They found that CRP levels 
before treatment were significantly higher in responders than in non-responders. Furthermore, 
response rate was significantly higher in patients with elevated CRP (>5 mg/l) than in patients 
with a normal CRP value before treatment. A subgroup analysis in their study found a 
significant association in patients with luminal disease who did not respond to treatment and a 
higher frequency of the rare allele A. Allelic and genotype frequencies, however for the -308 
TNF gene polymorphism were not significantly different between responders and non-
responders in either luminal or fistulizing Crohn’s disease.  
Similarly, Cimaz et al. investigated the genetic contributions of IL-1 and TNF-α gene 
polymorphisms and the response to treatment with anti-TNF-α inhibitors in patients with JIA 
(Cimaz et al. 2007). They also failed to find any significant differences for both allelic and 
genotypic frequencies of IL-1ra (+2018) and TNF-α (-238 and -308) between responders and 
non-responders in this cohort of patients with JIA. 
 
However, the methodology of these studies is limited by to the study of one or two cytokine, 
and the complex interaction between different genetic polymorphisms and their clinical 
response to treatment.  
These shortcomings may be minimized by looking at other polymorphic sites within the TNF 
locus that may predict clinical response to TNF-α blockage.  Among 13 genotyped SNPs in a 
Korean study, seven SNPs, which included -1031T/C, -863C/A, -857C/T, -308G/A, and -
238G/A in the TNF-α gene and +177A/G, and +319C/A in the lymphotoxin-α gene were 
polymorphic and within the Hardy-Weinberg equilibrium. Of these seven TNF SNPs, only the 
-857C/T SNP in the TNF-α promoter gene was associated with the etanercept response in 
patients with RhA, according to the American College of Rheumatology (ACR) criteria. More 
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so, patients who carried the T allele were more likely to respond than those who were 
homozygous for the C allele (Kang et al. 2005). This may be explained by the differences in 
the TNF-α gene expression due to allele-specific bindings, such as the transcription factor 
OCT-1 to the -857T allele, inhibiting the TNF-α gene activity, which in turn may result in less 
TNF-α production and better response to etanercept therapy (Hohjoh & Tokunaga 2001). 
These findings correlate to those by van Heel et al., who reported a higher TNF-α production 
in healthy -857C allele homozygous that in -857T allele carriers (van Heel et al. 2002). But 
controversy still remains as a Japanese study observed an increased TNF-α production in the 
carriers of the -857T allele (Soga et al. 2003).  
 
Therefore, another possible way to try to elucidate this controversy would be to combine 
different SNPs rather than one SNP as a more useful way of predicting responsiveness to anti-
TNF-α therapy.  In a cohort of 58 patients with RhA looking at TNF and TNF receptor 
polymorphisms and their response to anti-TNF-α therapy, no independent polymorphism was 
associated with the patient’s response to treatment, but the polymorphisms -857C/T and 
489G/A were found to be in LD. In addition, the combination of both TNFR2 polymorphism 
allele 676T, together with the genotypic association of -857C/489G was associated with good 
response to infliximab therapy (Chatzikyriakidou et al. 2007).  
 
The methodology used in all the above studies analyzes complex interactions between genetic 
polymorphisms and clinical response to TNF blockade, however most of these studies have an 
already selected population, in which patients were receiving treatment, and therefore already 
had severe disease. In addition to this, it is not always possible to reach universal agreement 
in defining clinical response depending on the condition treated.  Although most previous 
studies have focused on SNPs in the promoter regions, it is also known that LD is an 
important factor for the interpretation of genetic data. The TNF-α gene is located within the 
MHC class III region on chromosome 6. The class III region lies between the class I and class 
II regions, and it would be therefore possible that other genes within the MHC may contribute 
towards not only susceptibility, but also response to treatment. Few studies have looked at 
MHC polymorphisms in relation to anti-TNF-α therapy, but due to the small sample size, the 
authors did not extrapolate any meaningful conclusion from their study (Martinez et al. 2003).  
Genetic analysis performed in the majority of the studies published, are performed for a 
limited number of alleles, mainly those that are considered functionally relevant. Therefore, 
the cytokine gene polymorphisms investigated consist of only a minority of the existing 
polymorphisms, and are chosen on the basis of previous reports in their functional and, or 
clinical significance. However, the associations found in these studies might be a useful tool 
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for predicting the efficacy of the different biologic agents in refractory intraocular 
inflammation, and allowing for a targeted choice of agent and treatment regime. 
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to the knowledge about inflammation in the eye. It will therefore help us help people like you 
in the future who have inflammation and those that are damaged by it but the results will not 
help you at the present time. 
 
13. What if new information becomes available?: Sometimes during the course of a 
research project, new information becomes available about the treatment that is being studied. 
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form. 
 
14. What happens when the research study stops?: The results of the study will be very 
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15. What if something goes wrong? In many countries, taking eye fluids is a part of 
management of inflammation of the eye and we have done many hundreds here. No patient 
has suffered a problem because of the sample being taken. 
 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone's negligence, then you may have grounds for 
a legal action but you may have to pay for it. Regardless of this, if you wish to complain or 
have any concerns about any aspect of the way you have been approached or treated during 
the course of this study, the normal National Health Service complaints mechanisms should 
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16. Will my taking part in this study be kept confidential?: Yes. All information that is 
collected about you during the course of the research will be kept strictly confidential. Any 
information about you which leaves the hospital will have your name and address removed so 
that you cannot be recognised from it except the letter to your OP which will let him know. 
 
17. What will happen to the results of the research study?: All the information is presented to 
all the doctors involved in the management of patients with uveitis. This is done by presentation 
of the results at meetings and by publishing the information in the medical journals. No patient is 
individually identified in this but the results of the whole group are determined. Relevant patient 
groups are also informed of new advances in treatment. Some cells are stored for future study so 
that we can investigate new advances quickly when thy come along and help improve treatment 
prospects. 
 
18. Who is organising and funding the research?: This study is carried out by Professor 
Lightman and her team and organised through the Institute of Ophthalmology and Moorfields 
Eye Hospital. 
 
19. Who has reviewed this study?: This study has been approved by the Moorfields Eye 
Hospital Research Ethics Committee. 
 
20. Contact for further information: The doctor involved in your eye care is part of the team 
that looks after patients with eye inflammation. The medical supervisor of the study is Professor 
Susan Lightman and she can be contacted via her secretary on 020 7566 2252. 
 
You will be given a copy of this information sheet and a signed consent form for you to keep. 
 
Thank you for considering taking part in this study. 
 
 
………………………………………………………………… 
 
Susan Lightman FRCP FRCOphth PhD FMedSci Professor of Clinical Ophthalmology 
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APPENDIX 3 
Clinical outcomes of patients with chronic anterior uveitis 
AIMS: 
The aims of this study were to: 
1. Define the factors determining the ocular complications in a group of patients with 
chronic anterior uveitis. 
2. Determine the visual outcome of these patients. 
 
This research by the candidate in the clinical outcome of chronic anterior uveitis has contributed 
the following valuable information: 
1. Posterior synaechia is not significantly associated with worse visual outcome in 
patients with CAU  
2. Cystoid macular oedema, the most common cause of permanent visual loss in 
patients with uveitis is more likely to occur in patients in whom their uveitis is 
associated with a systemic autoimmune disease. 
3. The overall long-term visual prognosis in patients with CAU is good regardless the 
subtype of CAU, despite patients with an associated systemic inflammatory disorder 
having an increased risk of developing cystoid macular oedema. 
 
Published work: 
1. Menezo V, Lightman SL. The development of complications in patients with chronic 
anterior uveitis. Am J Ophthalmol 2005;139:988-992. 
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Cytokine and chemokine polymorphisms in anterior uveitis 
AIMS: 
The aims of these studies were to: 
1. Investigate the association between SNPs of key cytokine, chemokine and their receptor 
genes and AU. 
2. Investigate the association between these SNPs and the development of chronicity and/or 
complications in AU.  
3. Investigate their association with the presence of HLA-B27 antigen. 
 
This study has contributed the following valuable information: 
1. The identification of TNF-α -857T as markers of susceptibility to develop AAU. 
2. The identification of potential SNPs, such as TNFRSF1A -201G/T and TNFRSF1A -
1135C/T as potential contributors to the development of complications in patients 
with HLA-B27 associated AU.  
3. The identification of the IL-1ra +2081T/C polymorphism as predictor of chronic 
disease in patients with AU.  
4. The identification of MCP-1 polymorphism (MCP-1 -2076A/T) with a potential 
protective role against AU. 
 
Published works: 
1. Kuo NW, Lympany PA, Menezo V, Lagan AL, John S, Yeo TK, Liyanage S, du Bois 
RM, Welsh KI, Lightman SL. TNF-857T, a genetic risk marker for acute anterior uveitis. 
Invest Ophthalmol Vis Sci 2005;46:1565-1571. 
2. Menezo V, Bond SK, Towler HMA, Kuo NW, Baharlo B, Wilson AG, Lightman SL. 
Cytokine gene polymorphisms involved in the chronicity and complications of anterior 
uveitis. Cytokine 2006;35:200-206. 
3. Keo TK, Ahad MA, Kuo NW, Spagnolo P, Menezo V, Lympany P, Lightman SL. 
Chemokine gene polymorphisms in idiopathic anterior uveitis. Cytokine 2006;35:29-35 
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